# Patent

## Title
Fungicidal pyrazoles

## Abstract

Disclosed are compounds of Formula 1 and Formula 1A including all stereoisomers, N-oxides, and salts thereof,




wherein

    
    
        Q1, Q2, R1, R2, R4, R5 and X are as defined in the disclosure.
    
    


Also disclosed are compositions containing the compounds of Formula 1 or Formula 1A and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

## Background
This application is a divisional of application Ser. No. 13/816,847, filed Feb. 13, 2013 which is a national stage entry of PCT/US11/49908, filed Aug. 31, 2011. PCT/US11/49908 claims priority benefit from Provisional Application 61/379159, filed Sep. 1, 2010.


FIELD OF THE INVENTION
This invention relates to certain pyrazoles, their N-oxides, salts and compositions, and methods of their use as fungicides.
BACKGROUND OF THE INVENTION
The control of plant diseases caused by fungal plant pathogens is extremely important in achieving high crop efficiency. Plant disease damage to ornamental, vegetable, field, cereal, and fruit crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. Many products are commercially available for these purposes, but the need continues for new compounds which are more effective, less costly, less toxic, environmentally safer or have different sites of action.
PCT Patent Publication WO 2009/007098 A1 discloses certain pyrazole derivatives as fungicides.
SUMMARY OF THE INVENTION
This invention is directed to compounds of Formula 1 (including all stereoisomers), N-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides:




wherein

    
    
        Q1 is a phenyl ring substituted with 1 to 5 substituents independently selected from R3a;
        Q2 is a phenyl ring substituted with 1 to 5 substituents independently selected from R3a; or a 5- to 6-membered fully unsaturated heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon ring members are independently selected from C(═O) and C(═S), each ring optionally substituted with up to 5 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members;
        R1 is C1-C2 alkyl, halomethyl, cyanomethyl or cyclopropyl;
        R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C2 haloalkyl, C2-C3 cyanoalkyl, C1-C2 hydroxyalkyl, cyclopropyl, halocyclopropyl, C2-C3 alkoxyalkyl, C1-C2 alkylthio, C1-C2 alkoxy or C1-C2 haloalkoxy;
        each R3a is independently halogen, cyano, hydroxy, nitro, amino, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C4-C6 alkylcycloalkyl, C4-C6 cycloalkylalkyl, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C3 alkylsulfinyl, C1-C3 haloalkylsulfinyl, C1-C3 alkylsulfonyl, C1-C3 haloalkylsulfonyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C3-C6 cycloalkoxy, C1-C3 alkylsulfonyloxy, C1-C3 haloalkylsulfonyloxy, C2-C4 alkylcarbonyloxy, C2-C4 alkylcarbonyl, C1-C3 alkylamino, C2-C4 dialkylamino, C2-C4 alkylcarbonylamino, —CH(═O), —NHCH(═O), —SF5, —SC≡N or —U—V-T;
        each R3b is independently cyano, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, C3-C4 dialkylaminoalkyl, C1-C3 alkoxy, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl;
        R4 is halogen, —OR7 or —SC≡N;
        R5 is H or C1-C4 alkyl;
        R7 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cyanoalkyl, C2-C6 alkoxyalkyl, —CH(═O), —S(═O)2OM1 or —C(═W)R9;
        R9 is C1-C6 alkyl, C2-C6 alkoxyalkyl, C2-C6 alkylaminoalkyl, C3-C6 dialkylaminoalkyl, C2-C6 alkylthioalkyl, C1-C6 alkoxy or C1-C6 alkylthio;
        each U is independently O, S(═O)n, N(R10) or a direct bond;
        each V is independently C1-C6 alkylene, C2-C6 alkenylene, C3-C6 alkynylene, C3-C6 cycloalkylene or C3-C6 cycloalkenylene, wherein up to 3 carbon atoms are independently selected from C(═O), each optionally substituted with up to 5 substituents independently selected from halogen, cyano, nitro, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy;
        each T is independently cyano, N(R11a)(R11b), OR12 or S(═O)nR12;
        each R10 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl);
        each R11a and R11b is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl); or
        a pair of R11a and R11b are taken together with the nitrogen atom to which they are attached to form a form a 3- to 6-membered heterocyclic ring, the ring optionally substituted with up to 5 substituents independently selected from R13;
        each R12 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl);
        each R13 is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 alkoxy;
        W is O or S;
        M1 is K, Na or Li; and
        each n is independently 0, 1 or 2;
        provided that when Q2 is a phenyl ring which is not substituted with R3a at either ortho position, then Q1 is substituted by at least one R3a at an ortho position.
    
    


This invention is also directed to compounds of Formula 1A (including all stereoisomers), N-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides:




wherein

    
    
        Q1 is a phenyl ring substituted with 1 to 5 substituents independently selected from R3a;
        Q2 is a phenyl ring substituted with 1 to 5 substituents independently selected from R3a; or a 5- to 6-membered fully unsaturated heterocyclic ring, each ring containing ring members selected from carbon atoms and 1 to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon ring members are independently selected from C(═O) and C(═S), each ring optionally substituted with up to 5 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members;
        X is O, S(O)m, N(R6) or C(═O);
        R1 is C1-C2 alkyl, halomethyl, cyanomethyl or cyclopropyl;
        R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C2 haloalkyl, C2-C3 cyanoalkyl, C1-C2 hydroxyalkyl, cyclopropyl, halocyclopropyl, C2-C3 alkoxyalkyl, C1-C2 alkylthio, C1-C2 alkoxy or C1-C2 haloalkoxy;
        each R3a is independently halogen, cyano, hydroxy, nitro, amino, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C4-C6 alkylcycloalkyl, C4-C6 cycloalkylalkyl, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C3 alkylsulfinyl, C1-C3 haloalkylsulfinyl, C1-C3 alkylsulfonyl, C1-C3 haloalkylsulfonyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C3-C6 cycloalkoxy, C1-C3 alkylsulfonyloxy, C1-C3 haloalkylsulfonyloxy, C2-C4 alkylcarbonyloxy, C2-C4 alkylcarbonyl, C1-C3 alkylamino, C2-C4 dialkylamino, C2-C4 alkylcarbonylamino, —CH(═O), —NHCH(═O), —SF5, —SC≡N or —U—V-T;
        each R3b is independently cyano, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C3-C6 cycloalkyl, C2-C4 alkoxyalkyl, C2-C4 alkylaminoalkyl, C3-C4 dialkylaminoalkyl, C1-C3 alkoxy, C2-C4 alkylcarbonyl or C2-C4 alkoxycarbonyl;
        R6 is H, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 alkoxyalkyl, C2-C6 cyanoalkyl, NH2, —CH(═O), —OR7, —OS(═O)2M1, —S(═O)nR8 or —C(═W)R9;
        R7 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cyanoalkyl, C2-C6 alkoxyalkyl, —CH(═O), —S(═O)2OM1 or —C(═W)R9;
        R8 is C1-C6 alkyl or C1-C6 haloalkyl;
        R9 is C1-C6 alkyl, C2-C6 alkoxyalkyl, C2-C6 alkylaminoalkyl, C3-C6 dialkylaminoalkyl, C2-C6 alkylthioalkyl, C1-C6 alkoxy or C1-C6 alkylthio;
        each U is independently O, S(═O)n, N(R10) or a direct bond;
        each V is independently C1-C6 alkylene, C2-C6 alkenylene, C3-C6 alkynylene, C3-C6 cycloalkylene or C3-C6 cycloalkenylene, wherein up to 3 carbon atoms are independently selected from C(═O), each optionally substituted with up to 5 substituents independently selected from halogen, cyano, nitro, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy;
        each T is independently cyano, N(R11a)(R11b), OR12 or S(═O)nR12;
        each R10 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl);
        each R11a and R11b is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl); or
        a pair of R11a and R11b are taken together with the nitrogen atom to which they are attached to form a form a 3- to 6-membered heterocyclic ring, the ring optionally substituted with up to 5 substituents independently selected from R13;
        each R12 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl);
        each R13 is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 alkoxy;
        W is O or S;
        M1 is K, Na or Li;
        m is 0, 1 or 2; and
        each n is independently 0, 1 or 2;
    
    


provided that:

    
    
        (a) when Q2 is a phenyl ring which is not substituted with R3a at either ortho position, then Q1 is substituted by at least one R3a at an ortho position; and
        (b) the compound is other than 1-[2-[4-(2,4-dichlorobenzoyl)-1,3-dimethyl-1H-pyrazol-5-yl]phenyl]ethanone.
    
    


More particularly, this invention pertains to a compound selected from compounds of Formula 1 (including all stereoisomers), an N-oxide or a salt thereof; or a compound selected from compounds of Formula 1A (including all stereoisomers), an N-oxide or a salt thereof.
This invention also relates to a fungicidal composition comprising (a) a compound of the invention (i.e. in a fungicidally effective amount); and (b) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.
This invention also relates to a fungicidal composition comprising (a) a compound of the invention; and (b) at least one other fungicide (e.g., at least one other fungicide having a different site of action).
This invention further relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of the invention (e.g., as a composition described herein).


DETAILS OF THE INVENTION
As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains”, “containing,” “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.
The transitional phrase “consisting of” excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.
The transitional phrase “consisting essentially of” is used to define a composition, method or apparatus that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”.
Where applicants have defined an invention or a portion thereof with an open-ended term such as “comprising,” it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an invention using the terms “consisting essentially of” or “consisting of.”
Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).
Also, the indefinite articles “a” and “an” preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.
As referred to in the present disclosure and claims, “plant” includes members of Kingdom Plantae, particularly seed plants (Spermatopsida), at all life stages, including young plants (e.g., germinating seeds developing into seedlings) and mature, reproductive stages (e.g., plants producing flowers and seeds). Portions of plants include geotropic members typically growing beneath the surface of the growing medium (e.g., soil), such as roots, tubers, bulbs and corms, and also members growing above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds.
As referred to herein, the term “seedling”, used either alone or in a combination of words means a young plant developing from the embryo of a seed.
As referred to herein, the term “broadleaf” used either alone or in words such as “broadleaf crop” means dicot or dicotyledon, a term used to describe a group of angiosperms characterized by embryos having two cotyledons.
As used herein, the term “alkylating agent” refers to a chemical compound in which a carbon-containing radical is bound through a carbon atom to a leaving group such as halide or sulfonate, which is displaceable by bonding of a nucleophile to said carbon atom. Unless otherwise indicated, the term “alkylating agent” does not limit the carbon-containing radical to alkyl; the carbon-containing radicals in alkylating agents include the variety of carbon-bound substituent radicals specified, for example, for R1 and Q1.
In the above recitations, the term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain or branched alkyl such as methyl, ethyl, n-propyl, i-propyl, or the different butyl, pentyl or hexyl isomers. “Alkenyl” includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. “Alkynyl” includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. “Alkynyl” can also include moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. “Alkylene” denotes a straight-chain or branched alkanediyl. Examples of “alkylene” include CH2, CH2CH2, CH(CH3), CH2CH2CH2, CH2CH(CH3), and the different butylene, pentylene or hexylene isomers. “Alkenylene” denotes a straight-chain or branched alkenediyl containing one olefinic bond. Examples of “alkenylene” include CH═CH, CH2CH═CH and CH═C(CH3). “Alkynylene” denotes a straight-chain or branched alkynediyl containing one triple bond. Examples of “alkynylene” include CH2C≡C, C≡CCH2, and the different butynylene, pentynylene or hexynylene isomers.
The term “cycloalkyl” denotes a saturated carbocyclic ring consisting of 3 to 7 carbon atoms linked to one another by single bonds. Examples of “cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “alkylcycloalkyl” denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, i-propylcyclopropyl and methylcyclopentyl. The term “cycloalkylalkyl” denotes cycloalkyl substitution on an alkyl moiety. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups. The term “cycloalkylcycloalkyl” denotes cycloalkyl substitution on another cycloalkyl ring, wherein each cycloalkyl ring independently has from 3 to 7 carbon atom ring members. Examples of cycloalkylcycloalkyl include cyclopropylcyclopropyl (such as 1,1′-bicyclopropyl-1-yl, 1,1′-bicyclopropyl-2-yl), cyclohexylcyclopentyl (such as 4-cyclopentylcyclohexyl) and cyclohexylcyclohexyl (such as 1,1′-bicyclohexyl-1-yl), and the different cis- and trans-cycloalkylcycloalkyl isomers, (such as (1R,2S)-1,1′-bicyclopropyl-2-yl and (1R,2R)-1,1′-bicyclopropyl-2-yl). The term “cycloalkoxy” denotes cycloalkyl attached to and linked through an oxygen atom including, for example, cyclopentyloxy and cyclohexyloxy. “Cycloalkylcarbonyl” denotes cycloalkyl bonded to a C(═O) group including, for example, cyclopropylcarbonyl and cyclopentylcarbonyl. The term “cycloalkoxycarbonyl” means cycloalkoxy bonded to a C(═O) group, for example, cyclopropyloxycarbonyl and cyclopentyloxycarbonyl. The term “cycloalkylene” denotes a cycloalkanediyl ring. Examples of “cycloalkylene” include cyclopropylene, cyclobutylene, cyclopentylene and cyclohexylene. The term “cycloalkenylene” denotes a cycloalkenediyl ring containing one olefinic bond. Examples of “cycloalkenylene” include cyclopropylene, cyclobutylene and cyclopentylene.
“Alkoxy” includes, for example, methoxy, ethoxy, n-propyloxy, i-propyloxy and the different butoxy, pentoxy and hexyloxy isomers. “Alkylamino” includes an NH radical substituted with straight-chain or branched alkyl. Examples of “alkylamino” include CH3CH2NH, CH3CH2CH2NH and (CH3)2CHCH2NH. “Alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. “Alkylsulfinyl” includes both enantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl” include CH3S(═O), CH3CH2S(═O), CH3CH2CH2S(═O), (CH3)2CHS(═O), and the different ethylsulfinyl or propylsulfinyl isomers. Examples of “alkylsulfonyl” include CH3S(═O)2, CH3CH2S(═O)2, CH3CH2CH2S(═O)2, (CH3)2CHS(═O)2, and the different ethylsulfonyl or propylsulfonyl isomers. The term “alkylsulfonyloxy” denotes alkylsulfonyl attached to and linked through an oxygen atom. Examples of “alkylsulfonyloxy” include CH3S(═O)2O and CH3CH2S(═O)2O.
“Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2 and CH3CH2OCH2CH2. “Alkylthioalkyl” denotes alkylthio substitution on alkyl. Examples of “alkylthioalkyl” include CH3SCH2, CH3SCH2CH2, CH3CH2SCH2, CH3CH2CH2CH2SCH2 and CH3CH2SCH2CH2. “Alkylaminoalkyl” denotes alkylamino substitution on alkyl. Examples of “alkylaminoalkyl” include CH3NHCH2, CH3NHCH2CH2, CH3CH2NHCH2, CH3CH2CH2CH2NHCH2 and CH3CH2NHCH2CH2. Examples of “dialkylaminoalkyl” include (CH3CH)2NCH2 and CH3CH2(CH3)NCH2CH2.
“Cyanoalkyl” denotes an alkyl group substituted with one cyano group. Examples of “cyanoalkyl” include NCCH2, (also referred to herein as “cyanomethyl”) NCCH2CH2 and CH3CH(CN)CH2. “Hydroxyalkyl” denotes an alkyl group substituted with one hydroxy group. Examples of “hydroxyalkyl” include HOCH2, (also referred to herein as “hydroxymethyl”) and HOCH2CH2.
“Alkylcarbonyl” denotes a straight-chain or branched alkyl group bonded to a C(═O) moiety. Examples of “alkylcarbonyl” include CH3C(═O), CH3CH2CH2C(═O) and (CH3)2CHC(═O). Examples of “alkoxycarbonyl” include CH3OC(═O), CH3CH2OC(═O), CH3CH2CH2OC(═O), (CH3)2CHOC(═O) and the different pentoxy- or hexoxycarbonyl isomers. The term “alkylcarbonyloxy” denotes straight-chain or branched alkyl bonded to a C(═O)O moiety. Examples of “alkylcarbonyloxy” include CH3CH2C(═O)O and (CH3)2CHC(═O)O. “Alkoxy(thiocarbonyl)” denotes a straight-chain or branched alkoxy group bonded to a C(═S) moiety. Examples of “alkoxy(thiocarbonyl)” include CH3OC(═S), CH3CH2CH2OC(═S) and (CH3)2CHOC(═S). “(Alkylthio)carbonyl” denotes a straight-chain or branched alkylthio group bonded to a C(═O) moiety. Examples of “(alkylthio)carbonyl” include CH3SC(═O), CH3CH2CH2SC(═O) and (CH3)2CHSC(═O). The term “alkylcarbonylamino” denotes alkyl bonded to a C(═O)NH moiety. Examples of “alkylcarbonylamino” include CH3CH2C(═O)NH and CH3CH2CH2C(═O)NH.
The term “halogen”, either alone or in compound words such as “halomethyl”, “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” includes fluorine, chlorine, bromine or iodine. Further, when used in compound words such as “halomethyl”, “haloalkyl”, or when used in descriptions such as “alkyl substituted with halogen” said methyl or alkyl may be partially or fully substituted with halogen atoms which may be the same or different. Examples of “haloalkyl” or “alkyl substituted with halogen” include F3C, ClCH2, CF3CH2 and CF3CCl2. The terms “haloalkoxy”, “haloalkylthio”, “haloalkylsulfinyl” “haloalkylsulfonyl” and “halocycloalkyl” are defined analogously to the term “haloalkyl”. Examples of “haloalkoxy” include CF3O, CCl3CH2O, F2CHCH2CH2O and CF3CH2O. Examples of “haloalkylthio” include CF3S, CCl3S and CF3CH2S. Examples of “haloalkylsulfinyl” include CF3S(═O), CCl3S(═O), CF3CH2S(═O) and CF3CF2S(═O). Examples of “haloalkylsulfonyl” include CF3S(═O)2, CCl3S(═O)2, CF3CH2S(═O)2 and CF3CF2S(═O)2. Examples of “halocycloalkyl” include chlorocyclopropyl, fluorocyclobutyl and chlorocyclohexyl.
The total number of carbon atoms in a substituent group is indicated by the “Ci-Cj” prefix where i and j are numbers from 1 to 8. For example, C1-C4 alkylsulfonyl designates methylsulfonyl through butylsulfonyl; C2 alkoxyalkyl designates CH3OCH2; C3 alkoxyalkyl designates, for example, CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl designates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples including CH3CH2CH2OCH2 and CH3CH2OCH2CH2.
The term “unsubstituted” in connection with a group such as a ring means the group does not have any substituents other than its one or more attachments to the remainder of Formula 1 or Formula 1A. The term “optionally substituted” means that the number of substituents can be zero. Unless otherwise indicated, optionally substituted groups may be substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom. Commonly, the number of optional substituents (when present) range from 1 to 3. As used herein, the term “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted” or with the term “(un)substituted.”
The number of optional substituents may be restricted by an expressed limitation. For example, the phrase “optionally substituted with up to 3 substituents independently selected from R3a on carbon atom ring members” means that 0, 1, 2 or 3 substituents can be present (if the number of potential connection points allows). Similarly, the phrase “optionally substituted with up to 5 substituents independently selected from R3a on carbon atom ring members” means that 0, 1, 2, 3, 4 or 5 substituents can be present if the number of available connection points allows. When a range specified for the number of substituents (e.g., r being an integer from 0 to 4 in Exhibit 1) exceeds the number of positions available for substituents on a ring (e.g., only 2 positions are available for (Rv)r on A-11 in Exhibit 1), the actual higher end of the range is recognized to be the number of available positions.
When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents (e.g., (Rv)r wherein r is 1, 2, 3 or 4 in Exhibit 1). When a variable group is shown to be optionally attached, for example) (Rv)r wherein r may be 0, then hydrogen may be at the position even if not recited in the variable group definition. When one or more positions on a group are said to be “not substituted” or “unsubstituted”, then hydrogen atoms are attached to take up any free valency.
Unless otherwise indicated, a “ring” as a component of Formula 1 or Formula 1A (e.g., Q2) is carbocyclic (e.g., phenyl) or heterocyclic (e.g., pyridinyl). The term “ring member” refers to an atom (e.g., C, O, N or S) or other moiety (e.g., C(═O) or C(═S)) forming the backbone of a ring.
The term “nonaromatic” includes rings that are fully saturated as well as partially or fully unsaturated, provided that none of the rings are aromatic. The term “aromatic” indicates that each of the ring atoms of a fully unsaturated ring is essentially in the same plane and has a p-orbital perpendicular to the ring plane, and that (4n+2) π electrons, where n is a positive integer, are associated with the ring to comply with Hückel's rule. The term “fully unsaturated heterocyclic ring” includes both aromatic and nonaromatic fully unsaturated heterocycles.
The terms “carbocyclic ring” or “carbocycle” denote a ring wherein the atoms forming the ring backbone are selected only from carbon. When a fully unsaturated carbocyclic ring satisfies Hückel's rule, then said ring is also called an “aromatic carbocyclic ring”. The term “saturated carbocyclic ring” refers to a ring having a backbone consisting of carbon atoms linked to one another by single bonds; unless otherwise specified, the remaining carbon valences are occupied by hydrogen atoms.
The terms “heterocyclic ring” or “heterocycle” denote rings in which at least one atom forming the ring backbone is not carbon (e.g., N, O or S). Typically a heterocyclic ring contains no more than 3 N atoms, no more than 2 O atoms and no more than 2 S atoms. Unless otherwise indicated, a heterocyclic ring can be a saturated, partially unsaturated or fully unsaturated ring. When a fully unsaturated heterocyclic ring satisfies Hückel's rule, then said ring is also called a “heteroaromatic ring” or “aromatic heterocyclic ring”. Unless otherwise indicated, heterocyclic rings can be attached through any available carbon or nitrogen by replacement of a hydrogen on said carbon or nitrogen.
In the context of the present invention, when an instance of Q1 or Q2 comprises a phenyl or a 6-membered fully unsaturated heterocyclic ring, the ortho, meta and para positions of each ring is relative to the connection of the ring to the remainder of Formula 1.
As noted above, Q1 and Q2 can be, inter alia, phenyl optionally substituted with 1 to 5 substituents independently selected from R3a. In the circumstances when an instance of Q1 or Q2 comprises a phenyl ring substituted with 4 or less substituents independently selected from R3a, then hydrogen atoms are attached to take up any free valency.
As noted above, Q2 attached to Formula 1 or Formula 1A is, inter alia, a 5- to 6-membered fully unsaturated heterocyclic ring, each ring containing ring members selected from carbon atoms and up to 3 heteroatoms independently selected from up to 2 O, up to 2 S and up to 3 N atoms, wherein up to 2 carbon atom ring members are independently selected from C(═O) and C(═S), each ring optionally substituted with up to 5 substituents independently selected from any substituent as defined in the Summary of the Invention for Q2 (i.e. R3a on carbon atom ring members and R3b on nitrogen atom ring members). As the substituents are optional, 0 to 5 substituents may be present, limited only by the number of available points of attachment. In this definition the ring members selected from up to 2 O, up to 2 S and up to 3 N atoms are optional, provided at least one ring member is not carbon (e.g., N, O or S). The nitrogen atom ring members may be oxidized as N-oxides, because compounds relating to Formula 1 or Formula 1A also include N-oxide derivatives. The up to 2 carbon atom ring members selected from C(═O) and C(═S) are in addition to the up to 3 heteroatoms selected from up to 2 O, up to 2 S and up to 3 N atoms. Examples of a 5- to 6-membered fully unsaturated heterocyclic ring include the rings A-1 through A-31 illustrated in Exhibit 1. The variable Rv, in Exhibit 1, is any substituent as defined in the Summary of the Invention for Q2 (i.e. R3a on carbon atom ring members and R3b on nitrogen atom ring members) and r is an integer from 0 to 4, limited by the number of available positions on each depicted ring.
Although Rv groups are shown in the structures A-1 through A-31, it is noted that they do not need to be present since they are optional substituents. The nitrogen atoms that require substitution to fill their valence are substituted with H or Rv. Note that when the attachment point between (Rv)r and the depicted ring is illustrated as floating, (Rv)r can be attached to any available carbon or nitrogen atom of the depicted ring. Note that when the attachment point of the depicted ring to the remainder of Formula 1 or 1A is illustrated as floating, the ring can be attached to the remainder of Formula 1 or 1A through any available carbon or nitrogen of the depicted ring by replacement of a hydrogen atom.













A wide variety of synthetic methods are known in the art to enable preparation of aromatic heterocyclic rings; for extensive reviews see the eight volume set of Comprehensive Heterocyclic Chemistry, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984 and the twelve volume set of Comprehensive Heterocyclic Chemistry II, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996.
Compounds of this invention can exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers and geometric isomers. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. The compounds of the invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form. Of note are atropisomers, which are stereoisomeric conformations of a molecule that occur when rotation about a single bond is restricted such that interconversion is slow enough to allow separation. Restricted rotation of one or more bonds is a result of steric interaction with other parts of the molecule. In the present invention, compounds of Formula 1 and Formula 1A can exhibit atropisomerism when the energy barrier to free rotation around a single unsymmetrical bond is sufficiently high that separation of isomers is possible. Atropisomerism is defined to exist where the isomers have a half-life of at least 1000 seconds, which is a free energy barrier of at least about 22.3 kcal mol−1 at about 20° C. (Oki, Topics in Stereochemistry, Vol. 14, John Wiley & Sons, Inc., 1983). One skilled in the art will appreciate that one atropisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other atropisomer or when separated from the other atropisomer. Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said atropisomers. Further description of atropisomers can be found in March, Advanced Organic Chemistry, 101-102, 4th Ed. 1992; Oki, Topics in Stereochemistry, Vol. 14, John Wiley & Sons, Inc., 1983 and Gawronski et al, Chirality 2002, 14, 689-702. This invention includes compounds that are enriched compared to the racemic mixture in an atropisomer of Formula 1 or Formula 1A. Also included are the essentially pure atropisomers of compounds of Formula 1 or Formula 1A.
Also of note are enantiomers of Formula 1 and Formula 1A. For example, two possible enantiomers of Formula 1 are depicted below as Formula 1′ and Formula 1′′ wherein the chiral center is identified with an asterisk (*) and the substituents R4 and R5 are not identical.




Molecular depictions drawn herein follow standard conventions for depicting stereochemistry. To indicate stereoconfiguration, bonds rising from the plane of the drawing and towards the viewer are denoted by solid wedges wherein the broad end of the wedge is attached to the atom rising from the plane of the drawing towards the viewer. Bonds going below the plane of the drawing and away from the viewer are denoted by dashed wedges wherein the narrow end of the wedge is attached to the atom further away from the viewer. Constant width lines indicate bonds with a direction opposite or neutral relative to bonds shown with solid or dashed wedges; constant width lines also depict bonds in molecules or parts of molecules in which no particular stereoconfiguration is intended to be specified.
This invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1′ and 1′′. In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1 or 1A. Also included are the essentially pure enantiomers of compounds of Formula 1 or 1A, for example, Formula 1′ and Formula 1′′.
When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess (“ee”), which is defined as (2x−1)·100%, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20% corresponds to a 60:40 ratio of enantiomers).
Of note are compositions of this invention having at least a 50%, or at least a 75%, or at least a 90%, or at least a 94% enantiomeric excess of an isomer. Of particular note are enantiomerically pure embodiments.
Compounds of Formula 1 or Formula 1A can comprise additional chiral centers. For example, substituents such as R3a may themselves contain chiral centers.
One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of the compounds of Formula 1 and Formula 1A are useful for control of plant diseases caused by fungal plant pathogens (i.e. are agriculturally suitable). The salts of the compounds of Formula 1 and Formula 1A include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids.
Compounds selected from Formula 1 or Formula 1A, stereoisomers, N-oxides, and salts thereof, typically exist in more than one form, therefore Formula 1 and Formula 1A includes all crystalline and non-crystalline forms of the compounds that Formula 1 and Formula 1A represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term “polymorph” refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by Formula 1 or Formula 1A can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula 1 or Formula 1A. Preparation and isolation of a particular polymorph of a compound represented by Formula 1 or Formula 1A can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures.

    
    
        Embodiment s of the present invention as described in the Summary of the Invention include those described below. In the following Embodiments, Formula 1 includes stereoisomers, N-oxides and salts thereof, and reference to “a compound of Formula 1” includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments.
        Embodiment 1. A compound of Formula 1 wherein Q1 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a.
        Embodiment 2. A compound of Embodiment 1 wherein Q1 is a phenyl ring substituted with 2 to 3 substituents independently selected from R3a.
        Embodiment 3. A compound of Embodiment 1 wherein Q1 is a phenyl ring substituted with 1 substituent independently selected from R3a.
        Embodiment 4. A compound of Embodiment 1 wherein Q1 is a phenyl ring substituted with 2 substituents independently selected from R3a.
        Embodiment 5. A compound of Embodiment 1 wherein Q1 is a phenyl ring substituted with 3 substituents selected from R3a.
        Embodiment 6.A compound of Formula 1 or any one of Embodiments 1 through 5 wherein Q1 is a phenyl ring substituted with at least one R3a substituent attached at an ortho position (relative to the connection of the Q1 ring to the remainder of Formula 1).
        Embodiment 6a. A compound of Formula 1 or any one of Embodiments 1 through 6 wherein Q1 is a phenyl ring substituted with two R3a substituents attached at an ortho position and the para position (relative to the connection of the Q1 ring to the remainder of Formula 1).
        Embodiment 6b. A compound of Formula 1 or any one of Embodiments 1 through 6 wherein Q1 is a phenyl ring substituted with two R3a substituents attached at both ortho positions (relative to the connection of the Q1 ring to the remainder of Formula 1).
        Embodiment 6c. A compound of Formula 1 or any one of Embodiments 1 through 6 wherein Q1 is a phenyl ring substituted with three R3a substituents attached at both ortho positions and the para position (relative to the connection of the Q1 ring to the remainder of Formula 1).
        Embodiment 7. A compound of Formula 1 or any one of Embodiments 1 through 6c wherein Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl or pyrimidinyl ring, each ring optionally substituted with up to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members.
        Embodiment 8. A compound of Embodiment 7 wherein Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl or pyridinyl ring, each ring optionally substituted with 1 to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members.
        Embodiment 9. A compound of Embodiment 8 wherein Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a.
        Embodiment 9a. A compound of Embodiment 9 wherein Q2 is a phenyl ring substituted with 2 to 3 substituents independently selected from R3a.
        Embodiment 9b. A compound of Embodiment 9 wherein Q2 is a phenyl ring substituted with 1 substituent independently selected from R3a.
        Embodiment 9c. A compound of Embodiment 9 wherein Q2 is a phenyl ring substituted with 2 substituents independently selected from R3a.
        Embodiment 9d. A compound of Embodiment 9 wherein Q2 is a phenyl ring substituted with 3 substituents independently selected from R3a.
        Embodiment 9e. A compound of Formula 1 or any one of Embodiments 1 through 9 wherein Q2 is a phenyl ring substituted with two R3a substituents attached at an ortho position and the para position (relative to the connection of the Q2 ring to the remainder of Formula 1).
        Embodiment 9f. A compound of Formula 1 or any one of Embodiments 1 through 9 wherein Q2 is a phenyl ring substituted with two R3a substituents attached at both ortho positions (relative to the connection of the Q2 ring to the remainder of Formula 1).
        Embodiment 9g. A compound of Formula 1 or any one of Embodiments 1 through 9 wherein Q2 is a phenyl ring substituted with three R3a substituents attached at both ortho positions and the para position (relative to the connection of the Q2 ring to the remainder of Formula 1).
        Embodiment 10. A compound of Embodiment 8 wherein Q2 is a pyridinyl ring optionally substituted with up to 3 substituents independently selected from R3a.
        Embodiment 11. A compound of Embodiment 10 wherein Q2 is a pyridinyl ring substituted with 1 to 3 substituents independently selected from R3a.
        Embodiment 12. A compound of Formula 1 or any one of Embodiments 1 through 11 wherein when Q2 is a 6-membered fully unsaturated heterocyclic ring (e.g., pyridinyl, pyridazinyl, pyrazinyl or pyrimidinyl), then Q2 is substituted with at least one R3a substituent attached at an ortho position (relative to the connection of the Q2 ring to the remainder of Formula 1).
        Embodiment 13. A compound of Formula 1 or any one of Embodiments 1 through 12 wherein when Q1 and Q2 are each a phenyl substituted with 1 to 3 substituents independently selected from R3a, then one ring is substituted with 2 to 3 substituents and the ring is substituted with 1 to 3 substituents.
        Embodiment 14. A compound of Formula 1 or any one of Embodiments 1 through 12 wherein when Q1 and Q2 are each a phenyl ring substituted with 1 to 3 substituents independently selected from R3a, then one ring is substituted with 2 to 3 substituents and the other ring is substituted with 1 to 2 substituents.
        Embodiment 14a. A compound of Formula 1 or any one of Embodiments 1 through 12 wherein when Q1 and Q2 are each a phenyl ring substituted with 1 to 3 substituents independently selected from R3a, then one ring is substituted with 3 substituents and the other ring substituted with 2 substituents.
        Embodiment 14b. A compound of Formula 1 or any one of Embodiments 1 through 12 wherein Q1 and Q2 are both a phenyl ring substituted with 2 substituents independently selected from R3a.
        Embodiment 15. A compound of Formula 1 or any one of Embodiments 1 through 14b wherein R1 is C1-C2 alkyl, —CH2F, —CH2Cl or cyclopropyl.
        Embodiment 16. A compound of Embodiment 15 wherein R1 is methyl, —CH2F or —CH2Cl.
        Embodiment 17. A compound of Embodiment 16 wherein R1 is methyl.
        Embodiment 18. A compound of Formula 1 or any one of Embodiments 1 through 17 wherein R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, halomethyl, cyanomethyl, hydroxymethyl, C2-C3 alkoxyalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
        Embodiment 18a. A compound of Embodiment 18 wherein R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
        Embodiment 18b. A compound of Embodiment 18a wherein R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl or methoxy.
        Embodiment 19. A compound of Embodiment 18b wherein R2 is halogen, cyano, methyl, halomethyl or methoxy.
        Embodiment 20. A compound of Embodiment 19 wherein R2 is Br, Cl, F, cyano, methyl or methoxy.
        Embodiment 20a. A compound of Embodiment 20 wherein R2 is Br, Cl, methyl or methoxy.
        Embodiment 20b. A compound of Embodiment 20a wherein R2 is Br, Cl or methoxy.
        Embodiment 21. A compound of Embodiment 20a wherein R2 is methyl.
        Embodiment 22. A compound of Formula 1 or any one of Embodiments 1 through 21 wherein each R3a is independently halogen, cyano, C1-C2 alkyl, C1-C2 haloalkyl, cyclopropyl, C1-C2 alkoxy, C1-C2 alkylthio, C2-C3 alkylcarbonyl or —U—V-T.
        Embodiment 23. A compound of Embodiment 22 wherein each R3a is independently halogen, cyano, methyl, halomethyl, cyclopropyl, methoxy, methylthio, methylcarbonyl or —U—V-T.
        Embodiment 24. A compound of Embodiment 23 wherein each R3a is independently halogen, cyano, methyl, halomethyl or methoxy.
        Embodiment 25. A compound of Embodiment 24 wherein each R3a is independently halogen, cyano or methoxy.
        Embodiment 26. A compound of Embodiment 25 wherein each R3a is independently Br, Cl, F, cyano or methoxy.
        Embodiment 27. A compound of Embodiment 26 wherein each R3a is independently Cl or F.
        Embodiment 28. A compound of Formula 1 or any one of Embodiments 1 through 27 wherein each U is independently O, N(R10) or a direct bond.
        Embodiment 29. A compound of Embodiment 28 wherein each R10 is independently H or methyl.
        Embodiment 30. A compound of Embodiment 28 wherein each U is independently O, NH or a direct bond.
        Embodiment 31. A compound of Formula 1 or any one of Embodiments 1 through 30 wherein each V is independently C1-C4 alkylene, wherein up to 1 carbon atom is selected from C(═O).
        Embodiment 32. A compound of Embodiment 31 wherein each V is independently C1-C3 alkylene.
        Embodiment 33. A compound of Formula 1 or any one of Embodiments 1 through 32 wherein each T is independently N(R11a)(R11b) or OR12.
        Embodiment 34. A compound of Formula 1 or any one of Embodiments 1 through 33 wherein each R11a and R11b is independently H, C1-C6 alkyl or C1-C6 haloalkyl.
        Embodiment 35. A compound of Embodiment 34 wherein each R11a and R11b is independently H or methyl.
        Embodiment 36. A compound of Formula 1 or any one of Embodiments 1 through 35 wherein each R12 is independently H, C1-C6 alkyl or C1-C6 haloalkyl.
        Embodiment 37. A compound Embodiment 36 wherein each R12 is independently H, methyl or halomethyl.
        Embodiment 38. A compound of Formula 1 or any one of Embodiments 1 through 37 wherein each R3b is independently cyano, C1-C2 alkyl, cyclopropyl or C2-C3 alkoxyalkyl.
        Embodiment 39. A compound of Embodiment 38 wherein each R3b is methyl.
        Embodiment 40. A compound of Formula 1 or any one of Embodiments 1 through 39 wherein R4 is halogen or —SC≡N.
        Embodiment 41. A compound of Embodiment 40 wherein R4 is —SC≡N.
        Embodiment 42. A compound of Embodiment 40 wherein R4 is halogen.
        Embodiment 43. A compound of Embodiment 42 wherein R4 is Br, Cl or F.
        Embodiment 44. A compound of Formula 1 or any one of Embodiments 1 through 39 wherein R4 is —OR7.
        Embodiment 45. A compound of Formula 1 or any one of Embodiments 1 through 44 wherein R4 is Br, Cl, F, —OR7 or —SC≡N.
        Embodiment 46. A compound of Embodiment 45 wherein R4 is Br, Cl, F or —OR7.
        Embodiment 47. A compound of Formula 1 or any one of Embodiments 1 through 46 wherein R5 is H or methyl.
        Embodiment 48. A compound of Embodiment 47 wherein R5 is H.
        Embodiment 49. A compound of Formula 1 or any one of Embodiments 1 through 48 wherein R7 is H, C1-C3 alkyl, C2-C6 alkenyl, C1-C3 haloalkyl, cyclopropyl, C2-C3 cyanoalkyl, C2-C6 alkoxyalkyl, —S(═O)2OM1 or —C(═W)R9.
        Embodiment 50. A compound of Embodiment 49 wherein R7 is H, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C2-C3 cyanoalkyl, —S(═O)2OM1 or —C(═W)R9.
        Embodiment 51. A compound of Embodiment 50 wherein R7 is H, C1-C3 alkyl, C1-C3 haloalkyl, —S(═O)2OM1 or —C(═W)R9.
        Embodiment 52. A compound of Embodiment 51 wherein R7 is H, methyl or —C(═W)R9.
        Embodiment 53. A compound Embodiment 52 wherein R7 is H or methyl.
        Embodiment 54. A compound Embodiment 53 wherein R7 is H.
        Embodiment 55. A compound Formula 1 or any one of Embodiments 1 through 54 wherein R9 is methyl or methoxy.
        Embodiment 56. A compound of Embodiment 55 wherein R9 is methyl.
        Embodiment 57. A compound of Formula 1 or any one of Embodiments 1 through 56 wherein W is O.
        Embodiment 58. A compound of Formula 1 or any one of Embodiments 1 through 57 wherein M1 is Na or K.
        Embodiment 59. A compound of Embodiment 58 wherein M1 is Na.
    
    


Embodiment s of this invention, including Embodiments 1-59 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula 1 but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula 1. In addition, embodiments of this invention, including Embodiments 1-59 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.
Combinations of Embodiments 1-59 are illustrated by:

    
    
        Embodiment A. A compound of Formula 1 wherein
        
            Q1 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a;
            Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl or pyrimidinyl ring, each ring optionally substituted with up to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members;
            R1 is C1-C2 alkyl, —CH2F, —CH2Cl or cyclopropyl;
            R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, halomethyl, cyanomethyl, hydroxymethyl, C2-C3 alkoxyalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy;
            each R3a is independently halogen, cyano, C1-C2 alkyl, C1-C2 haloalkyl, cyclopropyl, C1-C2 alkoxy, C1-C2 alkylthio, C2-C3 alkylcarbonyl or —U—V-T;
            each R3b is independently cyano, C1-C2 alkyl, cyclopropyl or C2-C3 alkoxyalkyl;
            R4 is Br, Cl, F, —OR7 or —SC≡N;
            R5 is H or methyl;
            R7 is H, C1-C3 alkyl, C2-C6 alkenyl, C1-C3 haloalkyl, cyclopropyl, C2-C3 cyanoalkyl, C2-C6 alkoxyalkyl, —S(═O)2OM1 or —C(═W)R9;
            R9 is methyl or methoxy;
            each U is independently O, N(R10) or a direct bond;
            each R10 is independently H or methyl;
            each V is independently C1-C3 alkylene, wherein up to 1 carbon atom is selected from C(═O);
            each T is independently N(R11a)(R11b) or OR12;
            each R11a and R11b is independently H or methyl;
            each R12 is independently H, C1-C6 alkyl or C1-C6 haloalkyl;
            W is O; and
            M1 is Na or K.
        
        
        Embodiment B. A compound of Embodiment A wherein
        
            Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl or pyridinyl ring, each ring optionally substituted with 1 to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members;
            R1 is methyl, —CH2F or —CH2Cl;
            R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl, C1-C2 alkoxy or C1-C2 haloalkoxy;
            each R3a is independently halogen, cyano, methyl, halomethyl, cyclopropyl, methoxy, methylthio, methylcarbonyl or —U—V-T;
            each R3b is methyl;
            R4 is Br, Cl, F or —OR7;
            R7 is H, C1-C3 alkyl, C1-C3 haloalkyl, —S(═O)2OM1 or —C(═W)R9;
            each U is independently O, NH or a direct bond;
            each V is C1-C3 alkylene; and
            each R12 is independently H, methyl or halomethyl.
        
        
        Embodiment C. A compound of Embodiment B wherein
        
            Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a;
            R1 is methyl;
            R2 is halogen, cyano, methyl, halomethyl or methoxy;
            each R3a is independently halogen, cyano, methyl, halomethyl or methoxy;
            R4 is —OR7;
            R5 is H;
            R7 is H, methyl or —C(═W)R9; and
            R9 is methyl.
        
        
        Embodiment D. A compound of Embodiment C wherein
        
            R2 is Br, Cl, methyl or methoxy;
            each R3a is independently halogen, cyano or methoxy; and
            R7 is H.
        
        
        Embodiment E. A compound of Embodiment D wherein
        
            R2 methyl;
            each R3a is independently Br, Cl, F, cyano or methoxy; and
            one of Q1 and Q2 is substituted with 2 to 3 substituents and the other of Q1 and Q2 is substituted with 1 to 2 substituents.
        
        
    
    


Specific embodiments include compounds of Formula 1 selected from the group consisting of:

    α-(2-chloro-4-fluorophenyl)-5-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    (αS)-α-(2-chloro-4-fluorophenyl)-5-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    (αR)-α-(2-chloro-4-fluorophenyl)-5-(2-chloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    α-(2-chloro-4-fluorophenyl)-5-(2,6-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    (αS)-α-(2-chloro-4-fluorophenyl)-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    (αR)-α-(2-chloro-4-fluorophenyl)-5-(2,6-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    α,5-bis(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    5-(2-bromophenyl)-α-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    α-(2-chloro-4-fluorophenyl)-5-(2,6-dichlorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    α-(2-chloro-4-fluorophenyl)-1,3-dimethyl-5-(2,4,6-trifluorophenyl)-1H-pyrazole-4-methanol;
    α-(2-bromo-4-fluorophenyl)-5-(2,6-dichlorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    α-(2-bromo-4-fluorophenyl)-5-(2-chloro-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    3-bromo-5-(2-chloro-4-fluorophenyl)-α-(2,4-difluorophenyl)-1-methyl-1H-pyrazole-4-methanol;
    5-(2-chloro-4-fluorophenyl)-α-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    5-(2,4-dichlorophenyl)-α-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    5-(2-chloro-6-fluorophenyl)-α-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    α-(2,4-difluorophenyl)-5-(2,6-dichlorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    4-[4-[(2,4-difluorophenyl)hydroxymethyl]-1,3-dimethyl-1H-pyrazol-5-yl]-3,5-difluorobenzonitrile;
    5-(2-chloro-6-fluorophenyl)-α-(2,4-dichlorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    5-(2-chloro-6-fluorophenyl)-α-(2,6-dichlorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-α-(2,4,6-trifluorophenyl)-1H-pyrazole-4-methanol;
    5-(2-bromo-4-fluorophenyl)-1,3-dimethyl-α-(2,4,6-trifluorophenyl)-1H-pyrazole-4-methanol;
    5-(2-chloro-6-fluorophenyl)-α-(2-chloro-4-methoxyphenyl)-1,3-dimethyl-1H-pyrazole-4-methanol;
    3-bromo-α-(2-chloro-4-fluorophenyl)-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-4-methanol;
    3-chloro-α-(2-chloro-4-fluorophenyl)-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-4-methanol;
    α-(2-chloro-4-fluorophenyl)-5-(2,6-difluorophenyl)-3-methoxy-1-methyl-1H-pyrazole-4-methanol;
    α-(2-chloro-4-fluorophenyl)-5-(2-chloro-6-fluorophenyl)-3-methoxy-1-methyl-1H-pyrazole-4-methanol;
    5-(2,6-difluorophenyl)-α-(4-fluoro-2-methylphenyl)-3-methoxy-1-methyl-1H-pyrazole-4-methanol;
    α-(2-chloro-4-methoxphenyl)-5-(2,6-difluorophenyl)-3-methoxy-1-methyl-1H-pyrazole-4-methanol;
    5-(2,6-difluorophenyl)-3-methoxy-α-(4-methoxy-2-methylphenyl)-1-methyl-1H-pyrazole-4-methanol;
    5-(2-chloro-6-fluorophenyl)-α-(2-chloro-4-methoxyphenyl)-3-methoxy-1-methyl-1H-pyrazole-4-methanol;
    3-chloro-5-(2,6-difluorophenyl)-α-(4-methoxy-2-methylphenyl)-1-methyl-1H-pyrazole-4-methanol;
    3-chloro-5-(2,6-difluorophenyl)-α-(2-fluoro-4-methoxyphenyl)-1-methyl-1H-pyrazole-4-methanol;
    3-chloro-α-(2-chloro-4-methoxyphenyl)-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-4-methanol; and
    3-bromo-5-(2,6-difluorophenyl)-α-(4-methoxy-2-methylphenyl)-1-methyl-1H-pyrazole-4-methanol.


As noted in the Summary of the Invention, this invention is also directed to a compound of Formula 1A. Embodiments of Formula 1A include those described in the Summary of the Invention as well as the Embodiments below. In the following Embodiments, Formula 1A includes stereoisomers, N-oxides and salts thereof, and reference to “a compound of Formula 1A” includes the definitions of substituents specified in the Summary of the Invention unless further defined in the Embodiments.

    
    
        Embodiment A1. A compound of Formula 1A wherein Q1 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a.
        Embodiment A2. A compound of Embodiment A1 wherein Q1 is a phenyl ring substituted with 2 to 3 substituents independently selected from R3a.
        Embodiment A3. A compound of Embodiment A1 wherein Q1 is a phenyl ring substituted with 1 substituent independently selected from R3a.
        Embodiment A4. A compound of Embodiment A1 wherein Q1 is a phenyl ring substituted with 2 substituents independently selected from R3a.
        Embodiment A5. A compound of Embodiment A1 wherein Q1 is a phenyl ring substituted with 3 substituents selected from R3a.
        Embodiment A6. A compound of Formula 1A or any one of Embodiments A1 through A5 wherein Q1 is a phenyl ring substituted with at least one R3a substituent attached at an ortho position (relative to the connection of the Q1 ring to the remainder of Formula 1A).
        Embodiment A7. A compound of Formula 1A or any one of Embodiments A1 through A6 wherein Q1 is a phenyl ring substituted with two R3a substituents attached at an ortho position and the para position (relative to the connection of the Q1 ring to the remainder of Formula 1A).
        Embodiment A8. A compound of Formula 1A or any one of Embodiments A1 through A6 wherein Q1 is a phenyl ring substituted with two R3a substituents attached at both ortho positions (relative to the connection of the Q1 ring to the remainder of Formula 1A).
        Embodiment A9. A compound of Formula 1A or any one of Embodiments A1 through A6 wherein Q1 is a phenyl ring substituted with three R3a substituents attached at both ortho positions and the para position (relative to the connection of the Q1 ring to the remainder of Formula 1A).
        Embodiment A10. A compound of Formula 1A or any one of Embodiments A1 through A9 wherein Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl or pyrimidinyl ring, each ring optionally substituted with up to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members.
        Embodiment A11. A compound of Embodiment A10 wherein Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl or pyridinyl ring, each ring optionally substituted with 1 to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members.
        Embodiment A12. A compound of Embodiment A11 wherein Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a.
        Embodiment A13. A compound of Embodiment A12 wherein Q2 is a phenyl ring substituted with 2 to 3 substituents independently selected from R3a.
        Embodiment A14. A compound of Embodiment A13 wherein Q2 is a phenyl ring substituted with 1 substituent independently selected from R3a.
        Embodiment A15. A compound of Embodiment A13 wherein Q2 is a phenyl ring substituted with 2 substituents independently selected from R3a.
        Embodiment A16. A compound of Embodiment A13 wherein Q2 is a phenyl ring substituted with 3 substituents independently selected from R3a.
        Embodiment A17. A compound of Formula 1A or any one of Embodiments A1 through A16 wherein Q2 is a phenyl ring substituted with two R3a substituents attached at an ortho position and the para position (relative to the connection of the Q2 ring to the remainder of Formula 1A).
        Embodiment A18. A compound of Formula 1A or any one of Embodiments A1 through A17 wherein Q2 is a phenyl ring substituted with two R3a substituents attached at both ortho positions (relative to the connection of the Q2 ring to the remainder of Formula 1A).
        Embodiment A19. A compound of Formula 1A or any one of Embodiments A1 through A18 wherein Q2 is a phenyl ring substituted with three R3a substituents attached at both ortho positions and the para position (relative to the connection of the Q2 ring to the remainder of Formula 1A).
        Embodiment A20. A compound of Embodiment A11 wherein Q2 is a pyridinyl ring optionally substituted with up to 3 substituents independently selected from R3a.
        Embodiment A21. A compound of Embodiment A20 wherein Q2 is a pyridinyl ring substituted with 1 to 3 substituents independently selected from R3a.
        Embodiment A22. A compound of Formula 1A or any one of Embodiments A1 through A21 wherein when Q2 is a 6-membered fully unsaturated heterocyclic ring (e.g., pyridinyl, pyridazinyl, pyrazinyl or pyrimidinyl), then Q2 is substituted with at least one R3a substituent attached at an ortho position (relative to the connection of the Q2 ring to the remainder of Formula 1A).
        Embodiment A23. A compound of Formula 1A or any one of Embodiments A1 through A22 wherein when Q1 and Q2 are each a phenyl ring substituted with 1 to 3 substituents independently selected from R3a, then one ring substituted with 2 to 3 substituents and the other ring substituted with 1 to 3 substituents.
        Embodiment A24. A compound of Formula 1A or any one of Embodiments A1 through A23 wherein when Q1 and Q2 are each a phenyl ring substituted with 1 to 3 substituents independently selected from R3a, then one ring is substituted with 2 to 3 substituents and the other ring is substituted with 1 to 2 substituents.
        Embodiment A25. A compound of Formula 1A or any one of Embodiments A1 through A24 wherein when Q1 and Q2 are each a phenyl ring substituted with 1 to 3 substituents independently selected from R3a, then one ring is substituted with 3 substituents and the other ring is substituted with 2 substituents.
        Embodiment A26. A compound of Formula 1A or any one of Embodiments A1 through A25 wherein Q1 and Q2 are both a phenyl ring substituted with 2 substituents independently selected from R3a.
        Embodiment A27. A compound of Formula 1A or any one of Embodiments A1 through A26 wherein X is O, S, N(R6) or C(═O).
        Embodiment A28. A compound of Embodiment A27 wherein X is O, NH or C(═O).
        Embodiment A29. A compound of Embodiment A27 wherein X is N(R6).
        Embodiment A29a. A compound of Embodiment A29 wherein X is NH.
        Embodiment A30. A compound of Embodiments A28 wherein X is O.
        Embodiment A31. A compound of Embodiment A28 wherein X is C(═O).
        Embodiment A32. A compound of Formula 1A or any one of Embodiments A1 through A31 wherein R1 is C1-C2 alkyl, —CH2F, —CH2Cl or cyclopropyl.
        Embodiment A33. A compound of Embodiment A32 wherein R1 is methyl, —CH2F or —CH2Cl.
        Embodiment A34. A compound of Embodiment A33 wherein R1 is methyl.
        Embodiment A35. A compound of Formula 1A or any one of Embodiments A1 through A34 wherein R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, halomethyl, cyanomethyl, hydroxymethyl, C2-C3 alkoxyalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
        Embodiment A36. A compound of Embodiment A35 wherein R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
        Embodiment A37. A compound of Embodiment A36 wherein R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl or methoxy.
        Embodiment A38. A compound of Embodiment A37 wherein R2 is halogen, cyano, methyl, halomethyl or methoxy.
        Embodiment A39. A compound of Embodiment A38 wherein R2 is Br, Cl, F, cyano, methyl or methoxy.
        Embodiment A40. A compound of Embodiment A39 wherein R2 is Br, Cl, methyl or methoxy.
        Embodiment A41. A compound of Embodiment A40 wherein R2 is methyl.
        Embodiment A42. A compound of Formula 1A or any one of Embodiments A1 through A41 wherein each R3a is independently halogen, cyano, C1-C2 alkyl, C1-C2 haloalkyl, cyclopropyl, C1-C2 alkoxy, C1-C2 alkylthio, C2-C3 alkylcarbonyl or —U—V-T.
        Embodiment A43. A compound of Embodiment A42 wherein each R3a is independently halogen, cyano, methyl, halomethyl, cyclopropyl, methoxy, methylthio, methylcarbonyl or —U—V-T.
        Embodiment A44. A compound of Embodiment A43 wherein each R3a is independently halogen, cyano, methyl, halomethyl or methoxy.
        Embodiment A45. A compound of Embodiment A44 wherein each R3a is independently halogen, cyano or methoxy.
        Embodiment A46. A compound of Embodiment A45 wherein each R3a is independently Br, Cl, F, cyano or methoxy.
        Embodiment A47. A compound of Embodiment A46 wherein each R3a is independently Cl or F.
        Embodiment A48. A compound of Formula 1A or any one of Embodiments A1 through A47 wherein each U is independently O, N(R10) or a direct bond.
        Embodiment A49. A compound of Embodiment A48 wherein each R10 is independently H or methyl.
        Embodiment A50. A compound of Embodiment A48 wherein each U is independently O, NH or a direct bond.
        Embodiment A51. A compound of Formula 1A or any one of Embodiments A1 through A50 wherein each V is independently C1-C4 alkylene, wherein up to 1 carbon atom is selected from C(═O).
        Embodiment A52. A compound of Embodiment A51 wherein each V is independently C1-C3 alkylene.
        Embodiment A53. A compound of Formula 1A or any one of Embodiments A1 through A52 wherein each T is independently N(R11a)(R11b) or OR12.
        Embodiment A54. A compound of Formula 1A or any one of Embodiments A1 through A53 wherein each R11a and R11b is independently H, C1-C6 alkyl or C1-C6 haloalkyl.
        Embodiment A55. A compound of Embodiment A54 wherein each R11a and R11b is independently H or methyl.
        Embodiment A56. A compound of Formula 1A or any one of Embodiments A1 through A55 wherein each R12 is independently H, C1-C6 alkyl or C1-C6 haloalkyl.
        Embodiment A57. A compound Embodiment A56 wherein each R12 is independently H, methyl or halomethyl.
        Embodiment A58. A compound of Formula 1A or any one of Embodiments A1 through A57 wherein each R3b is independently cyano, C1-C2 alkyl, cyclopropyl or C2-C3 alkoxyalkyl.
        Embodiment A59. A compound of Embodiment A58 wherein each R3b is methyl.
        Embodiment A60. A compound of Formula 1A or any one of Embodiments A1 through A59 wherein R6 is H, hydroxy, C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkoxyalkyl, —CH(═O), —OR7, —OS(═O)2M1, —S(═O)—R8 or —C(═W)R9.
        Embodiment A61. A compound of Embodiments A60 wherein R6 is H, methyl, halomethyl or —OR7.
        Embodiment A62. A compound of Embodiment A61 wherein R6 is H.
        Embodiment A63. A compound of Formula 1A or any one of Embodiments A1 through A62 wherein R7 is H, C1-C3 alkyl, C2-C6 alkenyl, C1-C3 haloalkyl, cyclopropyl, C2-C3 cyanoalkyl, C2-C6 alkoxyalkyl, —S(═O)2OM1 or —C(═W)R9.
        Embodiment A64. A compound of Embodiment A63 wherein R7 is H, C1-C3 alkyl, C1-C3 haloalkyl, cyclopropyl, C2-C3 cyanoalkyl, —S(═O)2OM1 or —C(═W)R9.
        Embodiment A65. A compound of Embodiment A64 wherein R7 is H, C1-C3 alkyl, C1-C3 haloalkyl, —S(═O)2OM1 or —C(═W)R9.
        Embodiment A66. A compound of Embodiment A65 wherein R7 is H, methyl or —C(═W)R9.
        Embodiment A67. A compound Embodiment A66 wherein R7 is H or methyl.
        Embodiment A68. A compound Embodiment A67 wherein R7 is H.
        Embodiment A69. A compound of Formula 1A or any one of Embodiments A1 through A68 wherein R8 is methyl.
        Embodiment A70. A compound Formula 1A or any one of Embodiments A1 through A69 wherein R9 is methyl or methoxy.
        Embodiment A71. A compound of Embodiment A70 wherein R9 is methyl.
        Embodiment A72. A compound of Formula 1A or any one of Embodiments A1 through A72 wherein W is O.
        Embodiment A73. A compound of Formula 1A or any one of Embodiments A1 through A72 wherein M1 is Na or K.
        Embodiment A74. A compound of Embodiment A73 wherein M1 is Na.
    
    


Embodiment s of this invention, including Embodiments A1-A74 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula 1A but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula 1A. In addition, embodiments of this invention, including Embodiments A1-A74 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.
Combinations of Embodiments A1-A74 are illustrated by:

    
    
        Embodiment F. A compound of Formula 1A wherein
        
            Q1 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a;
            Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl or pyrimidinyl ring, each ring optionally substituted with up to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members;
            X is O, S, N(R6) or C(═O);
            R1 is C1-C2 alkyl, —CH2F, —CH2Cl or cyclopropyl;
            R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, halomethyl, cyanomethyl, hydroxymethyl, C2-C3 alkoxyalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy;
            each R3a is independently halogen, cyano, C1-C2 alkyl, C1-C2 haloalkyl, cyclopropyl, C1-C2 alkoxy, C1-C2 alkylthio, C2-C3 alkylcarbonyl or —U—V-T;
            each R3b is independently cyano, C1-C2 alkyl, cyclopropyl or C2-C3 alkoxyalkyl;
            R6 is H, hydroxy, —CH(═O), C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkoxyalkyl, —OR7, —S(═O)2OM1, —S(═O)—R8 or —C(═W)R9;
            R7 is H, C1-C3 alkyl, C2-C6 alkenyl, C1-C3 haloalkyl, cyclopropyl, C2-C3 cyanoalkyl, C2-C6 alkoxyalkyl, —S(═O)2OM1 or —C(═W)R9;
            R8 is methyl;
            R9 is methyl or methoxy;
            each U is independently O, N(R10) or a direct bond;
            each R10 is independently H or methyl;
            each V is independently C1-C3 alkylene, wherein up to 1 carbon atom is selected from C(═O);
            each T is independently N(R11a)(R11b) or OR12;
            each R11a and R11b is independently H or methyl;
            each R12 is independently H, C1-C6 alkyl or C1-C6 haloalkyl;
            W is O; and
            M1 is Na or K.
        
        
        Embodiment G. A compound of Embodiment F wherein
        
            Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a; or a pyrazolyl, imidazolyl or pyridinyl ring, each ring optionally substituted with 1 to 3 substituents independently selected from R3a on carbon atom ring members and R3b on nitrogen atom ring members;
            R1 is methyl, —CH2F or —CH2Cl;
            R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl, C1-C2 alkoxy or C1-C2 haloalkoxy;
            each R3a is independently halogen, cyano, methyl, halomethyl, cyclopropyl, methoxy, methylthio, methylcarbonyl or —U—V-T;
            each R3b is methyl;
            R6 is H, methyl, halomethyl or —OR7;
            R7 is H, C1-C3 alkyl, C1-C3 haloalkyl, —S(═O)2OM1 or —C(═W)R9;
            each U is independently O, NH or a direct bond;
            each V is C1-C3 alkylene; and
            each R12 is independently H, methyl or halomethyl.
        
        
        Embodiment H. A compound of Embodiment G wherein
        
            Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a;
            R1 is methyl;
            R2 is halogen, cyano, methyl, halomethyl or methoxy;
            each R3a is independently halogen, cyano, methyl, halomethyl or methoxy;
            R7 is H, methyl, or —C(═W)R9; and
            R9 is methyl.
        
        
        Embodiment I. A compound of Embodiment H wherein
        
            X is O, S, NH or C(═O);
            R2 is Br, Cl, methyl or methoxy; and
            each R3a is independently halogen, cyano or methoxy.
        
        
        Embodiment J. A compound of Embodiment I wherein
        
            R2 methyl;
            each R3a is independently Br, Cl, F, cyano or methoxy; and
            one of Q1 and Q2 is substituted with 2 to 3 substituents and the other of Q1 and Q2 is substituted with 1 to 2 substituents.
        
        
    
    


Specific embodiments include compounds of Formula 1A selected from the group consisting of:

    5-(2-chloro-4-methoxyphenyl)-4-(2,4-difluorophenoxy)-1,3-dimethyl-1H-pyrazole;
    4-(2-chloro-4-fluorophenoxy)-5-(2-chloro-4-methoxyphenyl)-1,3-dimethyl-1H-pyrazole;
    3-chloro-4-[4-(2-chloro-4-fluorophenoxy)-1,3-dimethyl-1H-pyrazol-5-yl]benzonitrile;
    4-[[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]amino]-3,5-difluorobenzonitrile;
    N,5-bis(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine;
    3-chloro-4-[[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]oxy]benzonitrile;
    5-(2-chloro-4-fluorophenyl)-N-(2,4-dichlorophenyl)-1,3-dimethyl-1H-pyrazole-4-amine;
    5-(2-chloro-4-fluorophenyl)-N-(4-chloro-2-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-amine;
    4-(2-chloro-4-fluorobenzoyl)-5-(2,4-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile;
    N-(2-bromo-4-fluorophenyl)-5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-amine;
    N-(2,4-dichlorophenyl)-5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine; and
    [5-(2,4-dichlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl](2,4-difluorophenyl)methanone.


Of note are compounds of Formula 1 and Formula 1A (including all stereoisomers), N-oxides, and salts thereof (including but not limited to Embodiments 1-59 and A1-A74 above) wherein R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl, cyclopropyl, halocyclopropyl, methylthio or methoxy.
Of further note are compounds of Formula 1 and Formula 1A (including all stereoisomers), N-oxides, and salts thereof (including but not limited to Embodiments 1-59 and A1-A74 above) wherein R7 is H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cyanoalkyl, —CH(═O), —S(═O)2OM1 or —C(═W)R9.
Additionally, of note are compounds of Formula 1 and Formula 1A (including all stereoisomers), N-oxides, and salts thereof (including but not limited to Embodiments 1-59 and A1-A74 above) wherein when each Q1 and Q2 is a phenyl ring substituted with 1 to 5 substituents independently selected from R3a, then Q2 is substituted with at least one R3a substituent at an ortho position.
Also of note are compounds of Formula 1 (including all stereoisomers), N-oxides, and salts thereof (including but not limited to Embodiments 1-59 above) wherein R4 is halogen, —OR7.
This invention provides a fungicidal composition comprising a compound of Formula 1 or Formula 1A (including all stereoisomers, N-oxides, and salts thereof), and at least one other fungicide. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.
This invention provides a fungicidal composition comprising a compound of Formula 1 or Formula 1A (including all stereoisomers, N-oxides, and salts thereof) (i.e. in a fungicidally effective amount), and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.
This invention provides a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1 or Formula 1A (including all stereoisomers, N-oxides, and salts thereof). Of note as embodiments of such methods are methods comprising applying a fungicidally effective amount of a compound corresponding to any of the compound embodiments describe above. Of particular note are embodiments where the compounds are applied as compositions of this invention.
One or more of the following methods and variations as described in Schemes 1-9 can be used to prepare the compounds of Formula 1 and compounds of Formula 1A. The definitions of Q1, Q2, R1, R2, R4, R5 and X in the compounds of Formulae 1-17 below are as defined above in the Summary of the Invention unless otherwise noted.
Certain compounds of Formula 1 and Formula 1A can be prepared as shown in Scheme 1. In this method a compound of Formula 2 is first treated with an organometallic agent of Formula 3 such an alkyl lithium base (e.g., n-butyllithium, s-butyllithium or lithium diisopropylamide) or a Grignard reagent in a solvent such as toluene, ethyl ether, tetrahydrofuran or dimethoxymethane at temperatures ranging from about −78° C. to ambient temperature. Anions of Formula 2a (i.e. metallated intermediates of Formula 2 generated in situ) are then contacted with an electrophile of Formulae 4 or 5. The use and choice of an appropriate electrophile of Formulae 4 or 5 will depend on the compound of Formula 1 or Formula 1A desired and will be apparent to one skilled in chemical synthesis. For example, aldehydes of the formula Q1CHO provide compounds Formula 1 wherein R4 is OH and R5 is H; benzoyl chlorides of formula Q1C(═O)Cl or benzamides of formula Q1C(═O)N(Me)OMe provide compounds Formula 1A wherein X is C(═O), chlorosulfides of formula Q1SCl or disulfides formula of Q1S—S-Q1 provide compounds Formula 1A wherein X is S, and nitrosobenzenes of formula Q1N(═O) provide compounds Formula 1A wherein X is N(OH). In cases where the electrophile is Q1C(═O)Cl, the addition of a second organometallic agent such as zinc chloride, zinc bromide or a monovalent copper salt such as copper(I) iodide or copper(I) cyanide before the addition of the electrophile promotes reactivity. There are a wide-variety of general methods described in the synthetic literature for metallation/alkylation reactions which can be readily adapted to prepare compounds of the present invention. In the present disclosure, Example 4, Step D, Example 6 and Example 9, Step E illustrate the method of Scheme 1.




Electrophiles of Formulae 4 and 5 are commercially available and can be prepared by methods known in the art. Compounds of Formula 2 are known and can be prepared by the method disclosed in Scheme 3 below, and by a variety of methods disclosed in the chemical literature.
As shown in Scheme 2, compounds of Formula 1a (i.e. Formula 1 wherein R4 is OH and R5 is H) can be reduced to provide the keto compounds of Formula 1Aa (i.e. Formula 1A wherein X is C(═O)) using standard reduction techniques. Typical reaction conditions involve contacting a boron-based reducing agent such as sodium borohydride or sodium triacetoxyborohydride with the compound of Formula 1Aa in a solvent such as lower alcohols or tetrahydrofuran. Other techniques known to those skilled in the art may also be employed. For relevant references see, for example, Organic Letters 2009, 11, 1659-1662, Journal of the American Chemical Society 2006, 128, 9998-9999, and Acta Chemica Scandinavica 1991, 45, 925-929. Also, Examples 8 and 11 illustrate the preparation of a compound of Formula 1a from the corresponding ketone of Formula 1Aa.




As shown in Scheme 3, keto compounds of Formula 1Aa (i.e. Formula 1A wherein X is C(═O)) can also be treated with alkylmagnesium halides to provide compounds of Formula 1b (i.e. Formula 1 wherein R4 is OH and R5 is C1-C4 alkyl). Typically the reaction use run in presence of zinc chloride and in a solvent such as diethyl ether or tetrahydrofuran at temperatures from about 0-100° C. (for references see, for example, Organic Lett. 2009, 11, 1659-1662, J. Am. Chem. Soc. 2006, 128, 9998-9999, and Acta Chemica Scandinavica 1991, 45, 925-929).




In an alternate approach to the method of Scheme 1, pyrazoles of Formula 1Aa (i.e. Formula 1A wherein X is C(═O)) can be prepared from compounds of Formula 6 using Friedel-Crafts acylation conditions as illustrated in Scheme 4. In this method, the compound of Formula 6 is contacted with an acid chloride of Formula 7 in the presence of a Lewis acid (e.g., aluminum chloride, boron trifluoride diethyl etherate or tin tetrachloride) in a solvent such as dichloromethane, tetrachloroethane, or nitrobenzene, at temperatures ranging between about 0 to 200° C. Present Example 7 and Example 10, Step C illustrate the method of Scheme 4.




As shown in Scheme 5, Compounds of Formula 1c (i.e. Formula 1 wherein R4 is OH) can be converted to the compounds of Formula 1d (i.e. Formula 1 wherein R4 is halogen) using a variety of conditions published in the chemical literature. For example, treatment of a compound of Formula 1c with a fluorinating agent (e.g., bis(2-methoxyethyl)aminosulfur (Deoxo-Fluor®), diethylaminosulfur trifluoride (DAST), HF-pyridine (Olah's reagent) or sulfur tetrafluoride) provides compounds of Formula 1d wherein R4 is F. For reaction conditions see C. J. Wang, Organic Reactions 2005, Vol. 34 (Wiley, New York, 1951) Chapter 2, pp. 319-321; also, present Example 5 illustrates the preparation of a compound of Formula 1d wherein R4 is F and R5 is H. Compounds of Formula 1d wherein R4 is Br can be prepared by treating the corresponding compound of Formula 1c with hydrobromic acid in a solvent such as glacial acetic acid using the method described by Beukers et al., Journal of Medicinal Chemistry 2004, 47(15), 3707-3709. Compounds of Formula 1d wherein R4 is Cl can be prepared by treating the corresponding compound of Formula 1c with thionyl chloride or phosphorus pentachloride in presence of a base such as triethylamine or pyridine in a solvent such as dichloromethane or pyridine at 25-110° C. Compounds of Formula 1d wherein R4 is I can be prepared by reacting corresponding compounds of Formula 1c with sodium iodide or potassium iodide in presence of BF3.Et2O and an ether solvent such as 1,4-dioxane or with hydroiodic acid in a solvent such as acetonitrile at 25-70° C. according to general methods described in Tetrahedron Letters 2001, 42, 951-953 and Journal of the American Chemical Society 1965, 87, 539-42.




As shown in Scheme 6, pyrazole intermediates of Formula 2 are readily prepared from corresponding pyrazoles of Formula 6 by treatment with a halogenating agent. Suitable halogenating agents for this method include N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), bromine, sodium bromite, thionyl chloride, oxalyl chloride, phenylphosphonic dichloride or phosgene. Particularly useful is N-bromosuccinimide (NBS) and N-iodo-succinimide (NIS). Suitable solvents for this reaction include, for example, N,N-dimethylformamide, N,N-dimethylacetamide, dichloromethane, chloroform, chlorobutane, benzene, xylenes, chlorobenzene, tetrahydrofuran, p-dioxane, acetonitrile, and the like. Optionally, an organic base such as triethylamine, pyridine, N,N-dimethylaniline, and the like can be added. Typical reaction temperatures range from about ambient temperature to 200° C. For representative procedures see Czarnocki et al., Synthesis 2006, 17, 2855-2864; Brana et al., Journal of Medicinal Chemistry 2005, 48, 6843-6854; Liu et al., Journal of Medicinal Chemistry 2007, 50, 3086-3100 and Chan et al., Journal of Medicinal Chemistry 2005, 48, 4420-4431. The method of Scheme 6 is also illustrated in Example 4, Step C, Example 3, Step C and Example 9, Step D.




As shown in Scheme 7, compounds of Formula 6 can be prepared by reaction of a 4-bromo or 4-iodo pyrazole of Formula 8 under transition-metal-catalyzed cross-coupling reaction conditions. In this method reaction of a pyrazole of Formula 8 with a compound of formula Q2-M1 in the presence of a suitable palladium, copper or nickel catalyst, affords the corresponding compound of Formula 6. In this method compounds of formula Q2-M1 are organoboronic acids (e.g., M1 is B(OH)2), organoboronic esters (e.g., M1 is B(—OC(CH3)2C(CH3)2O—)), organotrifluoroborates (e.g., M1 is BF3K), organotin reagents (e.g., M is Sn(n-Bu)3, Sn(Me)3), Grignard reagents (e.g., M1 is MgBr or MgCl) or organozinc reagents (e.g., M1 is ZnBr or ZnCl). Suitable metal catalysts include, but are not limited to: palladium(II) acetate, palladium(II) chloride, tetrakis(triphenylphosphine)-palladium(0), bis(triphenylphosphine)palladium(II) dichloride, dichloro[1,1′-bis(diphenyl-phosphino)ferrocene]palladium(II), bis(triphenylphosphine)dichloronickel(II) and copper(I) salts (e.g., copper(I) iodide, copper(I) bromide, copper(I) chloride, copper(I) cyanide or copper(I) triflate). Optimal conditions for each reaction will depend on the catalyst used and the counterion attached to the coupling reagent (i.e. M1), as is understood by one skilled in the art. In some cases the addition of a ligand such as a substituted phosphine or a substituted bisphosphinoalkane promotes reactivity. Also, the presence of a base such as an alkali carbonate, tertiary amine or alkali fluoride may be necessary for some reactions involving organoboron reagents of the formula Q2-M1. For reviews of this type of reaction see: E. Negishi, Handbook of Organopalladium Chemistry for Organic Synthesis, John Wiley and Sons, Inc., New York, 2002; N. Miyaura, Cross-Coupling Reactions: A Practical Guide, Springer, New York, 2002; H. C. Brown et al., Organic Synthesis via Boranes, Vol. 3, Aldrich Chemical Co., Milwaukee, Wis., 2002; Suzuki et al., Chemical Review 1995, 95, 2457-2483 and Molander et al., Accounts of Chemical Research 2007, 40, 275-286. Also, Example 9, Step C illustrates the synthesis of a compound of Formula 6 using the method of Scheme 7.




Alternatively, as shown in Scheme 8, compounds of Formula 6 can be prepared by cyclization of enones of Formula 9 with an appropriately substituted hydrazine of formula NH2NHR1 and subsequent oxidation of pyrazolines of Formula 10. Useful oxidizing reagents include bromine (for conditions see, for example, Indian Journal of Heterocyclic Chemistry, 2001, 11(1), 21-26), elemental sulfur, manganese dioxide, 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ), chloranil (for conditions see, for example, Russian Journal of Organic Chemistry 2006, 42(8), 1113-1119) and oxygen optionally in the presence of a metal catalyst such as cobalt acetate (for conditions see, for example, Tetrahedron 2006, 62(11), 2492-2496, Chinese Chemical Letters 2008, 19(9), 1013-1016). Useful solvents for this reaction include N,N-dimethylformamide, tetrahydrofuran, toluene, water, dichloromethane, tetrachloroethane, and mixtures of these or similar solvents, at temperatures from ambient to 200° C. The reaction of hydrazines with enones and the preparation of the enones is well-known in the art (see, for example, Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen 1925, 58B, 1974-86, and Journal of the American Chemical Society 1958, 80, 5524-7). Also, Example 4, Step B illustrates the synthesis of a compound of Formula 6 by the method of Scheme 8.




As shown in Scheme 9, compounds of Formula 8 can be prepared by alkylation of the corresponding pyrazole of Formula 11 with an alkylating agent of formula R1-L wherein L is a leaving group such as halogen or (halo)alkylsulfonate (e.g., Cl, Br, I, p-toluenesulfonate, methanesulfonate or trifluoromethanesulfonate). General procedures for alkylations of this type are well-known in the art and can be readily adapted to prepare compounds of the present invention. Particularly useful alkylating agents for preparing compounds of Formula 8 wherein R1 is methyl are diazomethane or iodomethane using general procedures known in the art, such as those described in Journal of Heterocyclic Chemistry 1988, 1307-1310. Example 9, Step B illustrates the method of Scheme 9 for the preparation of a compound of Formula 8 wherein R1 is methyl.




Starting compounds of Formula 11 are known and can be prepared by a variety of methods disclosed in the chemical literature. For a specific example, see Example 9, Step A.
As shown in Scheme 10, Compounds of Formula 1A can also be prepared by the reaction of compounds of Formula 12 (e.g., 4-aminopyrazoles of Formula 12 for X being N(R6), 4-hydroxypyrazoles (4-pyrazolones) of Formula 12 for X being O, and 4-mercaptopyrazoles of Formula 12 for X being S) with compounds of Formula 13 where L is a leaving group such as halogen or (halo)alkylsulfonate (e.g., Cl, Br, I, p-toluenesulfonate, methanesulfonate or trifluoromethanesulfonate), optionally in the presence of a metal catalyst, and generally in the presence of a base and a polar aprotic solvent such as N,N-dimethylformamide or dimethyl sulfoxide. Compounds of Formula 13 in which Q1 is a phenyl ring substituted with electron-withdrawing substituents react with Formula 12 compounds by direct displacement of the leaving group L from the Q1 ring to provide compounds of Formula 1A. Typically for these types of reactions L is F or Cl. Compounds of Formula 13 wherein Q1 is phenyl not substituted with an electron-withdrawing substituent, or in general, to improve reaction rate, yield or product purity, the use of a metal catalyst (e.g., metal or metal salt) in amounts ranging from catalytic up to superstoichiometric can facilitate the desired reaction. Typically for these conditions, L is Br or I or a sulfonate such as —OS(O)2CF3 or —OS(O)2(CF2)3CF3. For example, the reaction can be run in the presence of a metal catalyst such as copper salt complexes (e.g., CuI with N,N′-dimethylethylenediamine, proline or bipyridyl), palladium complexes (e.g., tris-(dibenzylideneacetone)dipalladium(0)) or palladium salts (e.g., palladium acetate) with ligands such as 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, 2-dicyclohexyl-phosphino-2′,4′,6′-triisopropylbiphenyl or 2,2′-bis(diphenylphosphino)1,1′-binaphthalene, with a base such as potassium carbonate, cesium carbonate, sodium phenoxide or sodium tert-butoxide, in a solvent such as N,N-dimethylformamide, 1,2-dimethoxyethane, dimethyl sulfoxide, 1,4-dioxane or toluene, optionally containing an alcohol such as ethanol. The method of Scheme 10 is illustrated in Example 1, Step C and Example 2, Step G.




Compounds of Formula 12 are commercially available and their preparation is known in the art; see, for example, Journal für Praktische Chemie (Liepzig) 1911, 83, 171-182 and Journal of the American Chemical Society 1954, 76, 501-503. Also, present Example 1, Steps A through B and Example 2, Steps A through F illustrate methods for preparing 4-aminopyrazoles of Formula 12.
As illustrated in Scheme 11, compounds of Formula 1Ab (i.e. Formula 1A wherein X is NH) can also be prepared by reaction of compounds of Formula 14 with compounds of Formula 15 under metal-catalyzed conditions similar to those described above for Scheme 7.




Compounds of Formula 14 are known and can be prepared by the method disclosed in Scheme 6, and by a variety of methods disclosed in the chemical literature.
As shown in Scheme 12, compounds of Formula 1A can also be prepared by reaction of a 5-bromo or 5-iodo pyrazole of Formula 16 with an organometallic compound of Formula 17 under transition-metal-catalyzed cross-coupling reaction conditions analogous to those described for Scheme 7. Reaction of a pyrazole of Formula 16 with a boronic acid, trialkyltin, zinc or organomagnesium reagent of Formula 16 in the presence of a palladium or nickel catalyst and optionally a ligand (e.g., triphenylphosphine, dibenzylideneacetone, dicyclohexyl(2′,6′-dimethoxy[1,1′-biphenyl]-2-yl)phosphine) and a base, if needed, affords the corresponding compound of Formula 1A. For example, a compound of Formula 17 wherein M is B(OH)2, B(OC(CH3)2C(CH3)2O)), B(O-i-Pr)3 Li reacts with a 5-bromo- or 5-iodopyrazole of Formula 16 in the presence of dichlorobis(triphenylphosphine) palladium(II) and aqueous base such as sodium carbonate or potassium hydroxide, in solvents such as 1,4-dioxane, 1,2-dimethoxyethane, toluene or ethyl alcohol, or under anhydrous conditions with the use of a ligand such as phosphine oxide or phosphite ligand (e.g., diphenylphosphine oxide) and potassium fluoride in a solvent such as 1,4-dioxane to provide the corresponding compound of Formula 1A (for references, see Angewandte Chemie, International Edition 2008, 47(25), 4695-4698 and Journal of the American Chemical Society 2010, 132(40), 14073-14075). The method of Scheme 12 is illustrated in Example 3, Step D.




Compounds of Formula 16 can be prepared via halogenation methods analogous to those described for Scheme 6, and illustrated in Example 3, Step C.
It will be recognized by one skilled in the art that various functional groups can be converted into others to provide different compounds of Formula 1 or Formula 1A. For example, compounds of Formula 1 or Formula 1A in which R2 is methyl, ethyl or cyclopropyl can be modified by free-radical halogenation to form compounds of Formula 1 or Formula 1A wherein R2 is halomethyl or halocyclopropyl. The halomethyl compounds can be used as intermediates to prepare compounds of Formula 1 or Formula 1A wherein R2 is hydroxymethyl or cyanomethyl. Compounds of Formula 1, Formula 1A or intermediates for their preparation may contain aromatic nitro groups, which can be reduced to amino groups, and then be converted via reactions well-known in the art, such as the Sandmeyer reaction, to various halides, providing other compounds of Formula 1 or Formula 1A. By similar known reactions, aromatic amines (anilines) can be converted via diazonium salts to phenols, which can then be alkylated to prepare compounds of Formula 1 or Formula 1A with alkoxy substituents. Likewise, aromatic halides such as bromides or iodides prepared via the Sandmeyer reaction can react with alcohols under copper-catalyzed conditions, such as the Ullmann reaction or known modifications thereof, to provide compounds of Formula 1 or Formula 1A that contain alkoxy substituents. Additionally, some halogen groups, such as fluorine or chlorine, can be displaced with alcohols under basic conditions to provide compounds of Formula 1 or Formula 1A containing the corresponding alkoxy substituents. The resultant alkoxy compounds can themselves be used in further reactions to prepare compounds of Formula 1 or Formula 1A wherein R3a is —U—V-T (see, for example, PCT Publication WO 2007/149448 A2). Compounds of Formula 1, Formula 1A or precursors thereof in which R2 is halide, preferably bromide or iodide, are particularly useful intermediates for transition metal-catalyzed cross-coupling reactions to prepare compounds of Formula 1 or Formula 1A. These types of reactions are well documented in the literature; see, for example, Tsuji in Transition Metal Reagents and Catalysts: Innovations in Organic Synthesis, John Wiley and Sons, Chichester, 2002; Tsuji in Palladium in Organic Synthesis, Springer, 2005; and Miyaura and Buchwald in Cross Coupling Reactions: A Practical Guide, 2002; and references cited therein.
It is recognized that some reagents and reaction conditions described above for preparing compounds of Formula 1 or Formula 1A may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula 1 and Formula 1A. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formula 1 and or Formula 1A.
One skilled in the art will also recognize that compounds of Formula 1, Formula 1A and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.
Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. MPLC refers to medium pressure liquid chromatography on silica gel. 1H NMR spectra are reported in ppm downfield from tetramethylsilane; “s” means singlet, “d” means doublet, “t” means triplet, “m” means multiplet, “dd” means doublet of doublets, “dt” means doublet of triplets and “br s” means broad singlet.
EXAMPLE 1
Preparation of 4-[[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]amino]-3,5-difluorobenzonitrile (Compound 40)
Step A: Preparation of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-4-nitro-1H-pyrazole
A mixture of 5-chloro-1,3-dimethyl-4-nitro-1H-pyrazole (2.50 g, 14.3 mmol), 2-chloro-4-fluorophenylboronic acid (2.98 g, 17.2 mmol), cesium carbonate (5.58 g, 17.2 mmol) and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane complex (1:1) (1.16 g, 1.43 mmol) in dioxane (50 mL) was heated at 100° C. for approximately 2.5 days. After cooling to room temperature, the reaction mixture was filtered through a pad of Celite® (diatomaceous earth) on a sintered glass frit funnel and the filtrate was concentrated under reduced pressure. The resulting material was dissolved in ethyl acetate and filtered through a plug of silica on a sintered glass frit funnel and the filtrate was concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (5 to 40% gradient of ethyl acetate in hexanes as eluant) to provide the title compound (0.32 g).
1H NMR (CDCl3): δ 7.32-7.26 (m, 2H), 7.16-7.09 (m, 1H), 3.58 (s, 3H), 2.57 (s, 3H).
Step B: Preparation of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine
A mixture of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-4-nitro-1H-pyrazole (i.e. the product of Step A) (0.2 g, 0.74 mmol), iron powder (0.2 g, 3.6 mmol) and saturated aqueous ammonium chloride solution (1 mL) in ethanol (5 mL) was heated at 80° C. for 4 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and filtered through a pad of Celite® (diatomaceous earth) on a sintered glass frit funnel. The filtrate was concentrated under reduced pressure and the resulting material was purified by silica gel column chromatography (ethyl acetate as eluant) to provide the title compound (0.14 g).
1H NMR (CDCl3): δ 7.36-7.20 (m, 2H), 7.17-7.05 (m, 1H), 3.57 (s, 3H), 2.66 (br s, 2H), 2.24 (s, 3H).
Step C: Preparation of 4-[[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]amino]-3,5-difluorobenzonitrile
A mixture of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amin (i.e. the product of Step B) (0.25 g, 1.0 mmol), 3,4,5-trifluorobenzonitrile (0.188 g, 1.2 mmol) and cesium carbonate (0.390 g, 1.2 mmol) in acetonitrile (3 mL) was heated at 210° C. in a Biotage InitiatorTM microwave apparatus for 2 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and filtered through a pad of silica gel on a sintered glass frit funnel. The filtrate was concentrated under reduced pressure and the resulting material was purified by silica gel chromatography (30% ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a solid (0.065 g).
1H NMR (CDCl3): δ 7.34-7.16 (m, 2H), 7.04 (m, 3H), 5.27 (br s, 1H), 3.64 (s, 3H), 2.18 (s, 3H).
EXAMPLE 2
Preparation of 4-(4-chloro-2-fluorophenyl)-5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine (Compound 45)
Step A: Preparation of methyl 3-(methylamino)-2-butenoate
To a mixture of methyl acetoacetate (23.2 g, 0.2 mol) in water (15 mL) at 10° C. was added dropwise methylamine (40% aqueous solution, 18.6 g, 0.24 mol). The reaction mixture was allowed to warm to room temperature and stirred for 2 h. The resulting solid precipitate was collected by filtration and washed with ice water (2×), and then dried in a vacuum oven at 55° C. overnight to provide the title compound as a white solid (20.9 g).
1H NMR (CDCl3): δ 8.45 (br s, 1H, NH), 4.47 (s, 1H), 3.62 (s, 3H), 2.91 (d, 3H), 1.92 (s, 3H).
Step B: Preparation of methyl 2-chloro-4-fluoro-α-[1-(methylamino)ethylidene]-β-oxobenzenepropanoate
To a mixture of methyl 3-(methylamino)-2-butenoate (i.e. the product of Step A) (10.25 g, 79.43 mmol) and triethylamine (13.26 mL, 9.63 g, 95.31 mmol) in toluene (125 mL) at 0° C. was added dropwise 2-chloro-4-fluorobenzoyl chloride (15.25 g, 79.48 mol) in toluene (25 mL) over 30 minutes while maintaining the temperature of the reaction mixture between about 0 to 5° C. The reaction mixture was allowed to warm to room temperature and stirred over night. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting dark yellow oil was triturated with hexanes and filtered to provide the title compound as a white solid (15.91 g).
1H NMR (CDCl3): δ 12.60 (s, 1H), 7.20-6.90 (m, 3H), 3.30 (s, 3H), 3.11 (s, 3H), 2.35 (s, 3H).
Step C: Preparation of methyl 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-carboxylate
A mixture of methyl 2-chloro-4-fluoro-α-[1-(methylamino)ethylidene]-β-oxobenzenepropanoate (i.e. the product of Step B) (15.91 g, 55.82 mmol) and methylhydrazine (3 mL, 56 mmol) in diethyl ether (150 mL) was stirred at room temperature for 48 h. The reaction mixture was concentrated under reduced pressure to provide the title compound as a colorless oil (15 g).
1H NMR (CDCl3): δ 7.32-7.25 (m, 2H), 7.10 (dt, 1H), 3.59 (s, 3H), 2.64 (s, 3H), 2.51 (s, 3H).
Step D: Preparation of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-carboxylic acid
A mixture of methyl 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-carboxylate (i.e. the product of Step C) (12.33 g, 43.7 mol) and sodium hydroxide (1 N, 70 mL) in methanol (70 mL) was heated at reflux for 2 h. The reaction mixture was cooled to about 0° C., and then the pH of the reaction mixture was adjusted to 3 by the addition of aqueous hydrochloric acid solution (1 N). The reaction mixture was extracted with ethyl acetate (3×70 mL) and the combined extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to provide the title compound as a white solid (11.14 g).
1H NMR (CDCl3): δ 12.00 (br s, 1H), 7.70-7.45 (m, 2H), 7.35 (dt, 1H), 3.48 (s, 3H), 2.37 (s, 3H).
Step E: Preparation of methyl N-[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]carbamate
A mixture of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-carboxylic acid (i.e. the product of Step D) (10.14 g, 37.8 mmol), diphenyl phosphoryl azide (8.15 mL, 10.4 g, 37.8 mmol) and triethylamine (6.32 mL, 4.59 g, 45.4 mmol) in toluene (100 mL) was stirred at room temperature for 2 h. After 2 h, the reaction mixture was added dropwise to toluene (100 mL) and heated at reflux for 2 h. The reaction mixture was cooled to about 70° C., methanol (30 mL) was added dropwise, and the mixture was again heated at reflux for an additional 40 minutes. The reaction mixture was diluted with water (100 mL), extracted with ethyl acetate (2×40 mL) and the combined extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to provide the title compound as a light yellow solid (9.77 g).
1H NMR (CDCl3): δ 7.42-7.26 (m, 2H), 7.08 (dt, 1H), 5.68 (br s, 1H, NH), 3.66 (br s, 3H), 3.62 (s, 3H), 2.24 (s, 3H).
Step F: Preparation of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine
A mixture of N-[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]carbamate (i.e. the product of Step E) (7.07 g, 23.8 mmol) and aqueous sodium hydroxide (1 N, 70 mL) in methanol (70 mL) was heated at reflux for 20 h. The reaction mixture was concentrated under reduced pressure, diluted with water and extracted with ethyl acetate (2×30 mL). The combined organic layers were extracted with hydrochloric acid (1 N, 2×30 mL), and the pH of the combined aqueous extracts was adjusted to 10 with the addition of sodium hydroxide (1 N). The aqueous mixture was extracted with ethyl acetate (2×40 mL). The combined organic extracts were washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure to provide the title compound as a viscous yellow oil (4.36 g).
1H NMR (CDCl3): δ 7.35-7.28 (m, 2H), 7.11 (m, 1H), 3.57 (s, 3H), 2.60 (br s, 2H, NH2), 2.23 (s, 3H).
Step G: Preparation of 4-(4-chloro-2-fluorophenyl)-5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine
A mixture of 5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine (i.e. the product of Step F) (7.07 g, 23.8 mmol), 4-chloro-2-fluoroiodobenzene (256 μL, 2.0 mmol), sodium tert-butoxide (0.192 g, 2.0 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]-dichloropalladium(II) (0.117 g, 0.16 mmol) in toluene (5 mL) was heated at 180° C. in a Biotage InitiatorTM microwave apparatus for 1 h. The resulting material was purified by flash chromatography on a silica gel (40 g), Varian Bond Elute SIC) column (30% ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a dark purple/brown oil (164 mg).
1H NMR (CDCl3): δ 7.26-7.15 (m, 2H), 7.03-6.95 (m, 2H), 6.75 (dt, 1H), 6.45-6.40 (m, 1H), 5.20 (s, 1H, NH), 3.67 (s, 3H), 2.13 (s, 3H).
EXAMPLE 3
Preparation of 4-(2-chloro-4-fluorophenoxy)-5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole (Compound 5)
Step A: Preparation of 1-(2-chloro-4-fluorophenoxy)-2-propanone
A mixture of 2-chloro-4-fluorophenol (3.00 g, 20.4 mmol), chloroacetone (2.12 mL, 26.6 mmol), potassium carbonate (4.24 g, 30.7 mmol) and potassium iodide (0.20 g, catalytic) in acetone (30 mL) was heated at reflux for 4 h, cooled and filtered. The filtrate was concentrated under reduced pressure to provide the title compound as a yellow solid (4.05 g).
1H NMR (CDCl3): δ 7.16 (dd, J=8.0, 3.0 Hz, 1H), 6.93 (m, 1H), 6.76 (m, 1H), 4.53 (s, 2H), 2.34 (s, 3H).
Step B: Preparation of 4-(2-chloro-4-fluorophenoxy)-1,3-dimethyl-1H-pyrazole
A mixture of 1-(2-chloro-4-fluorophenoxy)-2-propanone (i.e. the product of Step A) (1.40 g, 6.93 mmol) and N,N-dimethylformamide dimethyl acetal (1.38 mL, 10.4 mmol) was heated to 90° C. for 3 h, and then concentrated under reduced pressure. The resulting material was diluted with ethanol (15 mL), and then methylhydrazine (0.49 mL, 9.0 mmol) and acetic acid (0.1 mL) were added. After 15 h, the reaction mixture was concentrated under reduced pressure and the resulting material was purified by silica gel column chromatography (5 to 40% gradient of ethyl acetate in hexanes as eluant) to provide the title compound as a brown yellow oil (680 mg).
1H NMR (CDCl3): δ 7.16 (m, 2H), 6.78-6.88 (m, 2H), 3.81 (s, 3H), 2.10 (s, 3H).
Step C: Preparation of 5-bromo-4-(2-chloro-4-fluorophenoxy)-1,3-dimethyl-1H-pyrazole
To a mixture of 4-(2-chloro-4-fluorophenyoxy)-1,3-dimethyl-1H-pyrazole (i.e. the product of Step B) (680 mg, 2.82 mmol) and sodium carbonate (389 mg, 3.67 mmol) in dichloromethane (12 mL) at −40° C. was added a solution of bromine (474 mg, 2.96 mmol) in dichloromethane (1 mL). After the addition was complete, the reaction mixture temperature was maintained at about −30 to −20° C. for 5 h. The reaction mixture was diluted with dichloromethane (50 mL) and washed with water (2×10 mL), aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound as a yellow solid (720 mg).
1H NMR (CDCl3): δ 7.18 (dd, J=8.0, 3.0 Hz, 1H), 6.87 (m, 1H), 6.67 (m, 1H), 3.82 (s, 3H), 2.10 (s, 3H).
Step D: Preparation of 4-(2-chloro-4-fluorophenoxy)-5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole
A mixture of 5-bromo-4-(2-chloro-4-fluorophenoxy)-1,3-dimethyl-1H-pyrazole (i.e. the product of Step C) (250 mg, 0.78 mmol) in 1,2-dimethoxyethane/water (5 mL, 2:1) was sparged with a subsurface stream of argon for 30 minutes, and then 2,4-difluorophenylboronic acid (371 mg, 2.34 mmol), potassium carbonate (1.08g, 7.82 mmol) and tetrakis(triphenylphosphine)palladium (90 mg, 0.078 mmol) were added. The reaction mixture was heated to 80° C. for 15 h, and then cooled and extracted with ethyl acetate. The organic layer was washed with water and saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (5 to 30% gradient of ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a pale yellow solid (150 mg) melting at 70-72° C.
1H NMR (CDCl3): δ 7.27 (m, 1H), 7.07 (dd, J=8.0, 3.0 Hz, 1H), 6.90 (m, 2H), 6.79 (m, 1H), 6.69 (m, 1H), 3.71 (s, 3H), 2.12 (s, 3H).
EXAMPLE 4
Preparation of α-(2,4-difluorophenyl)-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol (Compound 14)
Step A: Preparation of 4-(2,6-difluorophenyl)-3-buten-2-one
To a mixture of 2,6-difluorobenzaldehyde (10.0 g, 70 mmol) in acetone (85 mL) was added sodium hydroxide (1 N solution, 106 mL). After stirring at room temperature for 1.5 h, the reaction mixture was diluted with saturated aqueous sodium chloride solution and extracted with chloroform (2×150 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (0 to 20% gradient of ethyl acetate in hexanes as eluant) to afford the title product as a solid (8.1 g).
1H NMR (CDCl3): δ 7.61 (d, 1H), 7.16 (m, 1H), 6.98 (m, 3H), 2.39 (s, 3H).
Step B: Preparation of 5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole
To a mixture of 4-(2,6-difluorophenyl)-3-buten-2-one (i.e. the product of Step A) (8.1 g, 44.5 mmol) in ethanol (50 mL) was added methylhydrazine (2.1 g, 49 mmol). After 24 h, the reaction mixture was concentrated under reduced pressure. To the resulting oil (10.1 g) was added 1,1,2,2-tetrachloroethane (65 mL) and manganese oxide (41.7 g, 480 mmol). The reaction mixture was heated at 140° C. for 20 minutes, and then cooled to room temperature and filtered through a pad of Celite® (diatomaceous earth) on a sintered glass frit funnel rinsing with dichloromethane (2×20 mL). The filtrate was concentrated under reduced pressure and the resulting material was purified by MPLC (10 to 50% gradient of ethyl acetate in hexanes as eluant) to provide the title compound as a light yellow solid (4.02 g).
1H NMR (CDCl3): δ 7.38 (m, 1H), 7.01 (m, 2H), 6.17 (s, 1H), 3.71 (s, 3H), 2.32 (s, 3H).
Step C: Preparation of 4-bromo-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole
To a mixture of 5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole (i.e. the product of Step B) (1.53 g, 7.3 mmol) in N,N-dimethylformamide (20 mL) at 0° C. was added portionwise N-bromosuccinimide (1.37 g, 7.7 mmol). After the addition was complete, the reaction mixture was allowed to warm to room temperature and stirred for 1 h. The reaction mixture was diluted with ice water (20 mL) and saturated aqueous sodium bisulfite solution (15 mL), briefly stirred, and then partitioned between water (75 mL) and ethyl acetate (100 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (10 to 40% gradient of ethyl acetate in hexanes as eluant) to provide the title compound as a solid (1.84 g).
1H NMR (CDCl3): δ 7.52-7.42 (m, 1H), 7.10-7.01 (m, 2H), 3.71 (s, 3H), 2.30 (s, 3H).
Step D: Preparation of α-(2,4-difluorophenyl)-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol
To a mixture of 4-bromo-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole (i.e. the product of Step C) (500 mg, 1.7 mmol) in tetrahydrofuran (15 mL) at −78° C. was added dropwise n-butyllithium (2.0 M in hexanes, 0.76 mL, 1.9 mmol). The reaction mixture was stirred at −78° C. for about 20 minutes, and then a solution of 2,4-difluorobenzaldehyde (1534, 1.4 mmol) in tetrahydrofuran (1 mL) was added dropwise. After the addition was complete, the reaction mixture was stirred at about −78° C. for about 15 minutes, and then diluted with saturated aqueous ammonium chloride solution (1 mL) and allowed to warm to room temperature. The resulting mixture was poured onto a solid phase extraction tube (Varian Chem Elute®, prepacked with diatomaceous earth) eluting with ethyl acetate (50 mL). The ethyl acetate eluant was concentrated under reduced pressure and the resulting material was purified by MPLC (20 to 50% gradient of ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a solid (560 mg).
1H NMR (CDCl3): δ 7.41-7.32 (m, 2H), 7.01-6.90 (m, 1H), 6.89-6.82 (m, 1H), 6.68-6.56 (m, 2H), 5.82 (d, 1H), 3.60 (s, 3H), 2.26 (s, 3H), 2.08 (br s, 1H).
EXAMPLE 5
Preparation of 5-(2,6-difluorophenyl)-4-[(2,4-difluorophenyl)fluoromethyl]-1,3-dimethyl-1H-pyrazole (Compound 68)
To a mixture of α-(2,4-difluorophenyl)-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol (i.e. the product of Example 4) (70 mg, 0.20 mmol) in dichloromethane (2 mL) at −78° C. was added bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-Fluor®) (40 μL, 0.24 mmol). The reaction mixture was stirred overnight at room temperature, and then cooled to −78° C. and saturated aqueous sodium bicarbonate solution (3 mL) was added dropwise. The resulting mixture was extracted with dichloromethane (3×) and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (50% ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a solid (30 mg)
1H NMR (CDCl3): δ 7.40-7.31 (m, 1H), 7.28-7.20 (m, 1H), 6.98-6.82 (m, 2H), 6.70-6.62 (m, 2H), 6.52 (d, 1H), 3.61 (s, 3H), 2.20 (s, 3H).
EXAMPLE 6
Preparation of 4-[(4-chlorophenyl)thio]-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole (Compound 56)
To a mixture of 4-bromo-5-(2,6-difluorophenyl)-1,3-dimethyl-1H-pyrazole (i.e. the product of Step C, Example 4) (250 mg, 0.87 mmol) in tetrahydrofuran at −78° C. was added dropwise n-butyllithium (2.5 M in hexanes, 0.38 ml, 0.96 mmol). The reaction mixture was stirred at about −78 to 0° C. for 15 minutes, and then 4,4′-dichlorodiphenyl disulfide (0.25 g, 0.87 mmol) in tetrahydrofuran (1 mL) was added. After about 10 minutes, the reaction mixture was diluted with saturated aqueous ammonium chloride solution and allowed to warm to room temperature. The resulting mixture was poured onto a solid phase extraction tube (Varian Chem Elute®, prepacked with diatomaceous earth) eluting with ethyl acetate. The ethyl acetate eluant was concentrated under reduced pressure and the resulting material was purified by MPLC (10 to 50% gradient of ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as an oil (130 mg).
1H NMR (CDCl3): δ 7.45-7.38 (m, 1H), 7.15-7.10 (d, 2H), 7.01-6.92 (m, 2H), 6.93-6.85 (d, 2H), 3.75 (s, 3H), 2.22 (s, 3H).
EXAMPLE 7
Preparation of (2,4-difluorophenyl)-[5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]methanone (Compound 32)
To a mixture of aluminum chloride (380 mg, 2.88 mmol) in tetrachloroethane (10 mL) at about 0° C. was added 2,4-difluorobenzoyl chloride (0.36 mL, 2.88 mmol). The reaction mixture was stirred for about 30 minutes, and then a mixture of 5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole (prepared by the method analogous to Example 4, Steps A-B starting with 2,4-difluorobenzaldehyde) in tetrachloroethane (0.5 mL) was added. The reaction mixture was allowed to warm to room temperature, stirred for 1 h, and then heated at reflux for 24 h. The reaction mixture was cooled to room temperature, poured over a mixture of ice/hydrochloric acid and extracted with dichloromethane (3×). The combined organic layers were washed with saturated sodium chloride solution, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by MPLC (50% ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a solid (0.16 g).
1H NMR (CDCl3) δ 7.28-7.38 (m, 1H), 7.08-7.01 (m, 1H), 6.79-6.70 (m, 3H), 6.50-6.42 (m, 1H), 3.67 (s, 3H), 2.48 (s, 3H).
EXAMPLE 8
Preparation of α-(2,4-difluorophenyl)-5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole-4-methanol (Compound 72)
To a mixture of (2,4-difluorophenyl)-[5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]methanone (i.e. the product of Example 7) (80 mg, 0.23 mmol) in ethanol (3 mL) at about 0° C. was added sodium borohydride (38 mg, 0.92 mmol). The reaction mixture was stirred at room temperature for 2 h, and then diluted with ice/hydrochloric acid (about 1 mL). The resulting mixture was poured onto a solid phase extraction tube (Varian Chem Elute®, prepacked with diatomaceous earth) eluting with ethyl acetate (75 mL). The ethyl acetate eluant was concentrated under reduced pressure and the resulting material was purified by MPLC (20 to 70% gradient of ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a solid (63 mg).
1H NMR (CD3OD): δ 8.01-6.62 (m, 6H), 5.85 and 5.71 (two s, 1H) 3.54 and 3.50 (two s, 3H), 2.26 and 2.13 (two s, 3H).
EXAMPLE 9
Preparation of 3-bromo-5-(2-chloro-4-fluorophenyl)-α-(2,4-difluorophenyl)-1-methyl-1H-pyrazole-4-methanol (Compound 30)
Step A: Preparation of 3,5-dibromo-1H-pyrazole
To mixture of 3,4,5-tribromo-1H-pyrazole (10.0 g, 32.8 mmol) in tetrahydrofuran (130 mL) at −70° C. under an atmosphere of argon was added n-butyllithium (28.8 mL, 72.1 mmol, 2.5 M in hexanes) over 20 minutes. The reaction mixture was stirred at −70° C. for 2 h, and then methanol/tetrahydrofuran (20 mL/30 mL) was added dropwise. The reaction mixture was allowed to warm to room temperature and concentrated under reduced pressure. The resulting material was diluted with diethyl ether (500 mL), washed with aqueous hydrochloric acid (1 N, 25 mL) and saturated aqueous sodium chloride solution (20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound as a yellow solid (6.20 g,) 1H NMR (DMSO-d6): δ 6.23 (s, 1H).
Step B: Preparation of 3,5-dibromo-1-methyl-1H-pyrazole
To a mixture of sodium hydride (2.74 g 60% in mineral oil, 68.6 mmol) in tetrahydrofuran (40 mL) at 0° C. was added 3,5-dibromo-1H-pyrazole (i.e. the product of Step A) (6.20 g, 27.4 mmol) in tetrahydrofuran (25 mL) over a period of 10 minutes. The reaction mixture was stirred for 1 h at 0° C., and then iodomethane (3.42 mL, 54.9 mmol) was added dropwise. After 3 h the reaction mixture was allowed to warm to room temperature, saturated aqueous ammonium chloride solution (10 mL) was added and the resulting mixture was extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with water and with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure to provide the title compound as a brownish-yellow solid (6.0 g)
1H NMR (CDCl3): δ 6.29 (s, 1H), 3.85 (s, 3H).
Step C: Preparation of 3-bromo-5-(2-chloro-4-fluorophenyl)-1-methyl-1H-pyrazole
A mixture of 3,5-dibromo-1-methyl-1H-pyrazole (i.e. the product of Step B) (2.00 g, 8.33 mmol) in toluene (40 mL) was sparged with a stream of argon for 45 minutes, and then 2-chloro-4-fluorophenylboronic acid (1.59 g, 9.11 mmol), potassium phosphate tribasic (5.30 g, 25.0 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.48 g, 0.41 mmol) were added. The reaction mixture was heated at 90° C. for 3 h, and then cooled to room temperature and diluted with ethyl acetate (250 mL). The mixture was washed with water (25 mL) and saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (5 to 40% gradient of ethyl acetate in hexanes as eluant) to provide the title compound as a white solid (620 mg).
1H NMR (CDCl3): δ 7.32-7.27 (m, 2H), 7.09 (m, 1H), 6.28 (s, 1H), 3.67 (s, 3H).
Step D: Preparation of 3-bromo-5-(2-chloro-4-fluorophenyl)-4-iodo-1-methyl-1H-pyrazole
To a mixture of 3-bromo-5-(2-chloro-4-fluorophenyl)-1-methyl-1H-pyrazole (i.e. the product of Step C) (620 mg, 2.14 mmol) in N,N-dimethylformamide (8 mL) at 60° C. was added N-iodosuccinimide (963 mg, 4.28 mmol). The reaction mixture was stirred at 60° C. for 3 h, and then diluted with ethyl acetate, washed with water and saturated aqueous sodium chloride solution, dried over sodium sulfate and concentrated under reduced pressure. The material was purified by silica gel chromatography (5 to 30% gradient of ethyl acetate in hexanes as eluant) to provide the title compound as a pale yellow solid (515 mg) melting at 139-141° C.
1H NMR (CDCl3): δ 7.30 (m, 2H), 7.15 (m, 2H), 3.72 (s, 3H).
Step E: Preparation of 3-bromo-5-(2-chloro-4-fluorophenyl)-α-(2,4-difluorophenyl)-1-methyl-1H-pyrazole-4-methanol
To a mixture of 3-bromo-5-(2-chloro-4-fluorophenyl)-4-iodo-1-methyl-1H-pyrazole (i.e. the product of Step D) (250 mg, 0.602 mmol) in tetrahydrofuran (3 mL) at −78° C. was added dropwise n-butyllithium (2.5 M solution in hexanes, 0.36 mL, 0.90 mmol). Stirring was continued for 1 h at −78 to −40° C., and then the reaction mixture was cooled to −78° C. and 2,4-difluorobenzaldehyde (103 mg, 0.72 mmol) in tetrahydrofuran (2 mL) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 3 h, and then saturated aqueous ammonium chloride solution was added and the mixture was extracted with ethyl acetate (2×20 mL). The combined organic layers were washed with water and saturated aqueous sodium chloride solution, dried over sodium sulfate and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (10 to 50% gradient of ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as an off-white solid (35 mg).
1H NMR (CDCl3): δ 7.22 (m, 2H), 6.87 (m, 1H), 6.77 (m, 1H), 6.63 (m, 2H), 5.90 (d, J=4.7 Hz, 1H), 3.53 (s, 3H), 2.17 (d, J=4.7 Hz, 1H).
EXAMPLE 10
Preparation of 4-(2-chloro-4-fluorobenzoyl)-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile (Compound 52)
Step A: Preparation of ethyl 5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carboxylate
To a mixture of 2,6-difluoroacetophenone (4.7 g, 0.03 mol) and 1,2-diethyl ethanedioate (4.8 g, 0.033 mol) in ethanol (33 mL) was added sodium tert-butoxide (3.17 g, 0.033 mol). After 1 h, more ethanol (30 mL) was added to the reaction mixture and stirring was continued for 1 h. The reaction mixture was partitioned between hydrochloric acid (1 N) and diethyl ether. The organic phase was separated, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to half its original volume. To the resulting mixture was added methylhydrazine (1.52 g, 0.033 mol) and stirring was continued overnight. The reaction mixture was concentrated under reduced pressure and the resulting material was purified by silica gel chromatography (5 to 20% gradient of ethyl acetate in methylene chloride as eluant) to provide the title compound as a solid (1.0 g).
1H NMR (CDCl3): δ 7.56-7.38 (m, 1H) 7.06 (m, 2H) 6.95 (s, 1H), 4.43 (d, 2H) 3.86 (s, 3H), 1.42 (t, 3H).
Step B: Preparation of 5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile
To a mixture of ammonium chloride (0.42 g, 7.52 mmol) in toluene (10 mL) at 0° C. was added dropwise trimethyl aluminum (2 M in toluene, 3.76 mL, 7.52 mmol). After the addition was complete, the reaction mixture was stirred at 0° C. for 1 h, warmed to room temperature, and then a mixture of ethyl 5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carboxylate (i.e. the product of Step A) (1 g, 3.76 mmol) in toluene (5 mL) was added and the mixture was heated at 110° C. for 4 h. The reaction mixture was allowed to cool to room temperature, partitioned between aqueous hydrochloric acid (1 N) and diethyl ether (about 20 mL) and the organic phase was separated. The aqueous phase was extracted with diethyl ether and the combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel column chromatography (10 to 20% gradient of ethyl acetate in hexanes) to provide the title compound as a solid (0.4 g).
1H NMR (CDCl3): δ 7.61-7.41 (m, 1H), 7.08 (m, 2H), 6.80 (s, 1H), 3.85 (s, 3H).
Step C: Preparation of 4-(2-chloro-4-fluorobenzoyl)-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile
To a mixture of aluminum chloride (0.18 g, 1.36 mmol) in 1,2-dichloroethane (2 mL) was added a mixture of 2-chloro-4-fluorobenzoyl chloride (0.26 g, 1.36 mmol) and 5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile (i.e. the product of Step B) (0.15 g, 0.68 mmol) in dichloroethane (1 mL). The reaction mixture was heated at 180° C. in a Biotage InitiatorTM microwave apparatus for 30 minutes. The resulting mixture was poured directly onto a Varian Bond Elute SIC) column and eluted with methylene chloride followed by 30% ethyl acetate in hexanes to provide the title compound, a compound of the present invention, as a solid (0.07 g).
1H NMR (CDCl3): δ 8.12-8.03 (m, 1H), 7.41-7.57 (m, 1H), 7.40-7.33 (m, 1H), 7.12-7.04 (m, 1H), 6.91-7.03 (m, 2H), 3.85 (s, 3H).
EXAMPLE 11
Preparation of 4-[(2-chloro-4-fluorophenyl)hydroxymethyl]-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile (Compound 53)
To a mixture of 4-(2-chloro-4-fluorobenzoyl)-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile (i.e. the product of Example 10) (0.05 g, 0.13 mmol) in ethanol (2 mL) was added sodium borohydride (0.005 g, 0.13 mmol). The reaction was stirred for 30 minutes, and then hydrochloric acid (1 N) (0.5 mL) was added and the mixture was concentrated under reduced pressure. The resulting material was diluted with methylene chloride (5 mL) and filter through a Celite® (diatomaceous earth) extraction tube rinsing with methylene chloride (15 mL). The filtrate was concentrated under reduced pressure and the resulting material purified by flash chromatography on a silica gel, Varian Bond Elute SI® column (10 to 50% gradient of ethyl acetate in hexanes as eluant) to provide the title compound, a compound of the present invention, as a solid (0.03 g).
1H NMR (CDCl3): δ 7.63-7.54 (m, 1H), 7.53-7.40 (m, 1H), 7.06-6.91 (m, 3H), 6.90-6.81 (m, 1H), 6.01 (d, 1H), 3.73 (s, 3H), 2.51 (d, 1H).
EXAMPLE 12
Preparation of 5-(2,6-difluorophenyl)-α-(4-fluoro-2-methylphenyl)-3-methoxy-1-methyl-1H-pyrazole-4-methanol (Compound 157)
Step A: Preparation of methyl 3-(2,6-difluorophenyl)-2-propynoate
To a mixture of (diazomethyl)trimethylsilane (2.0 M in hexanes, 25 mL, 50 mmol) in tetrahydrofuran (100 mL) at −78° C. was added n-butyllithium (2.5 M in hexanes, 20 mL, 50 mmol) over 5 minutes. After the addition was complete, the reaction mixture temperature was maintained at about −78° C. for 30 minutes and then 2,6-difluorobenzaldehyde (7.1 g, 50 mmol) was added portionwise. The reaction mixture was maintained at −78° C. for an additional 30 minutes and then allowed to warm to room temperature, during which time gas evolution occurred. The reaction mixture was again cooled to −78° C. and n-butyllithium (2.5 M in hexanes, 28 mL, 70 mmol) was added over 5 minutes. After 15 minutes at −78° C., methyl chloroformate (7.8 mL, 100 mmol) was added to the reaction mixture. After 30 minutes, the reaction mixture was allowed to warm to 0° C., and then partitioned between diethyl ether and saturated ammonium chloride solution. The organic phase was separated, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (0 to 100% gradient of ethyl acetate in hexanes as eluant) to provide the title compound (8.0 g).
1H NMR (CDCl3): δ 7.48-7.33 (m, 1H), 7.06-6.81 (m, 2H), 3.87 (s, 3H).
Step B: Preparation of 5-(2,6-difluorophenyl)-1,2-dihydro-1-methyl-3H-prazol-3-one
A mixture of methyl 3-(2,6-difluorophenyl)-2-propynoate (5.0 g, 25.5 mmol) (i.e. the product of Step A) and methylhydrazine (1.6 mL, 30.6 mmol) in a solution of ethanol/water (25 mL, 1:1 mixture) was heated at 70° C. overnight. The reaction mixture was concentrated under reduced pressure and the resulting material purified by silica gel chromatography (90% hexanes in ethyl acetate as eluant) to provide the title compound (2.5 g).
1H NMR (CDCl3): δ 11.85 (br s, 1H), 7.51-7.32 (m, 1H), 7.08-6.95 (m, 2H), 5.79 (s, 1H), 3.61 (s, 3H).
Step C: Preparation of 5-(2,6-difluorophenyl)-3-methoxy-1-methyl-1H-pyrazole
A mixture of 5-(2,6-difluorophenyl)-1,2-dihydro-1-methyl-3H-prazol-3-one (2.0 g, 9.6 mmol) (i.e. the product of Step B), potassium carbonate (1.9 g, 14 mmol) and iodomethane (0.75 mL, 12 mmol) in acetonitrile (20 mL) was heated at 70° C. for 4 h and then allowed to cool to room temperature. After about 48 h, the reaction was diluted with dichloromethane and the resulting mixture was filtered through a pad of Celite® (diatomaceous earth) on a sintered glass frit funnel. The filtrate was concentrated under reduced pressure and the resulting material was purified by silica gel chromatography (0 to 100% gradient of ethyl acetate in hexanes as eluant) to provide the title compound (1.3 g).
1H NMR (CDCl3): δ 7.48-7.34 (m, 1H), 7.09-6.93 (m, 2H), 5.79 (s, 1H), 3.92 (s, 3H), 3.62 (s, 3H).
Step D: Preparation of 5-(2,6-difluorophenyl)-3-methoxy-1-methyl-1H-pyrazole-4-carboxaldehyde
To a mixture of 5-(2,6-difluorophenyl)-3-methoxy-1-methyl-1H-pyrazole (0.5 g, 2.2 mmol) (i.e. the product of Step C) in dimethylformamide (5 mL) at 80° C. was added phosphorus oxychloride (0.31 ml, 3.3 mmol). After 2 h the reaction mixture was allowed to cool to room temperature. The reaction mixture was diluted with sodium hydroxide (1 N, about 5 mL) and water. The resulting mixture was extracted with diethyl ether (2×) and the combined organic layers were washed with water, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The resulting material was purified by silica gel chromatography (0 to 100% gradient of ethyl acetate in dichloromethane as eluant) to provide the title compound (0.5 g).
1H NMR (CDCl3): δ 9.65 (s, 1H), 7.59-7.44 (m, 1H), 7.12-7.02 (m, 2H), 4.05 (s, 3H), 3.63 (s, 3H).
Step E: Preparation of 5-(2,6-difluorophenyl)-α-(4-fluoro-2-methylphenyl)-3-methoxy-1-methyl-1H-pyrazole-4-methanol
To a mixture of 5-(2,6-difluorophenyl)-3-methoxy-1-methyl-1H-pyrazole-4-carboxaldehyde (0.25 g, 0.99 mmol) (i.e. the product of Step D) in tetrahydrofuran (5 mL) at −30° C. was added 4-fluoro-2-methylphenylmagnesium bromide (0.5 M in hexanes, 2.0 mL, 1.0 mmol). The reaction mixture was allowed to warm to 0° C., quenched with saturated ammonium chloride solution and concentrated under reduced pressure. The resulting material was diluted with dichloromethane and water, poured onto a solid phase extraction tube (Varian Chem Elute®, prepacked with diatomaceous earth) and eluted with dichloromethane. The dichloromethane eluant was concentrated under reduced pressure and the resulting material purified by silica gel chromatography (0 to 100% gradient of ethyl acetate in dichloromethane as eluant) to provide the title compound (0.3 g).
1H NMR (CDCl3): δ 7.40-7.20 (m, 2H), 6.93-6.80 (m, 1H), 6.80-6.68 (m, 1H), 6.67-6.58 (m, 1H), 6.58-6.48 (m, 1H), 5.87-5.75 (m, 1H), 4.01 (s, 3H), 3.47 (s, 3H), 2.50-2.37 (m, 1H), 2.05 (s, 3H).
By the procedures described herein together with methods known in the art, the compounds disclosed in the Tables that follow can be prepared. The following abbreviations are used in the Table which follows: Me means methyl, Et means ethyl, n-Pr means n-propyl, c-Pr means cyclopropyl, Ph means phenyl, MeO means methoxy, EtO means ethoxy, —CN means cyano and —NO2 means nitro.







TABLE 1








   Q2 is 2,6-di-F—Ph and R2 is Me.


 


(R3a)p







2-F


3-F


4-F


2-Cl


3-Cl


4-Cl


2-Br


3-Br


4-Br


4-Me


2,6-di-F


2,4-di-F


2,4-di-Cl


2,6-di-Cl


2,4-di-Me


2-F, 4-Cl


2-Cl, 4-F


2-F, 4-Br


2-Cl, 4-Br


2-Br, 4-Cl


2-Br, 4-F


2-I, 4-F


2-Me, 4-F


2-Cl, 4-CN


2-F, 4-CN


2-Br, 4-CN


2-CF3, 4-F


2-Me, 4-MeO


2-Me, 4-EtO


2-Br, 4-MeO


2-Cl, 4-MeO


2-F, 4-MeO


2-Cl, 4-EtO


2-F, 4-EtO


2,4,5-tri-F


2,3,5-tri-F


2,3,6-tri-F


2,4,6-tri-F


2,4,6-tri-Cl


2-Cl, 4,6-di-F


2,6-di-Cl, 4-F


2,4-di-Cl, 6-F


4-Cl, 2,6-di-F


2-Br, 4,6-di-F


4-Br, 2,6-di-F


2,4-di-Br, 6-F


2-Br, 4-Cl, 6-F


2-I, 4,6-di-F


4-I, 2,6-di-F


2,6-di-Cl, 4-CN


2,6-di-F, 4-CN


2,6-di-Cl, 4-MeO


2,6-di-F, 4-MeO


2,6-di-Cl, 4-EtO


2,6-di-F, 4-EtO


2-Br, 4-F, 6-Cl


2-Cl, 4-Br, 6-F


4-MeNH(CH2)3O


4-Me2N(CH2)3O


4-MeO(CH2)3O


2-F, 4-MeNH(CH2)3O


2-F, 4-Me2N(CH2)3O


2-Cl, 4-MeO(CH2)3O


2,6-di-F, 4-MeNH(CH2)3O


2,6-di-F, 4-MeNH(CH2)3


2,6-di-F, 4-Me2N(CH2)3O


2,6-di-F, 4-MeO(CH2)3O


2,6-di-F, 3-MeNH(CH2)3O


2,6-di-F, 3-MeNH(CH2)3


2,6-di-F, 3-Me2N(CH2)3O


2,6-di-F, 3-MeO(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3


2-Cl-6-F, 4-Me2N(CH2)3O


2-Cl-6-F, 4-MeO(CH2)3O









The present disclosure also includes Tables 1A through 164A, each of which is constructed the same as Table 1 above, except that the row heading in Table 1 (i.e. “Q2 is 2,6-di-F-Ph and R2 is Me.”) is replaced with the respective row heading shown below. For Example, in Table 1A the row heading is “Q2 is 2,6-di-F-Ph and R2 is Cl”, and (R3)p is as defined in Table 1 above. Thus, the first entry in Table 1A specifically discloses 3-chloro-5-(2,6-difluorophenyl)-N-(2-fluorophenyl)-1-methyl-1H-pyrazole-4-amine. Tables 2A through 164A are constructed similarly.











Table
Row Heading







 1A
Q2 is 2,6-di-F—Ph and R2 is Cl.


 2A
Q2 is 2,6-di-F—Ph and R2 is Br.


 3A
Q2 is 2,6-di-F—Ph and R2 is Et.


 4A
Q2 is 2,6-di-F—Ph and R2 is CN.


 5A
Q2 is 2,4-di-F—Ph and R2 is Me.


 6A
Q2 is 2,4-di-F—Ph and R2 is Cl.


 7A
Q2 is 2,4-di-F—Ph and R2 is Br.


 8A
Q2 is 2,4-di-F—Ph and R2 is Et.


 9A
Q2 is 2,4-di-F—Ph and R2 is CN.


10A
Q2 is 2,4,6-tri-F—Ph and R2 is Me.


11A
Q2 is 2,4,6-tri-F—Ph and R2 is Cl.


12A
Q2 is 2,4,6-tri-F—Ph and R2 is Br.


13A
Q2 is 2,4,6-tri-F—Ph and R2 is Et.


14A
Q2 is 2,4,6-tri-F—Ph and R2 is CN.


15A
Q2 is 2,6-di-F-4-MeO—Ph and R2 is Me.


16A
Q2 is 2,6-di-F-4-MeO—Ph and R2 is Cl.


17A
Q2 is 2,6-di-F-4-MeO—Ph and R2 is Br.


18A
Q2 is 2,6-di-F-4-MeO—Ph and R2 is Et.


19A
Q2 is 2,6-di-F-4-Me—Ph and R2 is CN.


20A
Q2 is 2,6-di-F-4-EtO—Ph and R2 is Me.


21A
Q2 is 2,6-di-F-4-EtO—Ph and R2 is Cl.


22A
Q2 is 2,6-di-F-4-EtO—Ph and R2 is Br.


23A
Q2 is 2,6-di-F-4-EtO—Ph and R2 is Et.


24A
Q2 is 2,6-di-F-4-EtO—Ph and R2 is CN.


25A
Q2 is 2,6-di-F-4-CN—Ph and R2 is Me.


26A
Q2 is 2,6-di-F-4-CN—Ph and R2 is Cl.


27A
Q2 is 2,6-di-F-4-CN—Ph and R2 is Br.


28A
Q2 is 2,6-di-F-4-CN—Ph and R2 is Et.


29A
Q2 is 2,6-di-F-4-CN—Ph and R2 is CN.


30A
Q2 is 2-Cl-4-F—Ph and R2 is Me.


31A
Q2 is 2-Cl-4-F—Ph and R2 is Cl.


32A
Q2 is 2-Cl-4-F—Ph and R2 is Br.


33A
Q2 is 2-Cl-4-F—Ph and R2 is Et.


34A
Q2 is 2-Cl-4-F—Ph and R2 is CN.


35A
Q2 is 2-Cl-6-F—Ph and R2 is Me.


36A
Q2 is 2-Cl-6-F—Ph and R2 is Cl.


37A
Q2 is 2-Cl-6-F—Ph and R2 is Br.


38A
Q2 is 2-Cl-6-F—Ph and R2 is Et.


39A
Q2 is 2-Cl-6-F—Ph and R2 is CN.


40A
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Me.


41A
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Cl.


42A
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Br.


43A
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Et.


44A
Q2 is 2-Cl-4,6-di-F—Ph and R2 is CN.


45A
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Me.


46A
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Cl.


47A
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Br.


48A
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Et.


49A
Q2 is 4-Cl-2,6-di-F—Ph and R2 is CN.


50A
Q2 is 2-Br-4-F—Ph and R2 is Me.


51A
Q2 is 2-Br-4-F—Ph and R2 is Cl.


52A
Q2 is 2-Br-4-F—Ph and R2 is Br.


53A
Q2 is 2-Br-4-F—Ph and R2 is Et.


54A
Q2 is 2-Br-4-F—Ph and R2 is CN.


55A
Q2 is 2-Br-6-F—Ph and R2 is Me.


56A
Q2 is 2-Br-6-F—Ph and R2 is Cl.


57A
Q2 is 2-Br-6-F—Ph and R2 is Br.


58A
Q2 is 2-Br-6-F—Ph and R2 is Et.


59A
Q2 is 2-Br-6-F—Ph and R2 is CN.


60A
Q2 is 2-Me-4-F—Ph and R2 is Me.


61A
Q2 is 2-Me-4-F—Ph and R2 is Cl.


62A
Q2 is 2-Me-4-F—Ph and R2 is Br.


63A
Q2 is 2-Me-4-F—Ph and R2 is Et.


64A
Q2 is 2-Me-4-F—Ph and R2 is CN.


65A
Q2 is 2-I-4-F—Ph and R2 is Me.


66A
Q2 is 2-I-4-F—Ph and R2 is Cl.


67A
Q2 is 2-I-4-F—Ph and R2 is Br.


68A
Q2 is 2-I-4-F—Ph and R2 is Et.


69A
Q2 is 2-I-4-F—Ph and R2 is CN.


70A
Q2 is 2-F—Ph and R2 is Me.


71A
Q2 is 2-F—Ph and R2 is Cl.


72A
Q2 is 2-F—Ph and R2 is Br.


73A
Q2 is 2-F—Ph and R2 is Et.


74A
Q2 is 2-F—Ph and R2 is CN.


75A
Q2 is 2-Cl—Ph and R2 is Me.


76A
Q2 is 2-Cl—Ph and R2 is Cl.


77A
Q2 is 2-Cl—Ph and R2 is Br.


78A
Q2 is 2-Cl—Ph and R2 is Et.


79A
Q2 is 2-Cl—Ph an R2 is CN.


80A
Q2 is 2-Br—Ph and R2 is Me.


81A
Q2 is 2-Br—Ph and R2 is Cl.


82A
Q2 is 2-Br—Ph and R2 is Br.


83A
Q2 is 2-Br—Ph and R2 is Et.


84A
Q2 is 2-Br—Ph and R2 is CN.


85A
Q2 is 2-F-4-Cl—Ph and R2 is Me.


86A
Q2 is 2-F-4-Cl—Ph and R2 is Cl.


87A
Q2 is 2-F-4-Cl—Ph and R2 is Br.


88A
Q2 is 2-F-4-Cl—Ph and R2 is Et.


89A
Q2 is 2-F-4-Cl—Ph and R2 is CN.


90A
Q2 is 2,4-di-Cl—Ph and R2 is Me.


91A
Q2 is 2,4-di-Cl—Ph and R2 is Cl.


92A
Q2 is 2,4-di-Cl—Ph and R2 is Br.


93A
Q2 is 2,4-di-Cl—Ph and R2 is Et.


94A
Q2 is 2,4-di-Cl—Ph and R2 is CN.


95A
Q2 is 2,6-di-Cl—Ph and R2 is Me.


96A
Q2 is 2,6-di-Cl—Ph and R2 is Cl.


97A
Q2 is 2,6-di-Cl—Ph and R2 is Br.


98A
Q2 is 2,6-di-Cl—Ph and R2 is Et.


99A
Q2 is 2,6-di-Cl—Ph and R2 is CN.


100A 
Q2 is 2-F-4-MeO—Ph and R2 is Me.


101A 
Q2 is 2-F-4-MeO—Ph and R2 is Cl.


102A 
Q2 is 2-F-4-MeO—Ph and R2 is Br.


103A 
Q2 is 2-F-4-MeO—Ph and R2 is Et.


104A 
Q2 is 2-F-4-MeO—Ph and R2 is CN.


105A 
Q2 is 2-F-4-EtO—Ph and R2 is Me.


106A 
Q2 is 2-F-4-EtO—Ph and R2 is Cl.


107A 
Q2 is 2-F-4-EtO—Ph and R2 is Br.


108A 
Q2 is 2-F-4-EtO—Ph and R2 is Et.


109A 
Q2 is 2-F-4-EtO—Ph and R2 is CN.


110A 
Q2 is 2-Cl-4-MeO—Ph and R2 is Me.


111A 
Q2 is 2-Cl-4-MeO—Ph and R2 is Cl.


112A 
Q2 is 2-Cl-4-MeO—Ph and R2 is Br.


113A 
Q2 is 2-Cl-4-MeO—Ph and R2 is Et.


114A 
Q2 is 2-Cl-4-MeO—Ph and R2 is CN.


115A 
Q2 is 2-Cl-4-EtO—Ph and R2 is Me.


116A 
Q2 is 2-Cl-4-EtO—Ph and R2 is Cl.


117A 
Q2 is 2-Cl-4-EtO—Ph and R2 is Br.


118A 
Q2 is 2-Cl-4-EtO—Ph and R2 is Et.


119A 
Q2 is 2-Cl-4-EtO—Ph and R2 is CN.


120A 
Q2 is 2-Br-4-MeO—Ph and R2 is Me.


121A 
Q2 is 2-Br-4-MeO—Ph and R2 is Cl.


122A 
Q2 is 2-Br-4-MeO—Ph and R2 is Br.


123A 
Q2 is 2-Br-4-MeO—Ph and R2 is Et.


124A 
Q2 is 2-Br-4-MeO—Ph and R2 is CN.


125A 
Q2 is 2-Br-4-EtO—Ph and R2 is Me.


126A 
Q2 is 2-Br-4-EtO—Ph and R2 is Cl.


127A 
Q2 is 2-Br-4-EtO—Ph and R2 is Br.


128A 
Q2 is 2-Br-4-EtO—Ph and R2 is Et.


129A 
Q2 is 2-Br-4-EtO—Ph and R2 is CN.


130A 
Q2 is 2-F-4-CN—Ph and R2 is Me.


131A 
Q2 is 2-F-4-CN—Ph and R2 is Cl.


132A 
Q2 is 2-F-4-CN—Ph and R2 is Br.


133A 
Q2 is 2-F-4-CN—Ph and R2 is Et.


134A 
Q2 is 2-F-4-CN—Ph and R2 is CN.


135A 
Q2 is 2-Cl-4-CN—Ph and R2 is Me.


136A 
Q2 is 2-Cl-4-CN—Ph and R2 is Cl.


137A 
Q2 is 2-Cl-4-CN—Ph and R2 is Br.


138A 
Q2 is 2-Cl-4-CN—Ph and R2 is Et.


139A 
Q2 is 2-Cl-4-CN—Ph and R2 is CN.


140A 
Q2 is 2-Br-4-CN—Ph and R2 is Me.


141A 
Q2 is 2-Br-4-CN—Ph and R2 is Cl.


142A 
Q2 is 2-Br-4-CN—Ph and R2 is Br.


143A 
Q2 is 2-Br-4-CN—Ph and R2 is Et.


144A 
Q2 is 2-Br-4-CN—Ph and R2 is CN.


145A 
Q2 is 3-Cl-2-pyridinyl and R2 is Me.


146A 
Q2 is 3-Cl-2-pyridinyl and R2 is Cl.


147A 
Q2 is 3-Cl-2-pyridinyl and R2 is Br.


148A 
Q2 is 3-Cl-2-pyridinyl and R2 is Et.


149A 
Q2 is 3-Cl-2-pyridinyl and R2 is CN.


150A 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Me.


151A 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Cl.


152A 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Br.


153A 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Et.


154A 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is CN.


155A 
Q2 is 2-Cl-3-thienyl and R2 is Me.


156A 
Q2 is 2-Cl-3-thienyl and R2 is Cl.


157A 
Q2 is 2-Cl-3-thienyl and R2 is Br.


158A 
Q2 is 2-Cl-3-thienyl and R2 is Et.


159A 
Q2 is 2-Cl-3-thienyl and R2 is CN.


160A 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Me.


161A 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Cl.


162A 
Q2 is 2,5-di-Cl-3-thienyand R2 is Br.


163A 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Et.


164A 
Q2 is 2,5-di-Cl-3-thienyl and R2 is CN.
















TABLE 2








   Q2 is 2,6-di-F—Ph and R2 is Me.


 


(R3a)p







2-F


3-F


4-F


2-Cl


3-Cl


4-Cl


2-Br


3-Br


4-Br


4-Me


2,6-di-F


2,4-di-F


2,4-di-Cl


2,6-di-Cl


2,4-di-Me


2-F, 4-Cl


2-Cl, 4-F


2-F, 4-Br


2-Cl, 4-Br


2-Br, 4-Cl


2-Br, 4-F


2-I, 4-F


2-Me, 4-F


2-Cl, 4-CN


2-F, 4-CN


2-Br, 4-CN


2-CF3, 4-F


2-Me, 4-MeO


2-Me, 4-EtO


2-Br, 4-MeO


2-Cl, 4-MeO


2-F, 4-MeO


2-Cl, 4-EtO


2-F, 4-EtO


2,4,5-tri-F


2,3,5-tri-F


2,3,6-tri-F


2,4,6-tri-F


2,4,6-tri-Cl


2-Cl, 4,6-di-F


2,6-di-Cl, 4-F


2,4-di-Cl, 6-F


4-Cl, 2,6-di-F 


2-Br, 4,6-di-F


4-Br, 2,6-di-F


2,4-di-Br, 6-F


2-Br, 4-Cl, 6-F


2-I, 4,6-di-F


4-I, 2,6-di-F


2,6-di-Cl, 4-CN


2,6-di-F, 4-CN


2,6-di-Cl, 4-MeO


2,6-di-F, 4-MeO


2,6-di-Cl, 4-EtO


2,6-di-F, 4-EtO


2-Br, 4-F, 6-Cl


2-Cl, 4-Br, 6-F


4-MeNH(CH2)3O


4-Me2N(CH2)3O


4-MeO(CH2)3O


2-F, 4-MeNH(CH2)3O


2-F, 4-Me2N(CH2)3O


2-Cl, 4-MeO(CH2)3O


2,6-di-F, 4-MeNH(CH2)3O


2,6-di-F, 4-MeNH(CH2)3


2,6-di-F, 4-Me2N(CH2)3O


2,6-di-F, 4-MeO(CH2)3O


2,6-di-F, 3-MeNH(CH2)3O


2,6-di-F, 3-MeNH(CH2)3


2,6-di-F, 3-Me2N(CH2)3O


2,6-di-F, 3-MeO(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3


2-Cl-6-F, 4-Me2N(CH2)3O


2-Cl-6-F, 4-MeO(CH2)3O









The present disclosure also includes Tables 1B through 164B, each of which is constructed the same as Table 2 above, except that the row heading in Table 2 (i.e. “Q2 is 2,6-di-F-Ph and R2 is Me”) is replaced with the respective row heading shown below. For Example, in Table 1B the row heading is “Q2 is 2,6-di-F-Ph and R2 is Cl”, and (R3)p is as defined in Table 2 above. Thus, the first entry in Table 1B specifically discloses 3-chloro-5-(2,6-difluorophenyl)-4-(2-fluorophenyl)-1-methyl-1H-pyrazole. Tables 2B through 164B are constructed similarly.











Table
Row Heading







 1B
Q2 is 2,6-di-F—Ph and R2 is Cl.


 2B
Q2 is 2,6-di-F—Ph and R2 is Br.


 3B
Q2 is 2,6-di-F—Ph and R2 is Et.


 4B
Q2 is 2,6-di-F—Ph and R2 is CN.


 5B
Q2 is 2,4-di-F—Ph and R2 is Me.


 6B
Q2 is 2,4-di-F—Ph and R2 is Cl.


 7B
Q2 is 2,4-di-F—Ph and R2 is Br.


 8B
Q2 is 2,4-di-F—Ph and R2 is Et.


 9B
Q2 is 2,4-di-F—Ph and R2 is CN.


10B
Q2 is 2,4,6-tri-F—Ph and R2 is Me.


11B
Q2 is 2,4,6-tri-F—Ph and R2 is Cl.


12B
Q2 is 2,4,6-tri-F—Ph and R2 is Br.


13B
Q2 is 2,4,6-tri-F—Ph and R2 is Et.


14B
Q2 is 2,4,6-tri-F—Ph and R2 is CN.


15B
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Me.


16B
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Cl.


17B
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Br.


18B
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Et.


19B
Q2 is 2,6-di-F-4-OMe—Ph and R2 is CN.


20B
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Me.


21B
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Cl.


22B
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Br.


23B
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Et.


24B
Q2 is 2,6-di-F-4-OEt—Ph and R2 is CN.


25B
Q2 is 2,6-di-F-4-CN—Ph and R2 is Me.


26B
Q2 is 2,6-di-F-4-CN—Ph and R2 is Cl.


27B
Q2 is 2,6-di-F-4-CN—Ph and R2 is Br.


28B
Q2 is 2,6-di-F-4-CN—Ph and R2 is Et.


29B
Q2 is 2,6-di-F-4-CN—Ph and R2 is CN.


30B
Q2 is 2-Cl-4-F—Ph and R2 is Me.


31B
Q2 is 2-Cl-4-F—Ph and R2 is Cl.


32B
Q2 is 2-Cl-4-F—Ph and R2 is Br.


33B
Q2 is 2-Cl-4-F—Ph and R2 is Et.


34B
Q2 is 2-Cl-4-F—Ph and R2 is CN.


35B
Q2 is 2-Cl-6-F—Ph and R2 is Me.


36B
Q2 is 2-Cl-6-F—Ph and R2 is Cl.


37B
Q2 is 2-Cl-6-F—Ph and R2 is Br.


38B
Q2 is 2-Cl-6-F—Ph and R2 is Et.


39B
Q2 is 2-Cl-6-F—Ph and R2 is CN.


40B
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Me.


41B
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Cl.


42B
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Br.


43B
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Et.


44B
Q2 is 2-Cl-4,6-di-F—Ph and R2 is CN.


45B
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Me.


46B
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Cl.


47B
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Br.


48B
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Et.


49B
Q2 is 4-Cl-2,6-di-F—Ph and R2 is CN.


50B
Q2 is 2-Br-4-F—Ph and R2 is Me.


51B
Q2 is 2-Br-4-F—Ph and R2 is Cl.


52B
Q2 is 2-Br-4-F—Ph and R2 is Br.


53B
Q2 is 2-Br-4-F—Ph and R2 is Et.


54B
Q2 is 2-Br-4-F—Ph and R2 is CN.


55B
Q2 is 2-Br-6-F—Ph and R2 is Me.


56B
Q2 is 2-Br-6-F—Ph and R2 is Cl.


57B
Q2 is 2-Br-6-F—Ph and R2 is Br.


58B
Q2 is 2-Br-6-F—Ph and R2 is Et.


59B
Q2 is 2-Br-6-F—Ph and R2 is CN.


60B
Q2 is 2-Me-4-F—Ph and R2 is Me.


61B
Q2 is 2-Me-4-F—Ph and R2 is Cl.


62B
Q2 is 2-Me-4-F—Ph and R2 is Br.


63B
Q2 is 2-Me-4-F—Ph and R2 is Et.


64B
Q2 is 2-Me-4-F—Ph and R2 is CN.


65B
Q2 is 2-I-4-F—Ph and R2 is Me.


66B
Q2 is 2-I-4-F—Ph and R2 is Cl.


67B
Q2 is 2-I-4-F—Ph and R2 is Br.


68B
Q2 is 2-I-4-F—Ph and R2 is Et.


69B
Q2 is 2-I-4-F—Ph and R2 is CN.


70B
Q2 is 2-F—Ph and R2 is Me.


71B
Q2 is 2-F—Ph and R2 is Cl.


72B
Q2 is 2-F—Ph and R2 is Br.


73B
Q2 is 2-F—Ph and R2 is Et.


74B
Q2 is 2-F—Ph and R2 is CN.


75B
Q2 is 2-Cl—Ph and R2 is Me.


76B
Q2 is 2-Cl—Ph and R2 is Cl.


77B
Q2 is 2-Cl—Ph and R2 is Br.


78B
Q2 is 2-Cl—Ph and R2 is Et.


79B
Q2 is 2-Cl—Ph an R2 is CN.


80B
Q2 is 2-Br—Ph and R2 is Me.


81B
Q2 is 2-Br—Ph and R2 is Cl.


82B
Q2 is 2-Br—Ph and R2 is Br.


83B
Q2 is 2-Br—Ph and R2 is Et.


84B
Q2 is 2-Br—Ph and R2 is CN.


85B
Q2 is 2-F-4-Cl—Ph and R2 is Me.


86B
Q2 is 2-F-4-Cl—Ph and R2 is Cl.


87B
Q2 is 2-F-4-Cl—Ph and R2 is Br.


88B
Q2 is 2-F-4-Cl—Ph and R2 is Et.


89B
Q2 is 2-F-4-Cl—Ph and R2 is CN.


90B
Q2 is 2,4-di-Cl—Ph and R2 is Me.


91B
Q2 is 2,4-di-Cl—Ph and R2 is Cl.


92B
Q2 is 2,4-di-Cl—Ph and R2 is Br.


93B
Q2 is 2,4-di-Cl—Ph and R2 is Et.


94B
Q2 is 2,4-di-Cl—Ph and R2 is CN.


95B
Q2 is 2,6-di-Cl—Ph and R2 is Me.


96B
Q2 is 2,6-di-Cl—Ph and R2 is Cl.


97B
Q2 is 2,6-di-Cl—Ph and R2 is Br.


98B
Q2 is 2,6-di-Cl—Ph and R2 is Et.


99B
Q2 is 2,6-di-Cl—Ph and R2 is CN.


100B 
Q2 is 2-F-4-MeO—Ph and R2 is Me.


101B 
Q2 is 2-F-4-MeO—Ph and R2 is Cl.


102B 
Q2 is 2-F-4-MeO—Ph and R2 is Br.


103B 
Q2 is 2-F-4-MeO—Ph and R2 is Et.


104B 
Q2 is 2-F-4-MeO—Ph and R2 is CN.


105B 
Q2 is 2-F-4-EtO—Ph and R2 is Me.


106B 
Q2 is 2-F-4-EtO—Ph and R2 is Cl.


107B 
Q2 is 2-F-4-EtO—Ph and R2 is Br.


108B 
Q2 is 2-F-4-EtO—Ph and R2 is Et.


109B 
Q2 is 2-F-4-EtO—Ph and R2 is CN.


110B 
Q2 is 2-Cl-4-MeO—Ph and R2 is Me.


111B 
Q2 is 2-Cl-4-MeO—Ph and R2 is Cl.


112B 
Q2 is 2-Cl-4-MeO—Ph and R2 is Br.


113B 
Q2 is 2-Cl-4-MeO—Ph and R2 is Et.


114B 
Q2 is 2-Cl-4-MeO—Ph and R2 is CN.


115B 
Q2 is 2-Cl-4-EtO—Ph and R2 is Me.


116B 
Q2 is 2-Cl-4-EtO—Ph and R2 is Cl.


117B 
Q2 is 2-Cl-4-EtO—Ph and R2 is Br.


118B 
Q2 is 2-Cl-4-EtO—Ph and R2 is Et.


119B 
Q2 is 2-Cl-4-EtO—Ph and R2 is CN.


120B 
Q2 is 2-Br-4-MeO—Ph and R2 is Me.


121B 
Q2 is 2-Br-4-MeO—Ph and R2 is Cl.


122B 
Q2 is 2-Br-4-MeO—Ph and R2 is Br.


123B 
Q2 is 2-Br-4-MeO—Ph and R2 is Et.


124B 
Q2 is 2-Br-4-MeO—Ph and R2 is CN.


125B 
Q2 is 2-Br-4-EtO—Ph and R2 is Me.


126B 
Q2 is 2-Br-4-EtO—Ph and R2 is Cl.


127B 
Q2 is 2-Br-4-EtO—Ph and R2 is Br.


128B 
Q2 is 2-Br-4-EtO—Ph and R2 is Et.


129B 
Q2 is 2-Br-4-EtO—Ph and R2 is CN.


130B 
Q2 is 2-F-4-CN—Ph and R2 is Me.


131B 
Q2 is 2-F-4-CN—Ph and R2 is Cl.


132B 
Q2 is 2-F-4-CN—Ph and R2 is Br.


133B 
Q2 is 2-F-4-CN—Ph and R2 is Et.


134B 
Q2 is 2-F-4-CN—Ph and R2 is CN.


135B 
Q2 is 2-Cl-4-CN—Ph and R2 is Me.


136B 
Q2 is 2-Cl-4-CN—Ph and R2 is Cl.


137B 
Q2 is 2-Cl-4-CN—Ph and R2 is Br.


138B 
Q2 is 2-Cl-4-CN—Ph and R2 is Et.


139B 
Q2 is 2-Cl-4-CN—Ph and R2 is CN.


140B 
Q2 is 2-Br-4-CN—Ph and R2 is Me.


141B 
Q2 is 2-Br-4-CN—Ph and R2 is Cl.


142B 
Q2 is 2-Br-4-CN—Ph and R2 is Br.


143B 
Q2 is 2-Br-4-CN—Ph and R2 is Et.


144B 
Q2 is 2-Br-4-CN—Ph and R2 is CN.


145B 
Q2 is 3-Cl-2-pyridinyl and R2 is Me.


146B 
Q2 is 3-Cl-2-pyridinyl and R2 is Cl.


147B 
Q2 is 3-Cl-2-pyridinyl and R2 is Br.


148B 
Q2 is 3-Cl-2-pyridinyl and R2 is Et.


149B 
Q2 is 3-Cl-2-pyridinyl, and R2 is CN.


150B 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Me.


151B 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Cl.


152B 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Br.


153B 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Et.


154B 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is CN.


155B 
Q2 is 2-Cl-3-thienyl and R2 is Me.


156B 
Q2 is 2-Cl-3-thienyl and R2 is Cl.


157B 
Q2 is 2-Cl-3-thienyl and R2 is Br.


158B 
Q2 is 2-Cl-3-thienyl and R2 is Et.


159B 
Q2 is 2-Cl-3-thienyl and R2 is CN.


160B 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Me.


161B 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Cl.


162B 
Q2 is 2,5-di-Cl-3-thienyl, and R2 is Br.


163B 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Et.


164B 
Q2 is 2,5-di-Cl-3-thienyl and R2 is CN.
















TABLE 3








   Q2 is 2,6-di-F—Ph and R2 is Me.


 


(R3a)p







2-F


3-F


4-F


2-Cl


3-Cl


4-Cl


2-Br


3-Br


4-Br


4-Me


2,6-di-F


2,4-di-F


2,4-di-Cl


2,6-di-Cl


2,4-di-Me


2-F, 4-Cl


2-Cl, 4-F


2-F, 4-Br


2-Cl, 4-Br


2-Br, 4-Cl


2-Br, 4-F


2-I, 4-F


2-Me, 4-F


2-Cl, 4-CN


2-F, 4-CN


2-Br, 4-CN


2-CF3, 4-F


2-Me, 4-MeO


2-Me, 4-EtO


2-Br, 4-MeO


2-Cl, 4-MeO


2-F, 4-MeO


2-Cl, 4-EtO


2-F, 4-EtO


2,4,5-tri-F


2,3,5-tri-F


2,3,6-tri-F


2,4,6-tri-F


2,4,6-tri-Cl


2-Cl, 4,6-di-F


2,6-di-Cl, 4-F


2,4-di-Cl, 6-F


4-Cl, 2,6-di-F


2-Br, 4,6-di-F


4-Br, 2,6-di-F


2,4-di-Br, 6-F


2-Br, 4-Cl, 6-F


2-I, 4,6-di-F


4-I, 2,6-di-F


2,6-di-Cl, 4-CN


2,6-di-F, 4-CN


2,6-di-Cl, 4-MeO


2,6-di-F, 4-MeO


2,6-di-Cl, 4-EtO


2,6-di-F, 4-EtO


2-Br, 4-F, 6-Cl


2-Cl, 4-Br, 6-F


4-MeNH(CH2)3O


4-Me2N(CH2)3O


4-MeO(CH2)3O


2-F, 4-MeNH(CH2)3O


2-F, 4-Me2N(CH2)3O


2-Cl, 4-MeO(CH2)3O


2,6-di-F, 4-MeNH(CH2)3O


2,6-di-F, 4-MeNH(CH2)3


2,6-di-F, 4-Me2N(CH2)3O


2,6-di-F, 4-MeO(CH2)3O


2,6-di-F, 3-MeNH(CH2)3O


2,6-di-F, 3-MeNH(CH2)3


2,6-di-F, 3-Me2N(CH2)3O


2,6-di-F, 3-MeO(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3


2-Cl-6-F, 4-Me2N(CH2)3O


2-Cl-6-F, 4-MeO(CH2)3O









The present disclosure also includes Tables 1C through 164C, each of which is constructed the same as Table 3 above, except that the row heading in Table 3 (i.e. “Q2 is 2,6-di-F-Ph and R2 is Me”) is replaced with the respective row heading shown below. For Example, in Table 1C the row heading is “Q2 is 2,6-di-F-Ph and R2 is Cl”, and (R3)p is as defined in Table 3 above. Thus, the first entry in Table 1C specifically discloses 3-chloro-5-(2,6-difluorophenyl)-4-[(2-fluorophenyl)thio]-1-methyl-1H-prazole. Tables 2C through 164C are constructed similarly.











Table
Row Heading







 1C
Q2 is 2,6-di-F—Ph and R2 is Cl.


 2C
Q2 is 2,6-di-F—Ph and R2 is Br.


 3C
Q2 is 2,6-di-F—Ph and R2 is Et.


 4C
Q2 is 2,6-di-F—Ph and R2 is CN.


 5C
Q2 is 2,4-di-F—Ph and R2 is Me.


 6C
Q2 is 2,4-di-F—Ph and R2 is Cl.


 7C
Q2 is 2,4-di-F—Ph and R2 is Br.


 8C
Q2 is 2,4-di-F—Ph and R2 is Et.


 9C
Q2 is 2,4-di-F—Ph and R2 is CN.


10C
Q2 is 2,4,6-tri-F—Ph and R2 is Me.


11C
Q2 is 2,4,6-tri-F—Ph and R2 is Cl.


12C
Q2 is 2,4,6-tri-F—Ph and R2 is Br.


13C
Q2 is 2,4,6-tri-F—Ph and R2 is Et.


14C
Q2 is 2,4,6-tri-F—Ph and R2 is CN.


15C
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Me.


16C
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Cl.


17C
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Br.


18C
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Et.


19C
Q2 is 2,6-di-F-4-OMe—Ph and R2 is CN.


20C
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Me.


21C
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Cl.


22C
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Br.


23C
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Et.


24C
Q2 is 2,6-di-F-4-OEt—Ph and R2 is CN.


25C
Q2 is 2,6-di-F-4-CN—Ph and R2 is Me.


26C
Q2 is 2,6-di-F-4-CN—Ph and R2 is Cl.


27C
Q2 is 2,6-di-F-4-CN—Ph and R2 is Br.


28C
Q2 is 2,6-di-F-4-CN—Ph and R2 is Et.


29C
Q2 is 2,6-di-F-4-CN—Ph and R2 is CN.


30C
Q2 is 2-Cl-4-F—Ph and R2 is Me.


31C
Q2 is 2-Cl-4-F—Ph and R2 is Cl.


32C
Q2 is 2-Cl-4-F—Ph and R2 is Br.


33C
Q2 is 2-Cl-4-F—Ph and R2 is Et.


34C
Q2 is 2-Cl-4-F—Ph and R2 is CN.


35C
Q2 is 2-Cl-6-F—Ph and R2 is Me.


36C
Q2 is 2-Cl-6-F—Ph and R2 is Cl.


37C
Q2 is 2-Cl-6-F—Ph and R2 is Br.


38C
Q2 is 2-Cl-6-F—Ph and R2 is Et.


39C
Q2 is 2-Cl-6-F—Ph and R2 is CN.


40C
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Me.


41C
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Cl.


42C
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Br.


43C
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Et.


44C
Q2 is 2-Cl-4,6-di-F—Ph and R2 is CN.


45C
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Me.


46C
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Cl.


47C
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Br.


48C
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Et.


49C
Q2 is 4-Cl-2,6-di-F—Ph and R2 is CN.


50C
Q2 is 2-Br-4-F—Ph and R2 is Me.


51C
Q2 is 2-Br-4-F—Ph and R2 is Cl.


52C
Q2 is 2-Br-4-F—Ph and R2 is Br.


53C
Q2 is 2-Br-4-F—Ph and R2 is Et.


54C
Q2 is 2-Br-4-F—Ph and R2 is CN.


55C
Q2 is 2-Br-6-F—Ph and R2 is Me.


56C
Q2 is 2-Br-6-F—Ph and R2 is Cl.


57C
Q2 is 2-Br-6-F—Ph and R2 is Br.


58C
Q2 is 2-Br-6-F—Ph and R2 is Et.


59C
Q2 is 2-Br-6-F—Ph and R2 is CN.


60C
Q2 is 2-Me-4-F—Ph and R2 is Me.


61C
Q2 is 2-Me-4-F—Ph and R2 is Cl.


62C
Q2 is 2-Me-4-F—Ph and R2 is Br.


63C
Q2 is 2-Me-4-F—Ph and R2 is Et.


64C
Q2 is 2-Me-4-F—Ph and R2 is CN.


65C
Q2 is 2-I-4-F—Ph and R2 is Me.


66C
Q2 is 2-I-4-F—Ph and R2 is Cl.


67C
Q2 is 2-I-4-F—Ph and R2 is Br.


68C
Q2 is 2-I-4-F—Ph and R2 is Et.


69C
Q2 is 2-I-4-F—Ph and R2 is CN.


70C
Q2 is 2-F—Ph and R2 is Me.


71C
Q2 is 2-F—Ph and R2 is Cl.


72C
Q2 is 2-F—Ph and R2 is Br.


73C
Q2 is 2-F—Ph and R2 is Et.


74C
Q2 is 2-F—Ph and R2 is CN.


75C
Q2 is 2-Cl—Ph and R2 is Me.


76C
Q2 is 2-Cl—Ph and R2 is Cl.


77C
Q2 is 2-Cl—Ph and R2 is Br.


78C
Q2 is 2-Cl—Ph and R2 is Et.


79C
Q2 is 2-Cl—Ph an R2 is CN.


80C
Q2 is 2-Br—Ph and R2 is Me.


81C
Q2 is 2-Br—Ph and R2 is Cl.


82C
Q2 is 2-Br—Ph and R2 is Br.


83C
Q2 is 2-Br—Ph and R2 is Et.


84C
Q2 is 2-Br—Ph and R2 is CN.


85C
Q2 is 2-F-4-Cl—Ph and R2 is Me.


86C
Q2 is 2-F-4-Cl—Ph and R2 is Cl.


87C
Q2 is 2-F-4-Cl—Ph and R2 is Br.


88C
Q2 is 2-F-4-Cl—Ph and R2 is Et.


89C
Q2 is 2-F-4-Cl—Ph and R2 is CN.


90C
Q2 is 2,4-di-Cl—Ph and R2 is Me.


91C
Q2 is 2,4-di-Cl—Ph and R2 is Cl.


92C
Q2 is 2,4-di-Cl—Ph and R2 is Br.


93C
Q2 is 2,4-di-Cl—Ph and R2 is Et.


94C
Q2 is 2,4-di-Cl—Ph and R2 is CN.


95C
Q2 is 2,6-di-Cl—Ph and R2 is Me.


96C
Q2 is 2,6-di-Cl—Ph and R2 is Cl.


97C
Q2 is 2,6-di-Cl—Ph and R2 is Br.


98C
Q2 is 2,6-di-Cl—Ph and R2 is Et.


99C
Q2 is 2,6-di-Cl—Ph and R2 is CN.


100C 
Q2 is 2-F-4-MeO—Ph and R2 is Me.


101C 
Q2 is 2-F-4-MeO—Ph and R2 is Cl.


102C 
Q2 is 2-F-4-MeO—Ph and R2 is Br.


103C 
Q2 is 2-F-4-MeO—Ph and R2 is Et.


104C 
Q2 is 2-F-4-MeO—Ph and R2 is CN.


105C 
Q2 is 2-F-4-EtO—Ph and R2 is Me.


106C 
Q2 is 2-F-4-EtO—Ph and R2 is Cl.


107C 
Q2 is 2-F-4-EtO—Ph and R2 is Br.


108C 
Q2 is 2-F-4-EtO—Ph and R2 is Et.


109C 
Q2 is 2-F-4-EtO—Ph and R2 is CN.


110C 
Q2 is 2-Cl-4-MeO—Ph and R2 is Me.


111C 
Q2 is 2-Cl-4-MeO—Ph and R2 is Cl.


112C 
Q2 is 2-Cl-4-MeO—Ph and R2 is Br.


113C 
Q2 is 2-Cl-4-MeO—Ph and R2 is Et.


114C 
Q2 is 2-Cl-4-MeO—Ph and R2 is CN.


115C 
Q2 is 2-Cl-4-EtO—Ph and R2 is Me.


116C 
Q2 is 2-Cl-4-EtO—Ph and R2 is Cl.


117C 
Q2 is 2-Cl-4-EtO—Ph and R2 is Br.


118C 
Q2 is 2-Cl-4-EtO—Ph and R2 is Et.


119C 
Q2 is 2-Cl-4-EtO—Ph and R2 is CN.


120C 
Q2 is 2-Br-4-MeO—Ph and R2 is Me.


121C 
Q2 is 2-Br-4-MeO—Ph and R2 is Cl.


122C 
Q2 is 2-Br-4-MeO—Ph and R2 is Br.


123C 
Q2 is 2-Br-4-MeO—Ph and R2 is Et.


124C 
Q2 is 2-Br-4-MeO—Ph and R2 is CN.


125C 
Q2 is 2-Br-4-EtO—Ph and R2 is Me.


126C 
Q2 is 2-Br-4-EtO—Ph and R2 is Cl.


127C 
Q2 is 2-Br-4-EtO—Ph and R2 is Br.


128C 
Q2 is 2-Br-4-EtO—Ph and R2 is Et.


129C 
Q2 is 2-Br-4-EtO—Ph and R2 is CN.


130C 
Q2 is 2-F-4-CN—Ph and R2 is Me.


131C 
Q2 is 2-F-4-CN—Ph and R2 is Cl.


132C 
Q2 is 2-F-4-CN—Ph and R2 is Br.


133C 
Q2 is 2-F-4-CN—Ph and R2 is Et.


134C 
Q2 is 2-F-4-CN—Ph and R2 is CN.


135C 
Q2 is 2-Cl-4-CN—Ph and R2 is Me.


136C 
Q2 is 2-Cl-4-CN—Ph and R2 is Cl.


137C 
Q2 is 2-Cl-4-CN—Ph and R2 is Br.


138C 
Q2 is 2-Cl-4-CN—Ph and R2 is Et.


139C 
Q2 is 2-Cl-4-CN—Ph and R2 is CN.


140C 
Q2 is 2-Br-4-CN—Ph and R2 is Me.


141C 
Q2 is 2-Br-4-CN—Ph and R2 is Cl.


142C 
Q2 is 2-Br-4-CN—Ph and R2 is Br.


143C 
Q2 is 2-Br-4-CN—Ph and R2 is Et.


144C 
Q2 is 2-Br-4-CN—Ph and R2 is CN.


145C 
Q2 is 3-Cl-2-pyridinyl and R2 is Me.


146C 
Q2 is 3-Cl-2-pyridinyl and R2 is Cl.


147C 
Q2 is 3-Cl-2-pyridinyl and R2 is Br.


148C 
Q2 is 3-Cl-2-pyridinyl and R2 is Et.


149C 
Q2 is 3-Cl-2-pyridinyl and R2 is CN.


150C 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Me.


151C 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Cl.


152C 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Br.


153C 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Et.


154C 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is CN.


155C 
Q2 is 2-Cl-3-thienyl and R2 is Me.


156C 
Q2 is 2-Cl-3-thienyl and R2 is Cl.


157C 
Q2 is 2-Cl-3-thienyl and R2 is Br.


158C 
Q2 is 2-Cl-3-thienyl and R2 is Et.


159C 
Q2 is 2-Cl-3-thienyl and R2 is CN.


160C 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Me.


161C 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Cl.


162C 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Br.


163C 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Et.


164C 
Q2 is 2,5-di-Cl-3-thienyl and R2 is CN.
















TABLE 4








   Q2 is 2,6-di-F—Ph and R2 is Me.


 


(R3a)p







2-F


3-F


4-F


2-Cl


3-Cl


4-Cl


2-Br


3-Br


4-Br


4-Me


2,6-di-F


2,4-di-F


2,4-di-Cl


2,6-di-Cl


2,4-di-Me


2-F, 4-Cl


2-Cl, 4-F


2-F, 4-Br


2-Cl, 4-Br


2-Br, 4-Cl


2-Br, 4-F


2-I, 4-F


2-Me, 4-F


2-Cl, 4-CN


2-F, 4-CN


2-Br, 4-CN


2-CF3, 4-F


2-Me, 4-MeO


2-Me, 4-EtO


2-Br, 4-MeO


2-Cl, 4-MeO


2-F, 4-MeO


2-Cl, 4-EtO


2-F, 4-EtO


2,4,5-tri-F


2,3,5-tri-F


2,3,6-tri-F


2,4,6-tri-F


2,4,6-tri-Cl


2-Cl, 4,6-di-F


2,6-di-Cl, 4-F


2,4-di-Cl, 6-F


4-Cl, 2,6-di-F


2-Br, 4,6-di-F


4-Br, 2,6-di-F


2,4-di-Br, 6-F


2-Br, 4-Cl, 6-F


2-I, 4,6-di-F


4-I, 2,6-di-F


2,6-di-Cl, 4-CN


2,6-di-F, 4-CN


2,6-di-Cl, 4-MeO


2,6-di-F, 4-MeO


2,6-di-Cl, 4-EtO


2,6-di-F, 4-EtO


2-Br, 4-F, 6-Cl


2-Cl, 4-Br, 6-F


4-MeNH(CH2)3O


4-Me2N(CH2)3O


4-MeO(CH2)3O


2-F, 4-MeNH(CH2)3O


2-F, 4-Me2N(CH2)3O


2-Cl, 4-MeO(CH2)3O


2,6-di-F, 4-MeNH(CH2)3O


2,6-di-F, 4-MeNH(CH2)3


2,6-di-F, 4-Me2N(CH2)3O


2,6-di-F, 4-MeO(CH2)3O


2,6-di-F, 3-MeNH(CH2)3O


2,6-di-F, 3-MeNH(CH2)3


2,6-di-F, 3-Me2N(CH2)3O


2,6-di-F, 3-MeO(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3


2-Cl-6-F, 4-Me2N(CH2)3O


2-Cl-6-F, 4-MeO(CH2)3O









The present disclosure also includes Tables 1D through 164D, each of which is constructed the same as Table 4 above, except that the row heading in Table 4 (i.e. “Q2 is 2,6-di-F-Ph and R2 is Me”) is replaced with the respective row heading shown below. For Example, in Table 1D the row heading is “Q2 is 2,6-di-F-Ph and R2 is Cl”, and (R3)p is as defined in Table 4 above. Thus, the first entry in Table 1D specifically discloses 3-chloro-5-(2,6-difluorophenyl)-α-(2-fluorophenyl)-1-methyl-1H-pyrazole-4-methanol. Tables 2D through 164D are constructed similarly.











Table
Row Heading







 1D
Q2 is 2,6-di-F—Ph and R2 is Cl.


 2D
Q2 is 2,6-di-F—Ph and R2 is Br.


 3D
Q2 is 2,6-di-F—Ph and R2 is Et.


 4D
Q2 is 2,6-di-F—Ph and R2 is CN.


 5D
Q2 is 2,4-di-F—Ph and R2 is Me.


 6D
Q2 is 2,4-di-F—Ph and R2 is Cl.


 7D
Q2 is 2,4-di-F—Ph and R2 is Br.


 8D
Q2 is 2,4-di-F—Ph and R2 is Et.


 9D
Q2 is 2,4-di-F—Ph and R2 is CN.


10D
Q2 is 2,4,6-tri-F—Ph and R2 is Me.


11D
Q2 is 2,4,6-tri-F—Ph and R2 is Cl.


12D
Q2 is 2,4,6-tri-F—Ph and R2 is Br.


13D
Q2 is 2,4,6-tri-F—Ph and R2 is Et.


14D
Q2 is 2,4,6-tri-F—Ph and R2 is CN.


15D
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Me.


16D
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Cl.


17D
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Br.


18D
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Et


19D
Q2 is 2,6-di-F-4-OMe—Ph and R2 is CN


20D
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Me.


21D
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Cl.


22D
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Br.


23D
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Et.


24D
Q2 is 2,6-di-F-4-OEt—Ph and R2 is CN.


25D
Q2 is 2,6-di-F-4-CN—Ph and R2 is Me.


26D
Q2 is 2,6-di-F-4-CN—Ph and R2 is Cl.


27D
Q2 is 2,6-di-F-4-CN—Ph and R2 is Br.


28D
Q2 is 2,6-di-F-4-CN—Ph and R2 is Et.


29D
Q2 is 2,6-di-F-4-CN—Ph and R2 is CN.


30D
Q2 is 2-Cl-4-F—Ph and R2 is Me.


31D
Q2 is 2-Cl-4-F—Ph and R2 is Cl.


32D
Q2 is 2-Cl-4-F—Ph and R2 is Br.


33D
Q2 is 2-Cl-4-F—Ph and R2 is Et.


34D
Q2 is 2-Cl-4-F—Ph and R2 is CN.


35D
Q2 is 2-Cl-6-F—Ph and R2 is Me.


36D
Q2 is 2-Cl-6-F—Ph and R2 is Cl.


37D
Q2 is 2-Cl-6-F—Ph and R2 is Br.


38D
Q2 is 2-Cl-6-F—Ph and R2 is Et.


39D
Q2 is 2-Cl-6-F—Ph and R2 is CN.


40D
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Me.


41D
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Cl.


42D
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Br.


43D
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Et.


44D
Q2 is 2-Cl-4,6-di-F—Ph and R2 is CN.


45D
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Me.


46D
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Cl.


47D
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Br.


48D
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Et.


49D
Q2 is 4-Cl-2,6-di-F—Ph and R2 is CN.


50D
Q2 is 2-Br-4-F—Ph and R2 is Me.


51D
Q2 is 2-Br-4-F—Ph and R2 is Cl.


52D
Q2 is 2-Br-4-F—Ph and R2 is Br.


53D
Q2 is 2-Br-4-F—Ph and R2 is Et.


54D
Q2 is 2-Br-4-F—Ph and R2 is CN.


55D
Q2 is 2-Br-6-F—Ph and R2 is Me.


56D
Q2 is 2-Br-6-F—Ph and R2 is Cl.


57D
Q2 is 2-Br-6-F—Ph and R2 is Br.


58D
Q2 is 2-Br-6-F—Ph and R2 is Et.


59D
Q2 is 2-Br-6-F—Ph and R2 is CN.


60D
Q2 is 2-Me-4-F—Ph and R2 is Me.


61D
Q2 is 2-Me-4-F—Ph and R2 is Cl.


62D
Q2 is 2-Me-4-F—Ph and R2 is Br.


63D
Q2 is 2-Me-4-F—Ph and R2 is Et.


64D
Q2 is 2-Me-4-F—Ph and R2 is CN.


65D
Q2 is 2-I-4-F—Ph and R2 is Me.


66D
Q2 is 2-I-4-F—Ph and R2 is Cl.


67D
Q2 is 2-I-4-F—Ph and R2 is Br.


68D
Q2 is 2-I-4-F—Ph and R2 is Et.


69D
Q2 is 2-I-4-F—Ph and R2 is CN.


70D
Q2 is 2-F—Ph and R2 is Me.


71D
Q2 is 2-F—Ph and R2 is Cl.


72D
Q2 is 2-F—Ph and R2 is Br.


73D
Q2 is 2-F—Ph and R2 is Et.


74D
Q2 is 2-F—Ph and R2 is CN.


75D
Q2 is 2-Cl—Ph and R2 is Me.


76D
Q2 is 2-Cl—Ph and R2 is Cl.


77D
Q2 is 2-Cl—Ph and R2 is Br.


78D
Q2 is 2-Cl—Ph and R2 is Et.


79D
Q2 is 2-Cl—Ph an R2 is CN


80D
Q2 is 2-Br—Ph and R2 is Me.


81D
Q2 is 2-Br—Ph and R2 is Cl.


82D
Q2 is 2-Br—Ph and R2 is Br.


83D
Q2 is 2-Br—Ph and R2 is Et.


84D
Q2 is 2-Br—Ph and R2 is CN.


85D
Q2 is 2-F-4-Cl—Ph and R2 is Me.


86D
Q2 is 2-F-4-Cl—Ph and R2 is Cl.


87D
Q2 is 2-F-4-Cl—Ph and R2 is Br.


88D
Q2 is 2-F-4-Cl—Ph and R2 is Et.


89D
Q2 is 2-F-4-Cl—Ph and R2 is CN.


90D
Q2 is 2,4-di-Cl—Ph and R2 is Me.


91D
Q2 is 2,4-di-Cl—Ph and R2 is Cl.


92D
Q2 is 2,4-di-Cl—Ph and R2 is Br.


93D
Q2 is 2,4-di-Cl—Ph and R2 is Et.


94D
Q2 is 2,4-di-Cl—Ph and R2 is CN.


95D
Q2 is 2,6-di-Cl—Ph and R2 is Me.


96D
Q2 is 2,6-di-Cl—Ph and R2 is Cl.


97D
Q2 is 2,6-di-Cl—Ph and R2 is Br.


98D
Q2 is 2,6-di-Cl—Ph and R2 is Et.


99D
Q2 is 2,6-di-Cl—Ph and R2 is CN.


100D 
Q2 is 2-F-4-MeO—Ph and R2 is Me.


101D 
Q2 is 2-F-4-MeO—Ph and R2 is Cl.


102D 
Q2 is 2-F-4-MeO—Ph and R2 is Br.


103D 
Q2 is 2-F-4-MeO—Ph and R2 is Et.


104D 
Q2 is 2-F-4-MeO—Ph and R2 is CN.


105D 
Q2 is 2-F-4-EtO—Ph and R2 is Me.


106D 
Q2 is 2-F-4-EtO—Ph and R2 is Cl.


107D 
Q2 is 2-F-4-EtO—Ph and R2 is Br.


108D 
Q2 is 2-F-4-EtO—Ph and R2 is Et.


109D 
Q2 is 2-F-4-EtO—Ph and R2 is CN.


110D 
Q2 is 2-Cl-4-MeO—Ph and R2 is Me.


111D 
Q2 is 2-Cl-4-MeO—Ph and R2 is Cl.


112D 
Q2 is 2-Cl-4-MeO—Ph and R2 is Br.


113D 
Q2 is 2-Cl-4-MeO—Ph and R2 is Et.


114D 
Q2 is 2-Cl-4-MeO—Ph and R2 is CN.


115D 
Q2 is 2-Cl-4-EtO—Ph and R2 is Me.


116D 
Q2 is 2-Cl-4-EtO—Ph and R2 is Cl.


117D 
Q2 is 2-Cl-4-EtO—Ph and R2 is Br.


118D 
Q2 is 2-Cl-4-EtO—Ph and R2 is Et.


119D 
Q2 is 2-Cl-4-EtO—Ph and R2 is CN.


120D 
Q2 is 2-Br-4-MeO—Ph and R2 is Me.


121D 
Q2 is 2-Br-4-MeO—Ph and R2 is Cl.


122D 
Q2 is 2-Br-4-MeO—Ph and R2 is Br.


123D 
Q2 is 2-Br-4-MeO—Ph and R2 is Et.


124D 
Q2 is 2-Br-4-MeO—Ph and R2 is CN.


125D 
Q2 is 2-Br-4-EtO—Ph and R2 is Me.


126D 
Q2 is 2-Br-4-EtO—Ph and R2 is Cl.


127D 
Q2 is 2-Br-4-EtO—Ph and R2 is Br.


128D 
Q2 is 2-Br-4-EtO—Ph and R2 is Et.


129D 
Q2 is 2-Br-4-EtO—Ph and R2 is CN.


130D 
Q2 is 2-F-4-CN—Ph and R2 is Me.


131D 
Q2 is 2-F-4-CN—Ph and R2 is Cl.


132D 
Q2 is 2-F-4-CN—Ph and R2 is Br.


133D 
Q2 is 2-F-4-CN—Ph and R2 is Et.


134D 
Q2 is 2-F-4-CN—Ph and R2 is CN.


135D 
Q2 is 2-Cl-4-CN—Ph and R2 is Me.


136D 
Q2 is 2-Cl-4-CN—Ph and R2 is Cl.


137D 
Q2 is 2-Cl-4-CN—Ph and R2 is Br.


138D 
Q2 is 2-Cl-4-CN—Ph and R2 is Et.


139D 
Q2 is 2-Cl-4-CN—Ph and R2 is CN.


140D 
Q2 is 2-Br-4-CN—Ph and R2 is Me.


141D 
Q2 is 2-Br-4-CN—Ph and R2 is Cl.


142D 
Q2 is 2-Br-4-CN—Ph and R2 is Br.


143D 
Q2 is 2-Br-4-CN—Ph and R2 is Et.


144D 
Q2 is 2-Br-4-CN—Ph and R2 is CN.


145D 
Q2 is 3-Cl-2-pyridinyl and R2 is Me.


146D 
Q2 is 3-Cl-2-pyridinyl and R2 is Cl.


147D 
Q2 is 3-Cl-2-pyridinyl and R2 is Br.


148D 
Q2 is 3-Cl-2-pyridinyl and R2 is Et.


149D 
Q2 is 3-Cl-2-pyridinyl and R2 is CN.


150D 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Me.


151D 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Cl.


152D 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Br.


153D 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Et.


154D 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is CN.


155D 
Q2 is 2-Cl-3-thienyl and R2 is Me.


156D 
Q2 is 2-Cl-3-thienyl and R2 is Cl.


157D 
Q2 is 2-Cl-3-thienyl and R2 is Br.


158D 
Q2 is 2-Cl-3-thienyl and R2 is Et.


159D 
Q2 is 2-Cl-3-thienyl and R2 is CN.


160D 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Me.


161D 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Cl.


162D 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Br.


163D 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Et.


164D 
Q2 is 2,5-di-Cl-3-thienyl and R2 is CN.
















TABLE 5








   Q2 is 2,6-di-F-Ph and R2 is Me.


 


(R3a)p







2-F


3-F


4-F


2-Cl


3-Cl


4-Cl


2-Br


3-Br


4-Br


4-Me


2,6-di-F


2,4-di-F


2,4-di-Cl


2,6-di-Cl


2,4-di-Me


2-F, 4-Cl


2-Cl, 4-F


2-F, 4-Br


2-Cl, 4-Br


2-Br, 4-Cl


2-Br, 4-F


2-I, 4-F


2-Me, 4-F


2-Cl, 4-CN


2-F, 4-CN


2-Br, 4-CN


2-CF3, 4-F


2-Me, 4-MeO


2-Me, 4-EtO


2-Br, 4-MeO


2-Cl, 4-MeO


2-F, 4-MeO


2-Cl, 4-EtO


2-F, 4-EtO


2,4,5-tri-F


2,3,5-tri-F


2,3,6-tri-F


2,4,6-tri-F


2,4,6-tri-Cl


2-Cl, 4,6-di-F


2,6-di-Cl, 4-F


2,4-di-Cl, 6-F


4-Cl, 2,6-di-F


2-Br, 4,6-di-F


4-Br, 2,6-di-F


2,4-di-Br, 6-F


2-Br, 4-Cl, 6-F


2-I, 4,6-di-F


4-I, 2,6-di-F


2,6-di-Cl, 4-CN


2,6-di-F, 4-CN


2,6-di-Cl, 4-MeO


2,6-di-F, 4-MeO


2,6-di-Cl, 4-EtO


2,6-di-F, 4-EtO


2-Br, 4-F, 6-Cl


2-Cl, 4-Br, 6-F


4-MeNH(CH2)3O


4-Me2N(CH2)3O


4-MeO(CH2)3O


2-F, 4-MeNH(CH2)3O


2-F, 4-Me2N(CH2)3O


2-Cl, 4-MeO(CH2)3O


2,6-di-F, 4-MeNH(CH2)3O


2,6-di-F, 4-MeNH(CH2)3


2,6-di-F, 4-Me2N(CH2)3O


2,6-di-F, 4-MeO(CH2)3O


2,6-di-F, 3-MeNH(CH2)3O


2,6-di-F, 3-MeNH(CH2)3


2,6-di-F, 3-Me2N(CH2)3O


2,6-di-F, 3-MeO(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3O


2-Cl-6-F, 4-MeNH(CH2)3


2-Cl-6-F, 4-Me2N(CH2)3O


2-Cl-6-F, 4-MeO(CH2)3O









The present disclosure also includes Tables 1E through 164E, each of which is constructed the same as Table 5 above, except that the row heading in Table 5 (i.e. “Q2 is 2,6-di-F-Ph and R2 is Me”) is replaced with the respective row heading shown below. For Example, in Table 1E the row heading is “Q2 is 2,6-di-F-Ph and R2 is Cl”, and (R3)p is as defined in Table 5 above. Thus, the first entry in Table 1E specifically discloses (3-chloro-5-(2,6-difluorophenyl)-1-methyl-1H-pyrazol-4-yl](2-fluorophenyl)methanol. Tables 2E through 164E are constructed similarly.











Table
Row Heading







 1E
Q2 is 2,6-di-F—Ph and R2 is Cl.


 2E
Q2 is 2,6-di-F—Ph and R2 is Br.


 3E
Q2 is 2,6-di-F—Ph and R2 is Et.


 4E
Q2 is 2,6-di-F—Ph and R2 is CN.


 5E
Q2 is 2,4-di-F—Ph and R2 is Me.


 6E
Q2 is 2,4-di-F—Ph and R2 is Cl.


 7E
Q2 is 2,4-di-F—Ph and R2 is Br.


 8E
Q2 is 2,4-di-F—Ph and R2 is Et.


 9E
Q2 is 2,4-di-F—Ph and R2 is CN.


10E
Q2 is 2,4,6-tri-F—Ph and R2 is Me.


11E
Q2 is 2,4,6-tri-F—Ph and R2 is Cl.


12E
Q2 is 2,4,6-tri-F—Ph and R2 is Br.


13E
Q2 is 2,4,6-tri-F—Ph and R2 is Et.


14E
Q2 is 2,4,6-tri-F—Ph and R2 is CN.


15E
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Me.


16E
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Cl.


17E
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Br.


18E
Q2 is 2,6-di-F-4-OMe—Ph and R2 is Et


19E
Q2 is 2,6-di-F-4-OMe—Ph and R2 is CN


20E
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Me.


21E
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Cl.


22E
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Br.


23E
Q2 is 2,6-di-F-4-OEt—Ph and R2 is Et.


24E
Q2 is 2,6-di-F-4-OEt—Ph and R2 is CN.


25E
Q2 is 2,6-di-F-4-CN—Ph and R2 is Me.


26E
Q2 is 2,6-di-F-4-CN—Ph and R2 is Cl.


27E
Q2 is 2,6-di-F-4-CN—Ph and R2 is Br.


28E
Q2 is 2,6-di-F-4-CN—Ph and R2 is Et.


29E
Q2 is 2,6-di-F-4-CN—Ph and R2 is CN.


30E
Q2 is 2-Cl-4-F—Ph and R2 is Me.


31E
Q2 is 2-Cl-4-F—Ph and R2 is Cl.


32E
Q2 is 2-Cl-4-F—Ph and R2 is Br.


33E
Q2 is 2-Cl-4-F—Ph and R2 is Et.


34E
Q2 is 2-Cl-4-F—Ph and R2 is CN.


35E
Q2 is 2-Cl-6-F—Ph and R2 is Me.


36E
Q2 is 2-Cl-6-F—Ph and R2 is Cl.


37E
Q2 is 2-Cl-6-F—Ph and R2 is Br.


38E
Q2 is 2-Cl-6-F—Ph and R2 is Et.


39E
Q2 is 2-Cl-6-F—Ph and R2 is CN.


40E
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Me.


41E
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Cl.


42E
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Br.


43E
Q2 is 2-Cl-4,6-di-F—Ph and R2 is Et.


44E
Q2 is 2-Cl-4,6-di-F—Ph and R2 is CN.


45E
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Me.


46E
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Cl.


47E
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Br.


48E
Q2 is 4-Cl-2,6-di-F—Ph and R2 is Et.


49E
Q2 is 4-Cl-2,6-di-F—Ph and R2 is CN.


50E
Q2 is 2-Br-4-F—Ph and R2 is Me.


51E
Q2 is 2-Br-4-F—Ph and R2 is Cl.


52E
Q2 is 2-Br-4-F—Ph and R2 is Br.


53E
Q2 is 2-Br-4-F—Ph and R2 is Et.


54E
Q2 is 2-Br-4-F—Ph and R2 is CN.


55E
Q2 is 2-Br-6-F—Ph and R2 is Me.


56E
Q2 is 2-Br-6-F—Ph and R2 is Cl.


57E
Q2 is 2-Br-6-F—Ph and R2 is Br.


58E
Q2 is 2-Br-6-F—Ph and R2 is Et.


59E
Q2 is 2-Br-6-F—Ph and R2 is CN.


60E
Q2 is 2-Me-4-F—Ph and R2 is Me.


61E
Q2 is 2-Me-4-F—Ph and R2 is Cl.


62E
Q2 is 2-Me-4-F—Ph and R2 is Br.


63E
Q2 is 2-Me-4-F—Ph and R2 is Et.


64E
Q2 is 2-Me-4-F—Ph and R2 is CN.


65E
Q2 is 2-I-4-F—Ph and R2 is Me.


66E
Q2 is 2-I-4-F—Ph and R2 is Cl.


67E
Q2 is 2-I-4-F—Ph and R2 is Br.


68E
Q2 is 2-I-4-F—Ph and R2 is Et.


69E
Q2 is 2-I-4-F—Ph and R2 is CN.


70E
Q2 is 2-F—Ph and R2 is Me.


71E
Q2 is 2-F—Ph and R2 is Cl.


72E
Q2 is 2-F—Ph and R2 is Br.


73E
Q2 is 2-F—Ph and R2 is Et.


74E
Q2 is 2-F—Ph and R2 is CN.


75E
Q2 is 2-Cl—Ph and R2 is Me.


76E
Q2 is 2-Cl—Ph and R2 is Cl.


77E
Q2 is 2-Cl—Ph and R2 is Br.


78E
Q2 is 2-Cl—Ph and R2 is Et.


79E
Q2 is 2-Cl—Ph an R2 is CN.


80E
Q2 is 2-Br—Ph and R2 is Me.


81E
Q2 is 2-Br—Ph and R2 is Cl.


82E
Q2 is 2-Br—Ph and R2 is Br.


83E
Q2 is 2-Br—Ph and R2 is Et.


84E
Q2 is 2-Br—Ph and R2 is CN.


85E
Q2 is 2-F-4-Cl—Ph and R2 is Me.


86E
Q2 is 2-F-4-Cl—Ph and R2 is Cl.


87E
Q2 is 2-F-4-Cl—Ph and R2 is Br.


88E
Q2 is 2-F-4-Cl—Ph and R2 is Et.


89E
Q2 is 2-F-4-Cl—Ph and R2 is CN.


90E
Q2 is 2,4-di-Cl—Ph and R2 is Me.


91E
Q2 is 2,4-di-Cl—Ph and R2 is Cl.


92E
Q2 is 2,4-di-Cl—Ph and R2 is Br.


93E
Q2 is 2,4-di-Cl—Ph and R2 is Et.


94E
Q2 is 2,4-di-Cl—Ph and R2 is CN.


95E
Q2 is 2,6-di-Cl—Ph and R2 is Me.


96E
Q2 is 2,6-di-Cl—Ph and R2 is Cl.


97E
Q2 is 2,6-di-Cl—Ph and R2 is Br.


98E
Q2 is 2,6-di-Cl—Ph and R2 is Et.


99E
Q2 is 2,6-di-Cl—Ph and R2 is CN.


100E 
Q2 is 2-F-4-MeO—Ph and R2 is Me.


101E 
Q2 is 2-F-4-MeO—Ph and R2 is Cl.


102E 
Q2 is 2-F-4-MeO—Ph and R2 is Br.


103E 
Q2 is 2-F-4-MeO—Ph and R2 is Et.


104E 
Q2 is 2-F-4-MeO—Ph and R2 is CN.


105E 
Q2 is 2-F-4-EtO—Ph and R2 is Me.


106E 
Q2 is 2-F-4-EtO—Ph and R2 is Cl.


107E 
Q2 is 2-F-4-EtO—Ph and R2 is Br.


108E 
Q2 is 2-F-4-EtO—Ph and R2 is Et.


109E 
Q2 is 2-F-4-EtO—Ph and R2 is CN.


110E 
Q2 is 2-Cl-4-MeO—Ph and R2 is Me.


111E 
Q2 is 2-Cl-4-MeO—Ph and R2 is Cl.


112E 
Q2 is 2-Cl-4-MeO—Ph and R2 is Br.


113E 
Q2 is 2-Cl-4-MeO—Ph and R2 is Et.


114E 
Q2 is 2-Cl-4-MeO—Ph and R2 is CN.


115E 
Q2 is 2-Cl-4-EtO—Ph and R2 is Me.


116E 
Q2 is 2-Cl-4-EtO—Ph and R2 is Cl.


117E 
Q2 is 2-Cl-4-EtO—Ph and R2 is Br.


118E 
Q2 is 2-Cl-4-EtO—Ph and R2 is Et.


119E 
Q2 is 2-Cl-4-EtO—Ph and R2 is CN.


120E 
Q2 is 2-Br-4-MeO—Ph and R2 is Me.


121E 
Q2 is 2-Br-4-MeO—Ph and R2 is Cl.


122E 
Q2 is 2-Br-4-MeO—Ph and R2 is Br.


123E 
Q2 is 2-Br-4-MeO—Ph and R2 is Et.


124E 
Q2 is 2-Br-4-MeO—Ph and R2 is CN.


125E 
Q2 is 2-Br-4-EtO—Ph and R2 is Me.


126E 
Q2 is 2-Br-4-EtO—Ph and R2 is Cl.


127E 
Q2 is 2-Br-4-EtO—Ph and R2 is Br.


128E 
Q2 is 2-Br-4-EtO—Ph and R2 is Et.


129E 
Q2 is 2-Br-4-EtO—Ph and R2 is CN.


130E 
Q2 is 2-F-4-CN—Ph and R2 is Me.


131E 
Q2 is 2-F-4-CN—Ph and R2 is Cl.


132E 
Q2 is 2-F-4-CN—Ph and R2 is Br.


133E 
Q2 is 2-F-4-CN—Ph and R2 is Et.


134E 
Q2 is 2-F-4-CN—Ph and R2 is CN.


135E 
Q2 is 2-Cl-4-CN—Ph and R2 is Me.


136E 
Q2 is 2-Cl-4-CN—Ph and R2 is Cl.


137E 
Q2 is 2-Cl-4-CN—Ph and R2 is Br.


138E 
Q2 is 2-Cl-4-CN—Ph and R2 is Et.


139E 
Q2 is 2-Cl-4-CN—Ph and R2 is CN.


140E 
Q2 is 2-Br-4-CN—Ph and R2 is Me.


141E 
Q2 is 2-Br-4-CN—Ph and R2 is Cl.


142E 
Q2 is 2-Br-4-CN—Ph and R2 is Br.


143E 
Q2 is 2-Br-4-CN—Ph and R2 is Et.


144E 
Q2 is 2-Br-4-CN—Ph and R2 is CN.


145E 
Q2 is 3-Cl-2-pyridinyl and R2 is Me.


146E 
Q2 is 3-Cl-2-pyridinyl and R2 is Cl.


147E 
Q2 is 3-Cl-2-pyridinyl and R2 is Br.


148E 
Q2 is 3-Cl-2-pyridinyl and R2 is Et.


149E 
Q2 is 3-Cl-2-pyridinyl and R2 is CN.


150E 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Me.


151E 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Cl.


152E 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Br.


153E 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is Et.


154E 
Q2 is 3,5-di-Cl-2-pyridinyl and R2 is CN.


155E 
Q2 is 2-Cl-3-thienyl and R2 is Me.


156E 
Q2 is 2-Cl-3-thienyl and R2 is Cl.


157E 
Q2 is 2-Cl-3-thienyl and R2 is Br.


158E 
Q2 is 2-Cl-3-thienyl and R2 is Et.


159E 
Q2 is 2-Cl-3-thienyl and R2 is CN.


160E 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Me.


161E 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Cl.


162E 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Br.


163E 
Q2 is 2,5-di-Cl-3-thienyl and R2 is Et.


164E 
Q2 is 2,5-di-Cl-3-thienyl and R2 is CN.









Formulation/Utility

A compound of this invention will generally be used as a fungicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serves as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature.
Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion and suspo-emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion. The general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible (“wettable”) or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or “overcoated”). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High-strength compositions are primarily used as intermediates for further formulation.
Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water. Spray volumes can range from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto seeds of crops and other desirable vegetation as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake.
The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.
Weight Percent















Active





Ingredient
Diluent
Surfactant



















Water-Dispersible and Water-
0.001-90
0-99.999
0-15


soluble Granules, Tablets and


Powders


Oil Dispersions, Suspensions,
   1-50
40-99   
0-50


Emulsions, Solutions


(including Emulsifiable


Concentrates)


Dusts
   1-25
70-99   
0-5 


Granules and Pellets
0.001-95
5-99.999
0-15


High Strength Compositions
  90-99
0-10   
0-2 









Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., Handbook of Insecticide Dust Diluents and Carriers, 2nd Ed., Dorland Books, Caldwell, N.J.
Liquid diluents include, for example, water, N,N-dimethylalkanamides (e.g., N,N-dimethylformamide), limonene, dimethyl sulfoxide, N-alkylpyrrolidones (e.g., N-methylpyrrolidinone), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol, aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone, acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters and γ-butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutyl alcohol, n-hexanol, 2-ethylhexanol, n-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C6-C22), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical liquid diluents are described in Marsden, Solvents Guide, 2nd Ed., Interscience, New York, 1950.
The solid and liquid compositions of the present invention often include one or more surfactants. When added to a liquid, surfactants (also known as “surface-active agents”) generally modify, most often reduce, the surface tension of the liquid. Depending on the nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifiers or defoaming agents.
Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol) resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar-derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.
Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as N,N-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts.
Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as N-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.
Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including McCutcheon's Emulsifiers and Detergents, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, Encyclopedia of Surface Active Agents, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, Synthetic Detergents, Seventh Edition, John Wiley and Sons, New York, 1987.
Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers), evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in McCutcheon's Volume 2: Functional Materials, annual International and North American editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.
The compound of Formula 1 or Formula 1A and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain particles with average diameters below 3 μm. Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. Pat. No. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, “Agglomeration”, Chemical Engineering, Dec. 4, 1967, pp 147-48, Perry's Chemical Engineer's Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. Pat. No. 4,172,714. Water-dispersible and water-soluble granules can be prepared as taught in U.S. Pat. Nos. 4,144,050, 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. Pat. Nos. 5,180,587, 5,232,701 and U.S. Pat. No. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. Pat. No. 3,299,566.
For further information regarding the art of formulation, see T. S. Woods, “The Formulator's Toolbox—Product Forms for Modern Agriculture” in Pesticide Chemistry and Bioscience, The Food-Environment Challenge, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120-133. See also U.S. Pat. No. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10-41; U.S. Pat. No. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138-140, 162-164, 166, 167 and 169-182; U.S. Pat. No. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1-4; Klingman, Weed Control as a Science, John Wiley and Sons, Inc., New York, 1961, pp 81-96; Hance et al., Weed Control Handbook, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and Developments in formulation technology, PJB Publications, Richmond, UK, 2000.
In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Tables A-C. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be constructed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Percentages are by weight except where otherwise indicated.
EXAMPLE A
High Strength Concentrate
















Compound 10
98.5%



silica aerogel
0.5%



synthetic amorphous fine silica
1.0%










EXAMPLE B
Wettable Powder
















Compound 3
65.0%



dodecylphenol polyethylene glycol ether
2.0%



sodium ligninsulfonate
4.0%



sodium silicoaluminate
6.0%



montmorillonite (calcined)
23.0%










EXAMPLE C
Granule
















Compound 10
10.0%



attapulgite granules (low volatile matter,
90.0%



0.71/0.30 mm; U.S.S. No. 25-50 sieves)










EXAMPLE D
Extruded Pellet
















Compound 14
25.0%



anhydrous sodium sulfate
10.0%



crude calcium ligninsulfonate
5.0%



sodium alkylnaphthalenesulfonate
1.0%



calcium/magnesium bentonite
59.0%










EXAMPLE E
Emulsifiable Concentrate
















Compound 3
10.0%



polyoxyethylene sorbitol hexoleate
20.0%



C6-C10 fatty acid methyl ester
70.0%










EXAMPLE F
Microemulsion
















Compound 10
5.0%



polyvinylpyrrolidone-vinyl acetate copolymer
30.0%



alkylpolyglycoside
30.0%



glyceryl monooleate
15.0%



water
20.0%










EXAMPLE G
Seed Treatment
















Compound 14
20.00%



polyvinylpyrrolidone-vinyl acetate copolymer
5.00%



montan acid wax
5.00%



calcium ligninsulfonate
1.00%



polyoxyethylene/polyoxypropylene block copolymers
1.00%



stearyl alcohol (POE 20)
2.00%



polyorganosilane
0.20%



colorant red dye
0.05%



water
65.75%










Water-soluble and water-dispersible formulations are typically diluted with water to form aqueous compositions before application. Aqueous compositions for direct applications to the plant or portion thereof (e.g., spray tank compositions) typically at least about 1 ppm or more (e.g., from 1 ppm to 100 ppm) of the compound(s) of this invention.
The compounds of this invention are useful as plant disease control agents. The present invention therefore further comprises a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof to be protected, or to the plant seed to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. The compounds and/or compositions of this invention provide control of diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and Deuteromycete classes. They are effective in controlling a broad spectrum of plant diseases, particularly foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops. These pathogens include: Oomycetes, including Phytophthora diseases such as Phytophthora infestans, Phytophthora megasperma, Phytophthora parasitica, Phytophthora cinnamomi and Phytophthora capsici, Pythium diseases such as Pythium aphanidermatum, and diseases in the Peronosporaceae family such as Plasmopara viticola, Peronospora spp. (including Peronospora tabacina and Peronospora parasitica), Pseudoperonospora spp. (including Pseudoperonospora cubensis) and Bremia lactucae; Ascomycetes, including Alternaria diseases such as Alternaria solani and Alternaria brassicae, Guignardia diseases such as Guignardia bidwell, Venturia diseases such as Venturia inaequalis, Septoria diseases such as Septoria nodorum and Septoria tritici, powdery mildew diseases such as Erysiphe spp. (including Erysiphe graminis and Erysiphe polygoni), Uncinula necatur, Sphaerotheca fuligena and Podosphaera leucotricha, Pseudocercosporella herpotrichoides, Botrytis diseases such as Botrytis cinerea, Monilinia fructicola, Sclerotinia diseases such as Sclerotinia sclerotiorum, Magnaporthe grisea, Phomopsis viticola, Helminthosporium diseases such as Helminthosporium tritici repentis, Pyrenophora teres, anthracnose diseases such as Glomerella or Colletotrichum spp. (such as Colletotrichum graminicola and Colletotrichum orbiculare), and Gaeumannomyces graminis; Basidiomycetes, including rust diseases caused by Puccinia spp. (such as Puccinia recondite, Puccinia striiformis, Puccinia hordei, Puccinia graminis and Puccinia arachidis), Hemileia vastatrix and Phakopsora pachyrhizi; other pathogens including Rutstroemia floccosum (also known as Sclerontina homoeocarpa); Rhizoctonia spp. (such as Rhizoctonia solani); Fusarium diseases such as Fusarium roseum, Fusarium graminearum and Fusarium oxysporum; Verticillium dahliae; Sclerotium rolfsii; Rynchosporium secalis; Cercosporidium personatum, Cercospora arachidicola and Cercospora beticola; and other genera and species closely related to these pathogens. In addition to their fungicidal activity, the compositions or combinations also have activity against bacteria such as Erwinia amylovora, Xanthomonas campestris, Pseudomonas syringae, and other related species.
Plant disease control is ordinarily accomplished by applying an effective amount of a compound of this invention either pre- or post-infection, to the portion of the plant to be protected such as the roots, stems, foliage, fruit, seeds, tubers or bulbs, or to the media (soil or sand) in which the plants to be protected are growing. The compounds can also be applied to seeds to protect the seeds and seedlings developing from the seeds. The compounds can also be applied through irrigation water to treat plants.
Rates of application for these compounds (i.e. a fungicidally effective amount) can be influenced by factors such as the plant diseases to be controlled, the plant species to be protected, ambient moisture and temperature and should be determined under actual use conditions. One skilled in the art can easily determine through simple experimentation the fungicidally effective amount necessary for the desired level of plant disease control. Foliage can normally be protected when treated at a rate of from less than about 1 g/ha to about 5,000 g/ha of active ingredient. Seed and seedlings can normally be protected when seed is treated at a rate of from about 0.1 to about 10 g per kilogram of seed.
Compounds of this invention can also be mixed with one or more other biologically active compounds or agents including fungicides, insecticides, nematocides, bactericides, acaricides, herbicides, herbicide safeners, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Thus the present invention also pertains to a composition comprising a compound of Formula 1 or Formula 1A (in a fungicidally effective amount) and at least one additional biologically active compound or agent (in a biologically effective amount) and can further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other biologically active compounds or agents can be formulated in compositions comprising at least one of a surfactant, solid or liquid diluent. For mixtures of the present invention, one or more other biologically active compounds or agents can be formulated together with a compound of Formula 1 or Formula 1A, to form a premix, or one or more other biologically active compounds or agents can be formulated separately from the compound of Formula 1 or Formula 1A, and the formulations combined together before application (e.g., in a spray tank) or, alternatively, applied in succession.
Of note is a composition which in addition to the compound of Formula 1 or Formula 1A include at least one fungicidal compound selected from the group consisting of the classes (1) methyl benzimidazole carbamate (MBC) fungicides; (2) dicarboximide fungicides; (3) demethylation inhibitor (DMI) fungicides; (4) phenylamide fungicides; (5) amine/morpholine fungicides; (6) phospholipid biosynthesis inhibitor fungicides; (7) carboxamide fungicides; (8) hydroxy(2-amino-)pyrimidine fungicides; (9) anilinopyrimidine fungicides; (10)N-phenyl carbamate fungicides; (11) quinone outside inhibitor (QoI) fungicides; (12) phenylpyrrole fungicides; (13) quinoline fungicides; (14) lipid peroxidation inhibitor fungicides; (15) melanin biosynthesis inhibitors-reductase (MBI-R) fungicides; (16) melanin biosynthesis inhibitors-dehydratase (MBI-D) fungicides; (17) hydroxyanilide fungicides; (18) squalene-epoxidase inhibitor fungicides; (19) polyoxin fungicides; (20) phenylurea fungicides; (21) quinone inside inhibitor (QiI) fungicides; (22) benzamide fungicides; (23) enopyranuronic acid antibiotic fungicides; (24) hexopyranosyl antibiotic fungicides; (25) glucopyranosyl antibiotic: protein synthesis fungicides; (26) glucopyranosyl antibiotic: trehalase and inositol biosynthesis fungicides; (27) cyanoacetamideoxime fungicides; (28) carbamate fungicides; (29) oxidative phosphorylation uncoupling fungicides; (30) organo tin fungicides; (31) carboxylic acid fungicides; (32) heteroaromatic fungicides; (33) phosphonate fungicides; (34) phthalamic acid fungicides; (35) benzotriazine fungicides; (36) benzene-sulfonamide fungicides; (37) pyridazinone fungicides; (38) thiophene-carboxamide fungicides; (39) pyrimidinamide fungicides; (40) carboxylic acid amide (CAA) fungicides; (41) tetracycline antibiotic fungicides; (42) thiocarbamate fungicides; (43) benzamide fungicides; (44) host plant defense induction fungicides; (45) multi-site contact activity fungicides; (46) fungicides other than classes (1) through (45); and salts of compounds of classes (1) through (46).
Further descriptions of these classes of fungicidal compounds are provided below.
(1) “Methyl benzimidazole carbamate (MBC) fungicides” (Fungicide Resistance Action Committee (FRAC) code 1) inhibit mitosis by binding to β-tubulin during microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Methyl benzimidazole carbamate fungicides include benzimidazole and thiophanate fungicides. The benzimidazoles include benomyl, carbendazim, fuberidazole and thiabendazole. The thiophanates include thiophanate and thiophanate-methyl.
(2) “Dicarboximide fungicides” (Fungicide Resistance Action Committee (FRAC) code 2) are proposed to inhibit a lipid peroxidation in fungi through interference with NADH cytochrome c reductase. Examples include chlozolinate, iprodione, procymidone and vinclozolin.
(3) “Demethylation inhibitor (DMI) fungicides” (Fungicide Resistance Action Committee (FRAC) code 3) inhibit C14-demethylase, which plays a role in sterol production. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. DMI fungicides are divided between several chemical classes: azoles (including triazoles and imidazoles), pyrimidines, piperazines and pyridines. The triazoles include azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole and uniconazole. The imidazoles include clotrimazole, imazalil, oxpoconazole, prochloraz, pefurazoate and triflumizole. The pyrimidines include fenarimol and nuarimol. The piperazines include triforine. The pyridines include pyrifenox. Biochemical investigations have shown that all of the above mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in Modern Selective Fungicides—Properties, Applications and Mechanisms of Action, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205-258.
(4) “Phenylamide fungicides” (Fungicide Resistance Action Committee (FRAC) code 4) are specific inhibitors of RNA polymerase in Oomycete fungi. Sensitive fungi exposed to these fungicides show a reduced capacity to incorporate uridine into rRNA. Growth and development in sensitive fungi is prevented by exposure to this class of fungicide. Phenylamide fungicides include acylalanine, oxazolidinone and butyrolactone fungicides. The acylalanines include benalaxyl, benalaxyl-M, furalaxyl, metalaxyl and metalaxyl-M/mefenoxam. The oxazolidinones include oxadixyl. The butyrolactones include ofurace.
(5) “Amine/morpholine fungicides” (Fungicide Resistance Action Committee (FRAC) code 5) inhibit two target sites within the sterol biosynthetic pathway, Δ8→Δ7 isomerase and Δ14 reductase. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Amine/morpholine fungicides (also known as non-DMI sterol biosynthesis inhibitors) include morpholine, piperidine and spiroketal-amine fungicides. The morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. The piperidines include fenpropidin and piperalin. The spiroketal-amines include spiroxamine.
(6) “Phospholipid biosynthesis inhibitor fungicides” (Fungicide Resistance Action Committee (FRAC) code 6) inhibit growth of fungi by affecting phospholipid biosynthesis. Phospholipid biosynthesis fungicides include phophorothiolate and dithiolane fungicides. The phosphorothiolates include edifenphos, iprobenfos and pyrazophos. The dithiolanes include isoprothiolane.
(7) “Carboxamide fungicides” (Fungicide Resistance Action Committee (FRAC) code 7) inhibit Complex II (succinate dehydrogenase) fungal respiration by disrupting a key enzyme in the Krebs Cycle (TCA cycle) named succinate dehydrogenase. Inhibiting respiration prevents the fungus from making ATP, and thus inhibits growth and reproduction. Carboxamide fungicides include benzamides, furan carboxamides, oxathiin carboxamides, thiazole carboxamides, pyrazole carboxamides and pyridine carboxamides. The benzamides include benodanil, flutolanil and mepronil. The furan carboxamides include fenfuram. The oxathiin carboxamides include carboxin and oxycarboxin. The thiazole carboxamides include thifluzamide. The pyrazole carboxamides include furametpyr, penthiopyrad, bixafen, isopyrazam, N-[2-(1S,2R)-[1,1′-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and penflufen (N-[2-(1,3-dimethyl-butyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide). The pyridine carboxamides include boscalid.
(8) “Hydroxy(2-amino-)pyrimidine fungicides” (Fungicide Resistance Action Committee (FRAC) code 8) inhibit nucleic acid synthesis by interfering with adenosine deaminase. Examples include bupirimate, dimethirimol and ethirimol.
(9) “Anilinopyrimidine fungicides” (Fungicide Resistance Action Committee (FRAC) code 9) are proposed to inhibit biosynthesis of the amino acid methionine and to disrupt the secretion of hydrolytic enzymes that lyse plant cells during infection. Examples include cyprodinil, mepanipyrim and pyrimethanil.
(10) “N-Phenyl carbamate fungicides” (Fungicide Resistance Action Committee (FRAC) code 10) inhibit mitosis by binding to β-tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Examples include diethofencarb.
(11) “Quinone outside inhibitor (QoI) fungicides” (Fungicide Resistance Action Committee (FRAC) code 11) inhibit Complex III mitochondrial respiration in fungi by affecting ubiquinol oxidase. Oxidation of ubiquinol is blocked at the “quinone outside” (QO) site of the cytochrome bc1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone outside inhibitor fungicides (also known as strobilurin fungicides) include methoxyacrylate, methoxycarbamate, oximinoacetate, oximinoacetamide, oxazolidinedione, dihydrodioxazine, imidazolinone and benzylcarbamate fungicides. The methoxyacrylates include azoxystrobin, enestroburin (SYP-Z071), picoxystrobin and pyraoxystrobin (SYP-3343). The methoxycarbamates include pyraclostrobin and pyrametostrobin (SYP-4155). The oximinoacetates include kresoxim-methyl and trifloxystrobin. The oximinoacetamides include dimoxystrobin, metominostrobin, orysastrobin, α-[methoxyimino]-N-methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]-methyl]benzeneacetamide and 2-[[[3-(2,6-dichlorophenyl)-1-methyl-2-propen-1-ylidene]-amino]oxy]methyl]-α-(methoxyimino)-N-methylbenzeneacetamide. The oxazolidinediones include famoxadone. The dihydrodioxazines include fluoxastrobin. The imidazolinones include fenamidone. The benzylcarbamates include pyribencarb.
(12) “Phenylpyrrole fungicides” (Fungicide Resistance Action Committee (FRAC) code 12) inhibit a MAP protein kinase associated with osmotic signal transduction in fungi. Fenpiclonil and fludioxonil are examples of this fungicide class.
(13) “Quinoline fungicides” (Fungicide Resistance Action Committee (FRAC) code 13) are proposed to inhibit signal transduction by affecting G-proteins in early cell signaling. They have been shown to interfere with germination and/or appressorium formation in fungi that cause powder mildew diseases. Quinoxyfen and tebufloquin are examples of this class of fungicide.
(14) “Lipid peroxidation inhibitor fungicides” (Fungicide Resistance Action Committee (FRAC) code 14) are proposed to inhibit lipid peroxidation which affects membrane synthesis in fungi. Members of this class, such as etridiazole, may also affect other biological processes such as respiration and melanin biosynthesis. Lipid peroxidation fungicides include aromatic carbon and 1,2,4-thiadiazole fungicides. The aromatic carbon fungicides include biphenyl, chloroneb, dicloran, quintozene, tecnazene and tolclofos-methyl. The 1,2,4-thiadiazole fungicides include etridiazole.
(15) “Melanin biosynthesis inhibitors-reductase (MBI-R) fungicides” (Fungicide Resistance Action Committee (FRAC) code 16.1) inhibit the naphthal reduction step in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitors-reductase fungicides include isobenzofuranone, pyrroloquinolinone and triazolobenzothiazole fungicides. The isobenzofuranones include fthalide. The pyrroloquinolinones include pyroquilon. The triazolobenzothiazoles include tricyclazole.
(16) “Melanin biosynthesis inhibitors-dehydratase (MBI-D) fungicides” (Fungicide Resistance Action Committee (FRAC) code 16.2) inhibit scytalone dehydratase in melanin biosynthesis. Melanin in required for host plant infection by some fungi. Melanin biosynthesis inhibitors-dehydratase fungicides include cyclopropanecarboxamide, carboxamide and propionamide fungicides. The cyclopropanecarboxamides include carpropamid. The carboxamides include diclocymet. The propionamides include fenoxanil.
(17) “Hydroxyanilide fungicides (Fungicide Resistance Action Committee (FRAC) code 17) inhibit C4-demethylase which plays a role in sterol production. Examples include fenhexamid.
(18) “Squalene-epoxidase inhibitor fungicides” (Fungicide Resistance Action Committee (FRAC) code 18) inhibit squalene-epoxidase in ergosterol biosynthesis pathway. Sterols such as ergosterol are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Squalene-epoxidase inhibitor fungicides include thiocarbamate and allylamine fungicides. The thiocarbamates include pyributicarb. The allylamines include naftifine and terbinafine.
(19) “Polyoxin fungicides” (Fungicide Resistance Action Committee (FRAC) code 19) inhibit chitin synthase. Examples include polyoxin.
(20) “Phenylurea fungicides” (Fungicide Resistance Action Committee (FRAC) code 20) are proposed to affect cell division. Examples include pencycuron.
(21) “Quinone inside inhibitor (QiI) fungicides” (Fungicide Resistance Action Committee (FRAC) code 21) inhibit Complex III mitochondrial respiration in fungi by affecting ubiquinol reductase. Reduction of ubiquinol is blocked at the “quinone inside” (Qi) site of the cytochrome bc1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone inside inhibitor fungicides include cyanoimidazole and sulfamoyltriazole fungicides. The cyanoimidazoles include cyazofamid. The sulfamoyltriazoles include amisulbrom.
(22) “Benzamide fungicides” (Fungicide Resistance Action Committee (FRAC) code 22) inhibit mitosis by binding to β-tubulin and disrupting microtubule assembly Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Examples include zoxamide.
(23) “Enopyranuronic acid antibiotic fungicides” (Fungicide Resistance Action Committee (FRAC) code 23) inhibit growth of fungi by affecting protein biosynthesis. Examples include blasticidin-S.
(24) “Hexopyranosyl antibiotic fungicides” (Fungicide Resistance Action Committee (FRAC) code 24) inhibit growth of fungi by affecting protein biosynthesis. Examples include kasugamycin.
(25) “Glucopyranosyl antibiotic: protein synthesis fungicides” (Fungicide Resistance Action Committee (FRAC) code 25) inhibit growth of fungi by affecting protein biosynthesis. Examples include streptomycin.
(26) “Glucopyranosyl antibiotic: trehalase and inositol biosynthesis fungicides” (Fungicide Resistance Action Committee (FRAC) code 26) inhibit trehalase in inositol biosynthesis pathway. Examples include validamycin.
(27) “Cyanoacetamideoxime fungicides (Fungicide Resistance Action Committee (FRAC) code 27) include cymoxanil.
(28) “Carbamate fungicides” (Fungicide Resistance Action Committee (FRAC) code 28) are considered multi-site inhibitors of fungal growth. They are proposed to interfere with the synthesis of fatty acids in cell membranes, which then disrupts cell membrane permeability. Propamacarb, propamacarb-hydrochloride, iodocarb, and prothiocarb are examples of this fungicide class.
(29) “Oxidative phosphorylation uncoupling fungicides” (Fungicide Resistance Action Committee (FRAC) code 29) inhibit fungal respiration by uncoupling oxidative phosphorylation. Inhibiting respiration prevents normal fungal growth and development. This class includes 2,6-dinitroanilines such as fluazinam, pyrimidonehydrazones such as ferimzone and dinitrophenyl crotonates such as dinocap, meptyldinocap and binapacryl.
(30) “Organo tin fungicides” (Fungicide Resistance Action Committee (FRAC) code 30) inhibit adenosine triphosphate (ATP) synthase in oxidative phosphorylation pathway. Examples include fentin acetate, fentin chloride and fentin hydroxide.
(31) “Carboxylic acid fungicides” (Fungicide Resistance Action Committee (FRAC) code 31) inhibit growth of fungi by affecting deoxyribonucleic acid (DNA) topoisomerase type II (gyrase). Examples include oxolinic acid.
(32) “Heteroaromatic fungicides” (Fungicide Resistance Action Committee (FRAC) code 32) are proposed to affect DNA/ribonucleic acid (RNA) synthesis. Heteroaromatic fungicides include isoxazole and isothiazolone fungicides. The isoxazoles include hymexazole and the isothiazolones include octhilinone.
(33) “Phosphonate fungicides” (Fungicide Resistance Action Committee (FRAC) code 33) include phosphorous acid and its various salts, including fosetyl-aluminum.
(34) “Phthalamic acid fungicides” (Fungicide Resistance Action Committee (FRAC) code 34) include teclofthalam.
(35) “Benzotriazine fungicides” (Fungicide Resistance Action Committee (FRAC) code 35) include triazoxide.
(36) “Benzene-sulfonamide fungicides” (Fungicide Resistance Action Committee (FRAC) code 36) include flusulfamide.
(37) “Pyridazinone fungicides” (Fungicide Resistance Action Committee (FRAC) code 37) include diclomezine.
(38) “Thiophene-carboxamide fungicides” (Fungicide Resistance Action Committee (FRAC) code 38) are proposed to affect ATP production. Examples include silthiofam.
(39) “Pyrimidinamide fungicides” (Fungicide Resistance Action Committee (FRAC) code 39) inhibit growth of fungi by affecting phospholipid biosynthesis and include diflumetorim.
(40) “Carboxylic acid amide (CAA) fungicides” (Fungicide Resistance Action Committee (FRAC) code 40) are proposed to inhibit phospholipid biosynthesis and cell wall deposition. Inhibition of these processes prevents growth and leads to death of the target fungus. Carboxylic acid amide fungicides include cinnamic acid amide, valinamide carbamate and mandelic acid amide fungicides. The cinnamic acid amides include dimethomorph and flumorph. The valinamide carbamates include benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, valifenalate and valiphenal. The mandelic acid amides include mandipropamid, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide and N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide.
(41) “Tetracycline antibiotic fungicides” (Fungicide Resistance Action Committee (FRAC) code 41) inhibit growth of fungi by affecting complex 1 nicotinamide adenine dinucleotide (NADH) oxidoreductase. Examples include oxytetracycline.
(42) “Thiocarbamate fungicides” (Fungicide Resistance Action Committee (FRAC) code 42) include methasulfocarb.
(43) “Benzamide fungicides” (Fungicide Resistance Action Committee (FRAC) code 43) inhibit growth of fungi by delocalization of spectrin-like proteins. Examples include acylpicolide fungicides such as fluopicolide and fluopyram.
(44) “Host plant defense induction fungicides” (Fungicide Resistance Action Committee (FRAC) code P) induce host plant defense mechanisms. Host plant defense induction fungicides include benzo-thiadiazole, benzisothiazole and thiadiazole-carboxamide fungicides. The benzo-thiadiazoles include acibenzolar-S-methyl. The benzisothiazoles include probenazole. The thiadiazole-carboxamides include tiadinil and isotianil.
(45) “Multi-site contact fungicides” inhibit fungal growth through multiple sites of action and have contact/preventive activity. This class of fungicides includes: (45.1) “copper fungicides” (Fungicide Resistance Action Committee (FRAC) code M1)”, (45.2) “sulfur fungicides” (Fungicide Resistance Action Committee (FRAC) code M2), (45.3) “dithiocarbamate fungicides” (Fungicide Resistance Action Committee (FRAC) code M3), (45.4) “phthalimide fungicides” (Fungicide Resistance Action Committee (FRAC) code M4), (45.5) “chloronitrile fungicides” (Fungicide Resistance Action Committee (FRAC) code M5), (45.6) “sulfamide fungicides” (Fungicide Resistance Action Committee (FRAC) code M6), (45.7) “guanidine fungicides” (Fungicide Resistance Action Committee (FRAC) code M7), (45.8) “triazine fungicides” (Fungicide Resistance Action Committee (FRAC) code M8) and (45.9) “quinone fungicides” (Fungicide Resistance Action Committee (FRAC) code M9). “Copper fungicides” are inorganic compounds containing copper, typically in the copper(II) oxidation state; examples include copper oxychloride, copper sulfate and copper hydroxide, including compositions such as Bordeaux mixture (tribasic copper sulfate). “Sulfur fungicides” are inorganic chemicals containing rings or chains of sulfur atoms; examples include elemental sulfur. “Dithiocarbamate fungicides” contain a dithiocarbamate molecular moiety; examples include mancozeb, metiram, propineb, ferbam, maneb, thiram, zineb and ziram. “Phthalimide fungicides” contain a phthalimide molecular moiety; examples include folpet, captan and captafol. “Chloronitrile fungicides” contain an aromatic ring substituted with chloro and cyano; examples include chlorothalonil. “Sulfamide fungicides” include dichlofluanid and tolyfluanid. “Guanidine fungicides” include dodine, guazatine, iminoctadine albesilate and iminoctadine triacetate. “Triazine fungicides” include anilazine. “Quinone fungicides” include dithianon.
(46) “Fungicides other than fungicides of classes (1) through (45)” include certain fungicides whose mode of action may be unknown. These include: (46.1) “thiazole carboxamide fungicides” (Fungicide Resistance Action Committee (FRAC) code U5), (46.2) “phenyl-acetamide fungicides” (Fungicide Resistance Action Committee (FRAC) code U6), (46.3) “quinazolinone fungicides” (Fungicide Resistance Action Committee (FRAC) code U7), (46.4) “benzophenone fungicides” (Fungicide Resistance Action Committee (FRAC) code U8) and (46.5) “triazolopyrimidine fungicides”. The thiazole carboxamides include ethaboxam. The phenyl-acetamides include cyflufenamid and N-[[(cyclopropylmethoxy)-amino][6-(difluoromethoxy)-2,3-difluorophenyl]-methylene]benzeneacetamide. The quinazolinones include proquinazid. The benzophenones include metrafenone. The triazolopyrimidines include ametoctradin. Class (46) (i.e. “Fungicides other than classes (1) through (45)”) also includes bethoxazin, fluxapyroxad, neo-asozin (ferric methanearsonate), pyriofenone, pyrrolnitrin, quinomethionate, tebufloquin, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide, N-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide, 2-[[2-fluoro-5-(trifluoromethyl)phenyl]thio]-2-[3-(2-methoxyphenyl)-2-thiazolidinylidene]acetonitrile, 3-[5-(4-chlorophenyl)-2,3-dimethyl-3-isoxazolidinyl]pyridine, 4-fluorophenyl N-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]-propyl]carbamate, 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl) [1,2,4 triazolo[1,5-c]pyrimidine, N-(4-chloro-2-nitrophenyl)-N-ethyl-4-methylbenzenesulfonamide, N-[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]-benzeneacetamide, N′-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, 1-[(2-propenylthio)carbonyl]-2-(1-methylethyl)-4-(2-methylphenyl)-5-amino-1H-pyrazol-3-one, N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, 3-(di-fluoromethyl)-N49-(difluoromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-1-methyl-1H-pyrazole-4-carboxamide, N-[9-(dibromomethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, N-[9-(dibromomethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, N-[9-(difluoromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide and N-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-2,5-dimethylphenyl]-N-ethyl-N-methyl-methanimidamide.
Therefore of note is a mixture (i.e. composition) comprising a compound of Formula 1 or Formula 1A and at least one fungicidal compound selected from the group consisting of the aforedescribed classes (1) through (46). Also of note is a composition comprising said mixture (in fungicidally effective amount) and further comprising at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of particular note is a mixture (i.e. composition) comprising a compound of Formula 1 or Formula 1A and at least one fungicidal compound selected from the group of specific compounds listed above in connection with classes (1) through (46). Also of particular note is a composition comprising said mixture (in fungicidally effective amount) and further comprising at least one additional surfactant selected from the group consisting of surfactants, solid diluents and liquid diluents.
Examples of other biologically active compounds or agents with which compounds of this invention can be formulated are: insecticides such as abamectin, acephate, acetamiprid, acrinathrin, amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, buprofezin, carbofuran, cartap, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyantraniliprole (3-bromo-1-(3-chloro-2-pyridinyl)-N-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1H-pyrazole-5-carboxamide), cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos, halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, meperfluthrin, metaflumizone, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, methoxyfenozide, metofluthrin, milbemycin oxime, monocrotophos, nicotine, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulfoxaflor, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tolfenpyrad, tralomethrin, triazamate, trichlorfon and triflumuron; and biological agents including entomopathogenic bacteria, such as Bacillus thuringiensis subsp. aizawai, Bacillus thuringiensis subsp. kurstaki, and the encapsulated delta-endotoxins of Bacillus thuringiensis (e.g., Cellcap, MPV, MPVII); entomopathogenic fungi, such as green muscardine fungus; and entomopathogenic virus including baculovirus, nucleopolyhedro virus (NPV) such as HzNPV, AfNPV; and granulosis virus (GV) such as CpGV.
Compounds of this invention and compositions thereof can be applied to plants genetically transformed to express proteins toxic to invertebrate pests (such as Bacillus thuringiensis delta-endotoxins). The effect of the exogenously applied fungicidal compounds of this invention may be synergistic with the expressed toxin proteins.
General references for agricultural protectants (i.e. insecticides, fungicides, nematocides, acaricides, herbicides and biological agents) include The Pesticide Manual, 13th Edition, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2003 and The BioPesticide Manual, 2nd Edition, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2001.
For embodiments where one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) to the compound of Formula 1 or Formula 1A is typically between about 1:3000 and about 3000:1. Of note are weight ratios between about 1:300 and about 300:1 (for example ratios between about 1:30 and about 30:1). One skilled in the art can easily determine through simple experimentation the biologically effective amounts of active ingredients necessary for the desired spectrum of biological activity. It will be evident that including these additional components may expand the spectrum of diseases controlled beyond the spectrum controlled by the compound of Formula 1 or Formula 1A alone.
In certain instances, combinations of a compound of this invention with other biologically active (particularly fungicidal) compounds or agents (i.e. active ingredients) can result in a greater-than-additive (i.e. synergistic) effect. Reducing the quantity of active ingredients released in the environment while ensuring effective pest control is always desirable. When synergism of fungicidal active ingredients occurs at application rates giving agronomically satisfactory levels of fungal control, such combinations can be advantageous for reducing crop production cost and decreasing environmental load.
Of note is a combination of a compound of Formula 1 or Formula 1A with at least one other fungicidal active ingredient. Of particular note is such a combination where the other fungicidal active ingredient has different site of action from the compound of Formula 1 or Formula 1A. In certain instances, a combination with at least one other fungicidal active ingredient having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can further comprise a biologically effective amount of at least one additional fungicidal active ingredient having a similar spectrum of control but a different site of action.
Of particular note are compositions which in addition to compound of Formula 1 or Formula 1A include at least one compound selected from the group consisting of (1) alkylenebis(dithiocarbamate) fungicides; (2) cymoxanil; (3) phenylamide fungicides; (4) proquinazid (6-iodo-3-propyl-2-propyloxy-4(3H)-quinazolinone); (5) chlorothalonil; (6) carboxamides acting at complex II of the fungal mitochondrial respiratory electron transfer site; (7) quinoxyfen; (8) metrafenone; (9) cyflufenamid; (10) cyprodinil; (11) copper compounds; (12) phthalimide fungicides; (13) fosetyl-aluminum; (14) benzimidazole fungicides; (15) cyazofamid; (16) fluazinam; (17) iprovalicarb; (18) propamocarb; (19) validomycin; (20) dichlorophenyl dicarboximide fungicides; (21) zoxamide; (22) fluopicolide; (23) mandipropamid; (24) carboxylic acid amides acting on phospholipid biosynthesis and cell wall deposition; (25) dimethomorph; (26) non-DMI sterol biosynthesis inhibitors; (27) inhibitors of demethylase in sterol biosynthesis; (28) bc1 complex fungicides; and salts of compounds of (1) through (28). Further descriptions of classes of fungicidal compounds are provided below.
Sterol biosynthesis inhibitors (group (27)) control fungi by inhibiting enzymes in the sterol biosynthesis pathway. Demethylase-inhibiting fungicides have a common site of action within the fungal sterol biosynthesis pathway, involving inhibition of demethylation at position 14 of lanosterol or 24-methylene dihydrolanosterol, which are precursors to sterols in fungi. Compounds acting at this site are often referred to as demethylase inhibitors, DMI fungicides, or DMIs. The demethylase enzyme is sometimes referred to by other names in the biochemical literature, including cytochrome P-450 (14DM). The demethylase enzyme is described in, for example, J. Biol. Chem. 1992, 267, 13175-79 and references cited therein. DMI fungicides are divided between several chemical classes: azoles (including triazoles and imidazoles), pyrimidines, piperazines and pyridines. The triazoles include azaconazole, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, quinconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole and uniconazole. The imidazoles include clotrimazole, econazole, imazalil, isoconazole, miconazole, oxpoconazole, prochloraz and triflumizole. The pyrimidines include fenarimol, nuarimol and triarimol. The piperazines include triforine. The pyridines include buthiobate and pyrifenox. Biochemical investigations have shown that all of the above mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in Modern Selective Fungicides—Properties, Applications and Mechanisms of Action, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205-258.
bc1 Complex Fungicides (group 28) have a fungicidal mode of action which inhibits the bc1 complex in the mitochondrial respiration chain. The bc1 complex is sometimes referred to by other names in the biochemical literature, including complex III of the electron transfer chain, and ubihydroquinone:cytochrome c oxidoreductase. This complex is uniquely identified by Enzyme Commission number EC1.10.2.2. The bc1 complex is described in, for example, J. Biol. Chem. 1989, 264, 14543-48; Methods Enzymol. 1986, 126, 253-71; and references cited therein. Strobilurin fungicides such as azoxystrobin, dimoxystrobin, enestroburin (SYP-Z071), fluoxastrobin, kresoxim-methyl, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin and trifloxystrobin are known to have this mode of action (H. Sauter et al., Angew. Chem. Int. Ed. 1999, 38, 1328-1349). Other fungicidal compounds that inhibit the bc1 complex in the mitochondrial respiration chain include famoxadone and fenamidone.
Alkylenebis(dithiocarbamate)s (group (1)) include compounds such as mancozeb, maneb, propineb and zineb. Phenylamides (group (3)) include compounds such as metalaxyl, benalaxyl, furalaxyl and oxadixyl. Carboxamides (group (6)) include compounds such as boscalid, carboxin, fenfuram, flutolanil, furametpyr, mepronil, oxycarboxin, thifluzamide, penthiopyrad and N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide (PCT Patent Publication WO 2003/010149), and are known to inhibit mitochondrial function by disrupting complex II (succinate dehydrogenase) in the respiratory electron transport chain. Copper compounds (group (11)) include compounds such as copper oxychloride, copper sulfate and copper hydroxide, including compositions such as Bordeaux mixture (tribasic copper sulfate). Phthalimides (group (12)) include compounds such as folpet and captan. Benzimidazole fungicides (group (14)) include benomyl and carbendazim. Dichlorophenyl dicarboximide fungicides (group (20)) include chlozolinate, dichlozoline, iprodione, isovaledione, myclozolin, procymidone and vinclozolin.
Non-DMI sterol biosynthesis inhibitors (group (26)) include morpholine and piperidine fungicides. The morpholines and piperidines are sterol biosynthesis inhibitors that have been shown to inhibit steps in the sterol biosynthesis pathway at a point later than the inhibitions achieved by the DMI sterol biosynthesis (group (27)). The morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. The piperidines include fenpropidin.
Of further note are combinations of compounds of Formula 1 or Formula 1A with azoxystrobin, kresoxim-methyl, trifloxystrobin, pyraclostrobin, picoxystrobin, dimoxystrobin, metominostrobinifenominostrobin, carbendazim, chlorothalonil, quinoxyfen, metrafenone, cyflufenamid, fenpropidine, fenpropimorph, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, fenbuconazole, flusilazole, hexaconazole, ipconazole, metconazole, penconazole, propiconazole, proquinazid, prothioconazole, tebuconazole, triticonazole, famoxadone, prochloraz, penthiopyrad and boscalid (nicobifen).
Specifically preferred mixtures (compound numbers refer to compounds in Index Tables A-C below) are selected from the group: combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with azoxystrobin, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with kresoxim-methyl, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with trifloxystrobin, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with picoxystrobin, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with metominostrobinifenominostrobin, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with quinoxyfen, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with metrafenone, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with fenpropidine, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with fenpropimorph, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with cyproconazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with epoxiconazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with flusilazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with metconazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with propiconazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with proquinazid, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with prothioconazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with tebuconazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with triticonazole, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with famoxadone, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with penthiopyrad, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with 3-(difluoromethyl)-1-methyl-N-(3′,4′,5′-trifluoro[1,1′-biphenyl]-2-yl)-1H-pyrazole-4-carboxamide, combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with 5-ethyl-6-octyl-[1,2,4]triazole[1,5-a]pyrimidin-7-amine, and combinations of Compound 3, Compound 10, Compound 12, Compound 14, Compound 17, Compound 18, Compound 19, Compound 21, Compound 30, Compound 31, Compound 33, Compound 36, Compound 37, Compound 40, Compound 42, Compound 45, Compound 61, Compound 69, Compound 80, Compound 82, Compound 85, Compound 90, Compound 97, Compound 112, Compound 119, Compound 120, Compound 126, Compound 137, Compound 142, Compound 157, Compound 160, or Compound 179 with Initium®.
The control efficacy of compounds of this invention on specific pathogens is demonstrated below in TABLE A. The pathogen control protection afforded by the compounds is not limited, however, to these species (i.e. species described in Tests A-F below). Descriptions of the compounds are provided in Index Tables A-C below. The following abbreviations are used in the index tables: Me is methyl, MeO is methoxy, EtO is ethoxy, CN is cyano, NO2 is nitro and Ph is phenyl. The abbreviation “Cmpd. No.” means compound number, and “Ex.” stands for “Example” and is followed by a number indicating in which example the compound is prepared. Mass spectra (MS) are reported as the molecular weight of the highest isotopic abundance parent ion (M+1) formed by addition of H+(molecular weight of 1) to the molecule, observed by mass spectrometry using atmospheric pressure chemical ionization (AP+).







INDEX TABLE A













 












Cmpd. No.
R2
Q1
Q2
m.p. (° C.)
AP+ (M + 1)





  3
Me
2-Cl, 4-F—Ph
2-Cl, 6-F—Ph

383


  9
Cl
2,4-di-F—Ph
2-Cl, 4-F—Ph
104-107



 10
Me
2-Cl, 4-F—Ph
2,6-di-F—Ph
142-144



14 (Ex. 4)
Me
2,4-di-F—Ph
2,6-di-F—Ph
**
**


 15
Me
2,4,6-tri-F—Ph
2,6-di-F—Ph

369


 16
Me
2,6-di-F, 4-MeO—Ph
2,6-di-F—Ph

381


 17
Me
2,4-di-F—Ph
2-Cl, 4-F—Ph

367


 18
Me
2-Cl, 4-F—Ph
2-Cl, 4-F—Ph

383


 19
Me
2,4,6-tri-F—Ph
2-Cl, 4-F—Ph

385


 20
Me
2,6-di-F, 4-MeO—Ph
2-Cl, 4-F—Ph

397


 21
Me
2-Br, 4-F—Ph
2,6-di-F—Ph

411


 22
Me
2-F, 4-CN—Ph
2,6-diF—Ph
*
*


 23
Me
2-Br, 4-F—Ph
2-Cl, 4-F—Ph

429


 25
Me
2-F, 4-CN—Ph
2-Cl, 4-F—Ph

374


30 (Ex. 9)
Br
2,4-di-F—Ph
2-Cl, 4-F—Ph
**
**


 33
Me
2,4-di-F—Ph
2-Cl, 6-F—Ph

367


 34
Me
2,4,6-tri-F—Ph
2-Cl, 6-F—Ph

385


 37
Me
2-Br, 4-F—Ph
2-Cl, 6-F—Ph

427


 38
Me
4-CN, 2-F—Ph
2-Cl, 6-F—Ph

374


 39
Me
2,6-di-F, 4-MeO—Ph
2-Cl, 6-F—Ph

397


53 (Ex. 11)
CN
2-Cl, 4-F—Ph
2,6-di-F—Ph
**
**


 55
Me
2,4,6-tri-Cl—Ph
2-Cl, 6-F—Ph

435


 61
Me
2-Cl, 4-F—Ph
2,4,6-tri-F—Ph

385


 66
Me
2,4-di-F—Ph
2,4,6-tri-F—Ph

369


 69
Me
2-Cl, 4-F—Ph
2,6-di-Cl—Ph
160-162



 70
Me
2,4,6-tri-F—Ph
2,6-di-Cl—Ph
137-139



 71
Me
2-Cl, 4-F—Ph
2,4-di-F—Ph
*
*


72 (Ex. 8)
Me
2,4-di-F—Ph
2,4-di-F—Ph
**
**


 74
Me
2,4-di-F—Ph
2,6-di-Cl—Ph
125-128



 76
Me
2,4-di-F—Ph
2-Br, 4-F—Ph

411


 77
Me
4-Cl—Ph
2,6-di-Cl—Ph

383


79 Note 1
Me
2-Cl, 4-F—Ph
2-Br

411


80 Note 2
Me
2-Cl, 4-F—Ph
2-Br

411


 82
Me
2,4,6-tri-F—Ph
2-Br, 4-F—Ph
*
*


 85
Me
2,6-di-Cl—Ph
2-Cl, 6-F—Ph

399


86 Note 3
Me
2-Cl, 4-F—Ph
2,6-di-F—Ph
61-71



87 Note 4
Me
2-Cl, 4-F—Ph
2,6-di-F—Ph

367


 88
Me
2-Br, 4-F—Ph
2-I

503


 90
Me
2,4-di-Cl—Ph
2-Cl, 6-F—Ph

401


 94
Me
2-Cl, 4-F—Ph
2-Br, 6-F—Ph

429


 95
Me
2-Cl, 4-F—Ph
2-Br, 4-F—Ph
*
*


 97
Me
2,4-di-F—Ph
2,4-di-Cl—Ph
123-127



 98
Me
2-Cl, 4-F—Ph
3,5-di-Cl-4-pyridinyl

400


 99
Me
2-I, 4-F—Ph
2-Cl, 4-F—Ph

475


100
Me
2-Cl, 4-F—Ph
2,4-di-ClPh

401


101
Me
4-Cl, 2-F—Ph
2,4-di-Cl—Ph
150-152



103 Note 3
Me
2-Cl, 4-F—Ph
4-F, 2-I—Ph
148-151



104 Note 4
Me
2-Cl, 4-F—Ph
4-F, 2-I—Ph

475


105
Me
2-Cl, 4-F—Ph
4-F—Ph

349


106
Me
2,4-di-F—Ph
4-Br-2,6-di-4-F—Ph

431


112
Me
2,4-di-F—Ph
4-CN-2,6-di-4-F—Ph
170-173



113
Br
2-Br, 4-F—Ph
2,6-di-4-F—Ph
118-120



114
Br
2,4,6-tri-F—Ph
2,6-di-4-F—Ph
168-170



117
Cl
2,4-di-F—Ph
2,6-di-4-F—Ph
97-99



118
MeO
2-Cl, 4-F—Ph
2-Cl, 4-F—Ph

399


119
Br
2-Cl, 4-F—Ph
2,6-di-4-F—Ph
83-86



120
MeO
2-Cl, 4-F—Ph
2-Cl, 6-F—Ph

399


124
Br
2,4-di-F—Ph
2,6-di-F—Ph
80-82



125
Br
2-Cl, 4-F—Ph
2-Cl, 4-F—Ph
142-144



126
MeO
2-Cl, 4-F—Ph
2,6-di-F—Ph

383


127
EtO
2-Cl, 4-F—Ph
2,6-di-F—Ph

397


128
F2CHO
2-Cl, 4-F—Ph
2,6-di-F—Ph

419


129
Me
2-Me, 4-F—Ph
2,6-di-F—Ph

347


130
H
2-Cl, 4-F—Ph
2,6-di-F—Ph
136-138



131
Br
2,4-di-F—Ph
2-Cl, 6-F—Ph
143-146



132
Br
2-Br, 4-F—Ph
2-Cl, 6-F—Ph
122-125



133
Cl
2,4-di-F—Ph
2-Cl, 6-F—Ph
157-160



134
Cl
2-Br, 4-F—Ph
2-Cl, 6-F—Ph
117-120



135
Cl
2-Cl, 4-F—Ph
2-Cl, 6-F—Ph
131-134



136
Cl
2-Br, 4-F—Ph
2,6-di-F—Ph
100-102



137
Cl
2-Cl, 4-F—Ph
2,6-di-F—Ph
113-115



138
MeO
2,3,6-tri-F—Ph
2,6-di-F—Ph

385


139
MeO
2-Cl, 3,6-di-F—Ph
2,6-di-F—Ph

400


140
MeO
2-Me, 4-F—Ph
2-Cl, 6-F—Ph

379


141
MeO
2-Cl, 4-F—Ph
2-Cl, 4,6-di-F—Ph

417


142
MeO
2-Cl, 4-MeO—Ph
2-Cl, 6-F—Ph

411


143
MeO
2-F, 4-MeO—Ph
2-Cl, 6-F—Ph

395


144
MeO
2-Cl, 3,6-di-F—Ph
2-Cl, 6-F—Ph

417


145
MeO
2,3,6-tri-F—Ph
2-Cl, 6-F—Ph

401


146
Me
2,4-di-F—Ph
2-Me-1H-imidazol-1-yl
180-183



147
Me
2-Me, 4-F—Ph
2-Me-1H-imidazol-1-yl

315


148
Br
2-Cl, 4-F—Ph
2-Cl, 6-F—Ph
131-134



149
Br
2-Me, 4-F—Ph
2-Cl, 6-F—Ph
133-136



150
Me
2-Me, 4-F—Ph
2-Cl-1H-imidazol-1-yl
165-168



151
Me
2,4-di-F—Ph
2-Cl-1H-imidazol-1-yl
183-186



152
MeO
2-Cl, 4-F—Ph
2,4,6-F—Ph

401


153
MeO
2,4-di-F—Ph
2,4,6-tri-F—Ph

385


154
MeO
2-F—Ph
2,4,6-tri-F—Ph

365


155
MeO
2-Cl, 6-F—Ph
2,4,6-tri-F—Ph

401


156
MeO
2,4-di-F—Ph
2,6-di-F—Ph

367


157 (Ex. 12)
MeO
2-Me, 4-F—Ph
2,6-di-F—Ph
**
**


158
Me
2-Me 4-F—Ph
3,5-di-Me-1H-pyrazol-1-yl
97-99



159
Me
2,4-di-F—Ph
3 ,5-di-Me-1H-pyrazol-1-yl
136-138



160
MeO
2-Cl, 4-MeO—Ph
2,6-di-F—Ph

365


161
MeO
2-F, 4-MeO—Ph
2,6-di-F—Ph

379


162
MeO
2-Cl, 4-F—Ph
4-Cl, 2,6-di-F—Ph

417


163
Br
2,4-di-Cl—Ph
2,6-di-F—Ph
174-176



164
Br
2-Br, 4-F—Ph
2-Cl, 4-F—Ph
148-150



165
Br
2-Me, 4-F—Ph
2,6-di-F—Ph
85-87



166
Me
2-Cl, 4-F—Ph
3,5-di-F-4-pyridinyl
*
*


167
Me
2,4-di-F—Ph
3,5-di-Cl-4-pyridinyl
*
*


168
Me
2,4-di-F—Ph
3,5-di-F-4-pyridinyl

352


169
Me
2-Cl, 4-MeO—Ph
2-Cl, 4-F—Ph

395


170
Me
2-Cl, 4-MeO—Ph
2-Cl, 6-F—Ph

395


171
Me
2-Cl, 4-F—Ph
2,6-di-F, 4-MeO—Ph

397


172
Me
2,4-di-F—Ph
2,6-di-F, 4-MeO—Ph

381


173
Me
2,4,6-tri-F—Ph
2,6-di-F, 4-MeO—Ph

399





* See Index Table D for 1H NMR data.


** See synthesis example for 1H NMR.


Note 1:


99% enantiomer A.


Note 2:


13% enantiomer A, 87% enantiomer B.


Note 3:


enantiomer A.


Note 4:


enantiomer B.













INDEX TABLE B













 



















AP+


Cmpd.





(M +


No.
R2
Q1
Q2
R4
R5
1)





 29
Me
2,4-di-F—Ph
2-Cl, 6-F—Ph
OH
Me
381


 54
Me
2-Cl, 4-F—Ph
2,6-di-F—Ph
F
H
369


 67
Me
2-Cl, 4-F—Ph
2-Cl, 6-F—Ph
MeO
H
397


 68
Me
2,4-di-F—Ph
2,6-di-F—Ph
F
H
**


(Ex. 5)








 75
Me
2,4,6-tri-F—Ph
2-Cl, 6-F—Ph
F
H
387


 84
Me
2-Cl, 4-F—Ph
2,6-di-F—Ph
Cl
H
383


 92
Me
2,4-di-Cl—Ph
2,6-di-F—Ph
F
H
384


107
Me
2-Cl, 4-F—Ph
2,6-di-4-F—Ph
N≡CCH2O
H
406


108
Me
2-Cl, 4-F—Ph
2,6-di-4-F—Ph
CH3C(═O)O
H
409


109
Me
2-Cl, 4-F—Ph
2,6-di-4-F—Ph
CH2═CHCH2O
H
407


110
Me
2-Cl, 4-F—Ph
2,6-di-4-F—Ph
CH3OCH2O
H
411


111
Me
2-Cl, 4-F
2,6-di-4-F—Ph
N≡CS
H
408


115
Me
2,4-di-F—Ph
2,6-di-4-F—Ph
N≡CS
H
392


116
Me
2,4,6-tri-F—Ph
2,6-di-4-F—Ph
N≡CS
H
410


121
Me
2-Cl, 4-F—Ph
2-Cl, 6-F—Ph
N≡CS
H
424


122
Me
2,4-di-4-F—Ph
2-Cl, 6-F—Ph
N≡CS
H
408


123
Me
2,4,6-tri-F—Ph
2-Cl, 6-F—Ph
N≡CS
H
426





** See synthesis example for 1H NMR.













INDEX TABLE C













 













Cmpd. No.
R2
Q1
Q2
X
m.p. (° C.)
AP+ (M + 1)





 1
Me
4-F—Ph
2,4-di-F—Ph
O
39-40



 2
Me
4-F—Ph
2-Cl, 4-F—Ph
O
71-73



 4
Me
2-Cl, 4-F—Ph
2-Cl, 4-F—Ph
O

369


5 (Ex. 3)
Me
2-Cl, 4-F—Ph
2,4-di-F—Ph
O
**
**


 6
Me
4-CN, 2-F—Ph
2-Cl, 4-F—Ph
O
126-128



 7
Me
4-CN, 2-F—Ph
2,4-di-F—Ph
O
131-133



 8
Me
2-Cl, 4-F—Ph
2-F, 4-CN—Ph
O
139-141



 11
Me
2,4-di-F—Ph
2-Cl, 4-F—Ph
O

353


 12
Me
2,4-di-F—Ph
2-Cl, 4-MeO—Ph
O

356


 13
Me
2,4-di-F—Ph
2,4-di-F—Ph
O
62-64



 24
Me
2,4-di-F—Ph
2,6-di-F—Ph
C(═O)

349


 26
Me
2,4-di-F—Ph
2-F, 4-CN—Ph
O
125-127



 27
Me
2,4-di-Cl—Ph
2-Cl, 6-F—Ph
C(═O)

399


 28
Me
2,4-di-F—Ph
2-Cl, 6-F—Ph
C(═O)

365


 31
Me
2-Cl, 4-F—Ph
2-Cl, 4-MeO—Ph
O

381


32 (Ex. 7) 
Me
2,4-di-F—Ph
2,4-di-F—Ph
C(═O)
**
**


 35
Me
2-Cl, 4-CN—Ph
2,4-di-F—Ph
O
132-134



 36
Me
2-Cl, 4-F—Ph
2-Cl, 4-CN—Ph
O
123-125



40 (Ex. 1) 
Me
4-CN, 2,6-di-F—Ph
2-Cl, 4-F—Ph
NH
**
**


 41
Me
4-F—Ph
2-Cl, 4-F—Ph
NH

334


 42
Me
2-Cl, 4-F—Ph
2-Cl, 4-F—Ph
NH

369


 43
Me
2-Cl, 4-CN—Ph
2-Cl, 4-F—Ph
O
133-135



 44
Me
2,4-di-Cl—Ph
2-Cl, 4-F—Ph
NH

384


45 (Ex. 2) 
Me
4-Cl, 2-F—Ph
2-Cl, 4-F—Ph
NH
**
**


 46
Me
2,6-di-Cl—Ph
2-Cl, 6-F—Ph
C(═O)

397


 47
Me
2-Cl, 4-F—Ph
2,6-di-F—Ph
C(═O)

365


 48
Br
2,4-di-F—Ph
2-C1,4-F—Ph
C(═O)
154-156



 49
Me
2,4-di-F—Ph
2-Cl, 4-F—Ph
NH

352


 50
Me
2-Cl, 4-F—Ph
2,6-di-F—Ph
NH

352


 51
Me
2,4,6-tri-Cl
2-Cl, 6-F—Ph
C(═O)

433


52 (Ex. 10)
CN
2-Cl, 4-F—Ph
2,6-di-F—Ph
C(═O)
**
**


56 (Ex. 6) 
Me
4-Cl—Ph
2,6-di-F—Ph
S
**
**


 57
Me
2-Cl, 4-F—Ph
2,4-di-F—Ph
NH

352


 58
Me
2-Br, 4-F—Ph
2-Cl, 4-F—Ph
NH

412


 59
Me
2-Cl, 4-F—Ph
2,4,6-tri-F—Ph
C(═O)

383


 60
Me
2,4-di-F—Ph
2,4,6-tri-F—Ph
C(═O)
*
*


 62
Me
4-Cl—Ph
2,6-di-F—Ph
S(═O)2

383


 63
Me
4-Cl—Ph
2,6-di-F—Ph
S(═O)

367


 64
Me
2,4-di-F—Ph
2,6-di-F—Ph
NH

336


 65
Me
2,4-di-Cl
2,4-di-F—Ph
NH

368


 73
Me
2,4-di-F—Ph
2-Br, 4-F—Ph
C(═O)

409


 78
Me
2-Cl, 4-F—Ph
2-Br—Ph
C(═O)

409


 81
Me
2-Br, 4-F—Ph
2-I—Ph
C(═O)

501


 83
Me
2-Cl, 4-F—Ph
2-Br, 4-F—Ph
C(═O)
*
*


 89
Me
2,4-di-F—Ph
2,4-di-Cl—Ph
C(═O)

381


 91
Me
2-Cl, 4-F—Ph
2,6-di-Cl—Ph
N(OH)

384


 93
Me
2-Cl, 4-F—Ph
2-Br, 6-F—Ph
C(═O)

427


 96
Me
2-Cl, 4-F—Ph
3,5-di-Cl-4-pyridinyl
C(═O)

398


102
Me
2,4-di-F—Ph
2,6-di-F, 4-Br—Ph
C(═O)

429





* See Index Table D for 1H NMR data.


** See synthesis example for 1H NMR.














INDEX TABLE D





Compd. No.
1H NMR Data (CDCl3 solution)a
















22
δ 7.57 (t, 1H), 7.45-7.36 (m, 1H), 7.28-7.24 (m, 1H), 7.16-



7.11 (m, 1H), 7.02-6.98 (m, 1H), 6.86-6.82 (m, 1H), 5.88



(d, 1H), 3.60 (s, 3H), 2.26 (s, 3H), 2.2 (br s, 1H).


60
δ 7.42-7.36 (m, 1H), 6.82-6.76 (m, 1H), 6.62-6.50 (m, 3H),



3.69 (s, 3H), 2.46 (s, 3H).


71
δ 7.55-7.35 (m, 1H), 7.28-6.69 (m, 5H), 5.78 (d, 1H), 3.51



(s, 3H), 2.16 (s, 3H), 2.2 (br s, 1H).


82
δ 7.26-7.15 (m, 2H), 7.0-7.12 (m, 1H), 6.40 (m, 2H), 6.0



(d, 1H), 3.46 (s, 3H), 2.38 (s, 3H), 2.42 (br s, 1H).


83
δ 7.26-7.12 (m, 3H), 6.94 (m, 1H), 6.85 (dd, 1H), 6.78-



6.70 (m, 1H), 3.57 (s, 3H), 2.49 (s, 3H), 2.2 (br s, 1H).


95
δ 7.38-7.27 (m, 2H), 6.97-6.92 (m, 1H), 6.82-6.78 (m, 1H),



6.68-6.61 (m, 2H), 5.88 (d, 1H), 3.46 (s, 3H), 2.36 (s,



3H), 2.2 (br s, 1H).


166
δ 8.37-8.28 (m, 2H), 7.43 (m, 1H), 6.91 (m, 1H), 6.74 (m,



1H), 5.84 (m, 1H), 3.57 (s, 3H, 2.38 (m, 1H), 2.20 (s, 3H).


167
δ 8.69 (s, 1H), 8.67 (s, 1H), 7.42 (m, 1H), 6.79 (m, 1H),



6.68 (m, 1H), 5.87 (m, 1H), 3.66 (s, 3H), 2.18 (s, 3H),



2.08 (m, 1H).





a1H NMR data are in ppm downfield from tetramethylsilane. Couplings are designated by (s)—singlet, (d)—doublet, (t)—triplet, (m)—multiplet, (dd)—doublet of doublets and (br s)—broad singlet.






BIOLOGICAL EXAMPLES OF THE INVENTION
General protocol for preparing test suspensions for Tests A-F: the test compounds were first dissolved in acetone in an amount equal to 3% of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water (50/50 mix by volume) containing 250 ppm of the surfactant Trem® 014 (polyhydric alcohol esters). The resulting test suspensions were then used in Tests A-F. Spraying a 200 ppm test suspension to the point of run-off on the test plants was the equivalent of a rate of 800 g/ha. Unless otherwise indicated, the rating values indicate a 200 ppm test suspension was used. (An asterisk “*” next to the rating value indicates a 40 ppm test suspension was used.)
Test A
The test suspension was sprayed to the point of run-off on tomato seedlings. The following day the seedlings were inoculated with a spore suspension of Botrytis cinerea (the causal agent of tomato Botrytis) and incubated in saturated atmosphere at 20° C. for 48 h, and then moved to a growth chamber at 24° C. for 3 days, after which time visual disease ratings were made.
Test B
The test suspension was sprayed to the point of run-off on tomato seedlings. The following day the seedlings were inoculated with a spore suspension of Alternaria solani (the causal agent of tomato early blight) and incubated in a saturated atmosphere at 27° C. for 48 h, and then moved to a growth chamber at 20° C. for 5 days, after which time visual disease ratings were made.
Test C
The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of Septoria nodorum (the causal agent of Septoria glume blotch) and incubated in a saturated atmosphere at 24° C. for 48 h, and then moved to a growth chamber at 20° C. for 6 days, after which time visual disease ratings were made.
Test D
The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of Septoria tritici (the causal agent of wheat leaf blotch) and incubated in saturated atmosphere at 24° C. for 48 h, and then moved to a growth chamber at 20° C. for 19 days, after which time visual disease ratings were made.
Test E1
Wheat seedlings were inoculated with a spore suspension of Puccinia recondite f. sp. tritici (the causal agent of wheat leaf rust) and incubated in a saturated atmosphere at 20° C. for 24 h, and then moved to a growth chamber at 20° C. for 2 days. After 2 days, the test suspension was sprayed to the point of run-off on the wheat seedlings, and then the seedlings were moved back to the growth chamber at 20° C. for 6 days. Upon removal, visual disease ratings were made.
Test E2
The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of Puccinia recondite f. sp. tritici (the causal agent of wheat leaf rust) and incubated in a saturated atmosphere at 20° C. for 24 h, and then moved to a growth chamber at 20° C. for 7 days, after which time visual disease ratings were made.
Test F
The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore dust of Blumeria graminis f. sp. tritici, (also known as Erysiphe graminis f. sp. tritici, the causal agent of wheat powdery mildew) and incubated in a growth chamber at 20° C. for 8 days, after which time visual disease ratings were made.
Results for Tests A-F are given in Table A. In the Table, a rating of 100 indicates 100% disease control and a rating of 0 indicates no disease control (relative to the controls). A dash (-) indicates no test results. An asterisk “*” next to the rating value indicates a 40 ppm test suspension was used.














TABLE A





Cmpd.






Test


No
Test A
Test B
Test C
Test D
Test E1
Test E2
F






















1
100
 0
 0
 0
 38
 68
 91


2
100
 0
 0
100
 77
 97
 99


3
100
100
100
100
 99
100
100


4
 98
 0
 0
100
 75
 98
 97


5
 87
 0
 0
 97
 23
 92
 66


6
100
 59
 0
100
 0
 99
100


7
 0
 96
 0
100
 0
 9
 0


8
100
 0
 0
 99
 0
 40
 99


9
100
 0
 0
100
100
100
 99


10
100
100
 99
100
 98
100
100


11
100
 0
 0
 95
 91
 97
 96


12
100
 93
 0
100
 65
 89
 98


13
100
 0
 0
 0
 66
 0
 72


14
100
100
 99
100
 96
100
100


15
100
100
 86
100
 68
100
100


16
100
 99
 0
100
 54
100
 93


17
100
 94
 60
100
 83
100
100


18
100
 83
 0
100
100
100
100


19
 99
100
100
100
100
100
100


20
 97*
 97*
 0*
100*
 99*
 99*
 92*


21
 99
100
100
100
100
100
 98


22
 88
 84
 0
100
 17
 88
 0


23
100
 67
 87
100
 98
100
 84


24
 9
 0
 0
 0
 9
 79
 96


25
100
 99
 89
100
 9
100
 96


26
100
 0
 0
—
 0
 79
 64


27
 0
 0
 0
 0
 0
 0
 81


28
 56
 0
 0
 0
 0
 8
 79


29
100
 64
 0
—
 0
100
 96


30
100
 9
 0
100
100
 99
 99


31
100
 0
 0
100
 0
 92
 96


32
 26
 0
 0
—
 0
 0
 0


33
100
100
100
100
 99
100
100


34
100
 99
100
100
 84
 99
100


35
 98
 0
 0
100
 9
 73
 0


36
 96
 0
 0
100
 18
100
100


37
100
 99
100
100
 
100
100


38
 85
 99
100
100
 0
100
 98


39
 95
 58
 60
100
 97
100
 99


40
100
 99
 99
100
 91
100
100


41
100
 64
 0
 98
 0
 41
 0


42
 99
 99
 0
100
 32
 99
100


43
 98
 0
 0
100
 0
 98
 97


44
 99*
 0*
 0*
 99*
 0*
 99*
100*


45
 98*
 33*
 0*
100*
 0*
 95*
100*


46
—
—
—
—
—
—
—


47
—
—
—
—
—
—
—


48
 26
 0
 0
 99
—
 0
 0


49
100*
 0*
 0*
 96*
—
 74*
 87*


50
 99
 93
 0
100
 0
 79
 98


51
—
—
—
—
—
—
—


52
—
—
—
—
—
—
—


53
 93*
 99*
 0*
100*
 0*
 93*
 43*


54
100
100
 99
100
100
 99
 99


55
 99
 97
 78
100
 99
100
 95


56
 0
 0
 0
 0
 60
 27
 97


57
 99*
 0*
 0*
 81*
 0*
 18*
 97*


58
100*
 8*
 0*
100*
 0*
 98*
 97*


59
 66
 0
 0
 58
 0
 80
100


60
 75
 0
 0
 0
 0
 55
 99


61
100
100
 99
100
 99
100
100


62
 0
 0
 0
 0
 0
 28
 94


63
 0
 0
 0
 0
 0
 28
 76


64
 99
 0
 0
 48
 0
 55
 97


65
100
 0
 0
100
 9
 89
100


66
100
100
 95
100
 55
100
 99


67
 57
 9
 0
100
 28
 90
100


68
100
 88
 99
100
100
100
100


69
 99
100
 96
100
 0
 99
 97


70
—
 99
 60
100
 94
100
 99


71
—
 78*
 73*
100*
 88*
 99*
 99*


72
—
 53*
 0*
100*
 18*
 96*
 98*


73
—
 60*
 0*
 14*
 0*
 0*
 34*


74
—
100
 92
 99
 0
 99
 98


75
—
100*
 87*
100*
 74*
100*
 99*


76
—
 99
 60
100
 99
100
100


77
—
 93
 0
 99
 0
 79
 89


78
 0
 31
 40
 0
 0
 79
 99


79
 98
 0
 0
100
 53
100
 99


80
 99
 97
 69
100
 99
 99
 99


81
 54
 46
 0
 0
—
 0
 99


82
 99
100
 92
 99
 27
100
100


83
 55*
 0*
 0*
 25*
 0*
 74*
 99*


84
 96*
100*
 99*
100*
 41*
100*
100*


85
 97
 84
 0
100
 9
100
 50


86
 99
100*
 99*
100
 99*
100
100


87
100
 0*
100
 99*
 0*
 99
 99


88
—
 0
 0
 99
 0
 68
 89


89
—
 0
 0
 93
 0
 89
100


90
—
100*
 99*
100*
 74*
100*
100


91
—
 0
 0
100
 0
 68
 99


92
—
 99*
 94*
100*
 74*
 99*
100*


93
 90
—
—
 7
—
 91
100


94
 99
—
—
100
—
100
100


95
 94*
—
—
 99*
—
 98*
 95*


96
 60*
 0*
 0*
 0*
—
 0*
 26*


97
 99
—
—
100
—
100
 99


98
 94*
—
—
100*
—
100*
100*


99
 97
—
—
100
—
100
 99


100
—
—
—
100
—
100
 99


101
—
—
—
100
—
 99
 72


102
 0
—
—
 0
—
 55
 97


103
 99
—
—
 98
—
 96
 95


104
 0*
—
—
 98*
—
 97*
 72*


105
 0*
—
—
100*
—
 98*
 81*


106
 98
—
—
100
—
 97
 0


107
 9*
—
—
 99*
—
 99*
 99*


108
 99*
—
—
100*
—
100*
100*


109
 0*
—
—
100*
—
 98*
 97*


110
 0*
—
—
100*
—
 98*
 99*


111
100
—
—
100
—
100
100


112
 80
—
—
100
—
100
 97


113
 99
—
—
100
—
100
100


114
 21
—
—
100
—
 98
 98


115
 88*
—
—
100*
—
 94*
 99*


116
 0*
—
—
 78*
—
 9*
 0*


117
100
—
—
100
—
100
100


118
100
—
—
100
—
 99
100


119
100
—
—
100
—
100
100


120
100
—
—
100
—
100
100


121
 97*
—
—
100*
—
100*
100*


122
 98*
—
—
100*
—
100*
 99*


123
 87*
—
—
100*
—
 99*
 90*


124
 99
—
—
100
—
100
100


125
 82
—
—
100
—
100
 87


126
100
—
—
100
—
100
100


127
 76
—
—
100
—
 91
 99


128
 43*
—
 0*
100*
—
 85*
 56*


129
100
—
—
100
—
 99
100


130
100
—
—
100
—
100
100


131
 98
—
—
100
—
100
 98


132
 0
—
—
100*
—
 99*
100


133
100
—
—
100
—
100
 99


134
100
—
—
100
—
100
 99


135
100
—
—
100
—
100
 99


136
100
—
—
100
—
100
100


137
100
—
—
100
—
100
100


138
 66*
—
—
 16*
—
 55*
 93*


139
 83*
—
—
100*
—
 80*
 96*


140
100*
—
 99*
100*
—
 99*
100*


141
100*
—
 97*
100*
—
 99*
 99*


142
100*
—
 60*
100*
—
100*
100*


143
100*
—
 0*
100*
—
 99*
 98*


144
 78*
—
 0*
100*
—
100*
 98*


145
 26*
—
 0*
 35*
—
 82*
 73*


146
 0
—
—
 18
—
 17
 0


147
 0*
—
—
 0*
—
 17*
 0*


148
100
—
—
100
—
100
 99


149
100
—
—
100
—
100
100


150
 8
—
—
 0
—
 9
 0


151
 16
—
—
 0
—
 99
 43


152
100*
—
—
100*
—
100*
100*


153
100*
—
—
100*
—
100*
100*


154
100
—
—
100
—
100
100


155
 99*
—
—
100*
—
100*
 99*


156
100*
—
—
100*
—
 99*
 99*


157
100*
—
—
100*
—
100*
100*


158
 0
—
—
 8
—
 0
 13


159
 0
—
—
 0
—
 0
 0


160
 95*
—
—
100*
—
100*
 98*


161
 94*
—
—
100*
—
 92*
 90*


162
 99*
—
—
100*
—
 86*
 64*


163
100
—
—
100
—
100
 98


164
100
—
—
100
—
100
 0


165
100
—
—
100
—
100
100


166
 99*
—
—
100*
—
 99*
 93*


167
 0*
—
—
 58*
—
 0*
 0*


168
 21*
—
—
100*
—
 88*
100*


169
 0*
—
—
 68*
—
 88*
 0*


170
100*
—
—
100*
—
100*
 98*


171
100*
—
—
100*
—
100*
 89*


172
 99*
—
—
100*
—
100*
100*


173
 87*
—
—
100*
—
100*
 95*

## Claims

1. A compound selected from Formula 1A, N-oxides, and salts thereof,



wherein
Q1 is a phenyl ring substituted with 1 to 5 substituents independently selected from R3a;
Q2 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a;
X is O, S(O)m, N(R6) or C(═O);
R1 is C1-C2 alkyl, halomethyl, cyanomethyl or cyclopropyl;
R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C2 haloalkyl, C2-C3 cyanoalkyl, C1-C2 hydroxyalkyl, cyclopropyl, halocyclopropyl, C2-C3 alkoxyalkyl, C1-C2 alkylthio, C1-C2 alkoxy or C1-C2 haloalkoxy;
each R3a is independently halogen, cyano, hydroxy, nitro, amino, C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C4-C6 alkylcycloalkyl, C4-C6 cycloalkylalkyl, C1-C3 alkylthio, C1-C3 haloalkylthio, C1-C3 alkylsulfinyl, C1-C3 haloalkylsulfinyl, C1-C3 alkylsulfonyl, C1-C3 haloalkylsulfonyl, C1-C3 alkoxy, C1-C3 haloalkoxy, C3-C6 cycloalkoxy, C1-C3 alkylsulfonyloxy, C1-C3 haloalkylsulfonyloxy, C2-C4 alkylcarbonyloxy, C2-C4 alkylcarbonyl, C1-C3 alkylamino, C2-C4 dialkylamino, C2-C4 alkylcarbonylamino, —CH(═O), —NHCH(═O), —SF5, —SC≡N or —U—V-T;
R6 is H, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 alkoxyalkyl, C2-C6 cyanoalkyl, NH2, —CH(═O), —OR7, —OS(═O)2M1, —S(═O)nR8 or —C(═W)R9;
R7 is C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C2-C6 cyanoalkyl, C2-C6 alkoxyalkyl, —CH(═O), —S(═O)2OM1 or —C(═W)R9;
R8 is C1-C6 alkyl or C1-C6 haloalkyl;
R9 is C1-C6 alkyl, C2-C6 alkoxyalkyl, C2-C6 alkylaminoalkyl, C3-C6 dialkylaminoalkyl, C2-C6 alkylthioalkyl, C1-C6 alkoxy or C1-C6 alkylthio;
each U is independently O, S(═O)n, N(R10) or a direct bond;
each V is independently C1-C6 alkylene, C2-C6 alkenylene, C3-C6 alkynylene, C3-C6 cycloalkylene or C3-C6 cycloalkenylene, wherein up to 3 carbon atoms are independently selected from C(═O), each optionally substituted with up to 5 substituents independently selected from halogen, cyano, nitro, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy and C1-C6 haloalkoxy;
each T is independently cyano, N(R11a)(R11b), OR12 or S(═O)nR12;
each R10 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl);
each R11a and R11b is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl); or
a pair of R11a and R11b are taken together with the nitrogen atom to which they are attached to form a form a 3- to 6-membered heterocyclic ring, the ring optionally substituted with up to 5 substituents independently selected from R13;
each R12 is independently H, C1-C6 alkyl, C1-C6 haloalkyl, C2-C6 alkenyl, C3-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C2-C6 alkylcarbonyl, C2-C6 alkoxycarbonyl, C2-C6 (alkylthio)carbonyl, C2-C6 alkoxy(thiocarbonyl), C4-C8 cycloalkylcarbonyl, C4-C8 cycloalkoxycarbonyl, C4-C8 (cycloalkylthio)carbonyl or C4-C8 cycloalkoxy(thiocarbonyl);
each R13 is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl or C1-C6 alkoxy;
W is O or S;
M1 is K, Na or Li;
m is 0, 1 or 2; and
each n is independently 0, 1 or 2;
provided that:
(a) when Q2 is a phenyl ring which is not substituted with R3a at either ortho position, then Q1 is substituted by at least one R3a at an ortho position; and
(b) the compound is other than 1-[2-[4-(2,4-dichlorobenzoyl)-1,3-dimethyl-1H-pyrazol-5-yl]phenyl]ethanone.

2. A compound of claim 1 wherein:
Q1 is a phenyl ring substituted with 1 to 3 substituents independently selected from R3a;
X is O, S, N(R6) or C(═O);
R1 is C1-C2 alkyl, —CH2F, —CH2Cl or cyclopropyl;
R2 is H, halogen, cyano, C1-C2 alkyl, C2-C4 alkenyl, halomethyl, cyanomethyl, hydroxymethyl, C2-C3 alkoxyalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy;
each R3a is independently halogen, cyano, C1-C2 alkyl, C1-C2 haloalkyl, cyclopropyl, C1-C2 alkoxy, C1-C2 alkylthio, C2-C3 alkylcarbonyl or —U—V-T;
R6 is H, hydroxy, —CH(═O), C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkoxyalkyl, —OR7, —OS(═O)2M1, —S(═O)nR8 or —C(═W)R9;
R7 is H, C1-C3 alkyl, C2-C6 alkenyl, C1-C3 haloalkyl, cyclopropyl, C2-C3 cyanoalkyl, C2-C6 alkoxyalkyl, —S(═O)2OM1 or —C(═W)R9;
R8 is methyl;
R9 is methyl or methoxy;
each U is independently O, N(R10) or a direct bond;
each R10 is independently H or methyl;
each V is independently C1-C3 alkylene, wherein up to 1 carbon atom is selected from C(═O);
each T is independently N(R11a)(R11b) or OR12;
each R11a and R11b is independently H or methyl;
each R12 is independently H, C1-C6 alkyl or C1-C6 haloalkyl;
W is O; and
M1 is Na or K.

3. A compound of claim 2 wherein:
R1 is methyl, —CH2F or —CH2Cl;
R2 is halogen, cyano, C1-C2 alkyl, halomethyl, cyanomethyl, hydroxymethyl, C1-C2 alkoxy or C1-C2 haloalkoxy;
each R3a is independently halogen, cyano, methyl, halomethyl, cyclopropyl, methoxy, methylthio, methylcarbonyl or —U—V-T;
R6 is H, methyl, halomethyl or —OR7;
R7 is H, C1-C3 alkyl, C1-C3 haloalkyl, —S(═O)2OM1 or —C(═W)R9;
each U is independently O, NH or a direct bond;
each V is C1-C3 alkylene; and
each R12 is independently H, methyl or halomethyl.

4. A compound of claim 3 wherein:
R1 is methyl;
R2 is halogen, cyano, methyl, halomethyl or methoxy;
each R3a is independently halogen, cyano, methyl, halomethyl or methoxy;
R7 is H, methyl or —C(═W)R9; and
R9 is methyl.

5. A compound of claim 4 wherein:
X is O, S, NH or C(═O);
R2 is Br, Cl, methyl or methoxy; and
each R3a is independently halogen, cyano or methoxy.

6. A compound of claim 5 wherein:
R2 is methyl;
each R3a is independently Br, Cl, F, cyano or methoxy; and
one of Q1 and Q2 is substituted with 2 to 3 substituents and the other of Q1 and Q2 is substituted with 1 to 2 substituents.

7. The compound of claim 1 which is selected from the group:
5-(2-chloro-4-methoxyphenyl)-4-(2,4-difluorophenoxy)-1,3-dimethyl-1H-pyrazole;
4-(2-chloro-4-fluorophenoxy)-5-(2-chloro-4-methoxyphenyl)-1,3-dimethyl-1H-pyrazole;
3-chloro-4-[4-(2-chloro-4-fluorophenoxy)-1,3-dimethyl-1H-pyrazol-5-yl]benzonitrile;
4-[[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]amino]-3,5-difluorobenzonitrile;
N,5-bis(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine;
3-chloro-4-[[5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl]oxy]benzonitrile;
5-(2-chloro-4-fluorophenyl)-N-(2,4-dichlorophenyl)-1,3-dimethyl-1H-pyrazole-4-amine;
5-(2-chloro-4-fluorophenyl)-N-(4-chloro-2-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-amine;
4-(2-chloro-4-fluorobenzoyl)-5-(2,4-difluorophenyl)-1-methyl-1H-pyrazole-3-carbonitrile;
N-(2-bromo-4-fluorophenyl)-5-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-4-amine;
N-(2,4-dichlorophenyl)-5-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazol-4-amine; and
[5-(2,4-dichlorophenyl)-1,3-dimethyl-1H-pyrazol-4-yl](2,4-difluorophenyl)methanone.

8. A fungicidal composition comprising (a) a compound of claim 1; and (b) at least one other fungicide.

9. A fungicidal composition comprising (a) a compound of claim 1; and (b) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.

10. A method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of claim 1.